


Hemmstofftestsysteme der AiM GmbH unabhängig zertifiziert

**Independent certification
of AiM GmbH's
Inhibitor Test Systems**





Hemmstofftestsysteme der AiM GmbH unabhängig zertifiziert

Die AiM GmbH hat mit der unabhängigen Validierung ihrer Hemmstofftestsysteme und deren Zertifizierung durch NordVal International einen wichtigen Schritt zur internationalen Akzeptanz ihrer Produkte realisiert und gleichzeitig als erster Hersteller seine Tests nach der neuen Norm ISO/TS 16393 und der gerade initiierten Norm ISO/TS 23758 (IDF/RM 251) „Guidelines for the validation of qualitative screening tests for the detection of residues of veterinary drugs in milk and milk products“ überprüfen lassen.

Neben der Ermittlung der Nachweisempfindlichkeiten wurden erstmals Standardkurven für alle untersuchten antibiotischen Substanzen bestimmt. Außerdem wurden die Selektivität, die Vergleichbarkeit der Chargen, die Performance mit Routineproben sowie die Falsch-positiv- und die Falsch-negativ-Raten und der Einsatz in einer internationalen Hemmstoff-Eignungsprüfung untersucht. Das umfassende Datenmaterial wurde mittels einer speziell für diese Validierung entwickelten Statistik-Methode ausgewertet und die Ergebnisse anschaulich für jedes Testsystem separat in einem ausführlichen Bericht dargestellt. Für kein anderes Testsystem zum Nachweis von Antibiotika in Milch liegen aktuell derart dichte und aussagekräftige Daten vor, die den Kunden in die Lage versetzen das optimale Testsystem auszuwählen und die Ergebnisse maximal abzusichern.


Ihr Team der AiM GmbH

Independent certification of AiM GmbH's Inhibitor Test Systems

With the independent validation of the inhibitor test systems and its certification by NordVal International, AiM GmbH implemented an important milestone for the international acceptance of its products. Simultaneously, AiM GmbH is the first manufacturer to have commissioned an evaluation of its test systems according to the new norm ISO/TS 16393 and the just initialized norm ISO/TS 23758 (IDF/RM 251) „Guidelines for the validation of qualitative screening tests for the detection of residues of veterinary drugs in milk and milk products“.

In addition to the assessment of the detection sensitivities, dose-response curves for all examined antibiotic substances were determined for the first time. Selectivity, batch-to-batch variability, performance with field samples as well as false-positive and false-negative rate and the performance in an international proficiency test for inhibitors were tested as well. The comprehensive data set obtained was evaluated statistically using a method developed specifically for this validation study and the results were depicted in detailed reports for each test system. At the moment, no other test system for the detection of antibiotic residues in milk is provided with such dense and significant data, which enable the customers to choose the optimal test system and assure the results at a maximum.

Your AiM GmbH Team



Inhalt

| | |
|-----|---|
| 7 | Zertifikate |
| 9 | Zertifikat – BRT Hemmstofftest |
| 11 | Zertifikat – BRT MRL-Suchtest |
| 13 | Zertifikat – BRT hi-sense |
| 15 | Validierungsberichte |
| 17 | Validierungsbericht – BRT Hemmstofftest |
| 55 | Validierungsbericht – BRT MRL-Suchtest |
| 93 | Validierungsbericht – BRT hi-sense |
| 133 | Nachweisempfindlichkeiten |

Content

| | |
|-----|--|
| 7 | Certificates |
| 9 | Certificate – BRT Inhibitor Test |
| 11 | Certificate – BRT MRL-Screening Test |
| 13 | Certificate – BRT hi-sense |
| 15 | Validation Reports |
| 17 | Validation Report – BRT Inhibitor Test |
| 55 | Validation Report – BRT MRL-Screening Test |
| 93 | Validation Report – BRT hi-sense |
| 133 | Detection sensitivities |

Zertifikate

Certificates

Die vollständigen Zertifikate stehen ab sofort auf der Homepage der AiM GmbH (www.aim-bayern.de) oder direkt bei NordVal International zum Download bereit (<https://www.nmkl.org/index.php/en/component/zoo/category/chemical-nordval-certificates?f=1&Itemid=618>).

The entire certificates are available for download on the homepage of AiM GmbH (www.aim-bayern.de) as well as directly on the homepage of NordVal International (<https://www.nmkl.org/index.php/en/component/zoo/category/chemical-nordval-certificates?f=1&Itemid=618>).



NordVal International Certificate

| | |
|----------------------|--------------------|
| Issued for: | BRT Inhibitor Test |
| NordVal No: | 051 |
| First approval date: | 01 March 2019 |
| Renewal date: | 01 March 2021 |
| Valid until: | 01 March 2023 |

BRT Inhibitor Test

Manufactured by:

Analytik in Milch Produktions- und Vertriebs-GmbH
Kaiser-Ludwig-Platz 2
80336 München
Germany

fulfils the validation requirements of the NordVal Validation Protocol 2. The BRT Inhibitor Test is a brilliant black reduction test for detection of antibiotic residues.


The method is tested for penicillins, cephalosporins, macrolides, sulfonamides, tetracyclines, aminoglycosides and Chloramphenicol in raw bovine milk on microtiter plates. Detection capability for clear results and presumptive results of photometric and visual reading is stated. In order for the method to be applicable in the EU, the detection capabilities for the substances of interest must be below given EU Maximum Residue Limits (MRL). The detection capabilities and associated MRLs for the substances tested are given in Table 2. Examples of the probability of detection (POD) / dose-response curves are given in the certificate for illustration. POD curves for all substances are given in the validation report, which is enclosed as an annex.

The performance of the method was tested in a comprehensive validation study carried out at the laboratory of Milchprüfing Bayern e. V. and tested in a large proficiency test.


The production of BRT Inhibitor Test is ISO 9001:2015-accredited by LGA InterCert GmbH.

Date: 01 February 2021

Yours sincerely,

A handwritten signature in purple ink, appearing to read 'Hilde Skår Norli'.

Hilde Skår Norli
Chair of NordVal International

A handwritten signature in black ink, appearing to read 'Eystein Oveland'.

Eystein Oveland
NMKL Secretary General

Zertifikat – BRT MRL-Suchtest
Certificate – BRT MRL-Screening Test

Validierungsbericht – Seite 55
Validation Report – page 55



NordVal International Certificate

| | |
|----------------------|------------------------|
| Issued for: | BRT MRL Screening Test |
| NordVal No: | 052 |
| First approval date: | 01 March 2019 |
| Renewal date: | 01 March 2021 |
| Valid until: | 01 March 2023 |

BRT MRL Screening Test

Manufactured by:

Analytik in Milch Produktions- und Vertriebs-GmbH
Kaiser-Ludwig-Platz 2
80336 München
Germany

fulfils the validation requirements of the NordVal Validation Protocol 2. The BRT MRL Screening Test is a Brilliant Black Reduction Test for the detection of antibiotic residues.

The method is tested for penicillins, cephalosporins, macrolides, sulfonamides, tetracyclines, aminoglycosides and Chloramphenicol in raw bovine milk on microtiter plates. Detection capability for clear results and presumptive results of photometric and visual reading is stated. In order for the method to be applicable in the EU, the detection capabilities for the substances of interest must be below given EU Maximum Residue Limits (MRL). The detection capabilities and associated MRLs for the substances tested are given in Table 2. Examples of the probability of detection (POD) / dose-response curves are given in the certificate for illustration. POD-curves for all substances are given in the validation report, which is enclosed as an annex.

The performance of the method was tested in a comprehensive validation study carried out at the laboratory of Milchprüfing Bayern e. V. and tested in a large proficiency test.


The production of BRT MRL Screening Test is ISO 9001:2015-accredited by LGA InterCert GmbH.

Date: 01 February 2021

Yours sincerely,

A handwritten signature in purple ink, appearing to read 'Hilde Skår Norli'.

Hilde Skår Norli
Chair of NordVal International

A handwritten signature in black ink, appearing to read 'Eystein Oveland'.

Eystein Oveland
NMKL Secretary General



NordVal International Certificate

| | |
|----------------------|---------------|
| Issued for: | BRT hi-sense |
| NordVal No: | 053 |
| First approval date: | 01 March 2019 |
| Renewal date: | 01 March 2021 |
| Valid until: | 01 March 2023 |

BRT hi-sense

Manufactured by:

Analytik in Milch Produktions- und Vertriebs-GmbH
Kaiser-Ludwig-Platz 2
80336 München
Germany

fulfils the validation requirements of the NordVal Validation Protocol 2. The BRT hi-sense is a brilliant black reduction test for the detection of antibiotic residues.


The method is tested for penicillins, cephalosporins, macrolides, sulfonamides, tetracyclines, aminoglycosides and Chloramphenicol in raw bovine milk on microtiter plates. Detection capability for clear results and presumptive results of photometric and visual reading is stated. In order for the method to be applicable in the EU, the detection capabilities for the substances of interest must be below given EU Maximum Residue Limits (MRL). The detection capabilities and associated MRLs for the substances tested are given in Table 2. Examples of the probability of detection (POD) / dose-response curves are given in the certificate for illustration. POD curves for all substances are given in the validation report, which is enclosed as an annex.

The performance of the method was tested in a comprehensive validation study carried out at the laboratory of Milchprüfing Bayern e. V. and tested in a large proficiency test


The production of BRT hi-sense is according to ISO 9001:2015-accredited by LGA InterCert GmbH.

Date: 01 February 2021

Yours sincerely,

A handwritten signature in purple ink, appearing to read 'Hilde Skår Norli'.

Hilde Skår Norli
Chair of NordVal International

A handwritten signature in black ink, appearing to read 'Eystein Oveland'.

Eystein Oveland
NMKL Secretary General

Validierungsberichte

Validation Reports

Validierungsbericht **Validation Report**

BRT Hemmstofftest **BRT Inhibitor Test**



1) Introduction

The BRT Inhibitor Test (AiM – Analytik in Milch GmbH, www.aimbavaria.com) is a microbiological inhibitor test for the qualitative broad-spectrum detection of antibiotic residues in cow milk. The validation study was carried out at the laboratory of Milchprüfning Bayern e. V. (MPR Bayern, www.mpr-bayern.de), a large raw milk testing laboratory performing 1.8 million inhibitor tests per year, under the conduct of Silvia Orlandini (AEOS) and Christian Baumgartner (MPR Bayern), in accordance with the Commission Decision 2002/657/EC and the CRL Guidelines (Anonymous, 2010).

2) Test Principle, Test Procedure, Reading Methods and Plate Batches

The BRT Inhibitor Test (Figure 1) is a Brilliant Black Reduction Test (BRT) containing the test bacteria *G. stearothermophilus* var. *calidolactis* C953, the redox indicator brilliant black, nutrients and other supplements. Antibiotic residues present in a sample can inhibit the growth of the test bacteria, thus preventing or decelerating the reduction of the color indicator brilliant black and the consecutive color change of the test medium from blue to yellow. The BRT Inhibitor Test detects a broad spectrum of antibiotics, but is especially sensitive to beta-lactams.

The test is designed in particular to satisfy the demands of milk quality regulation in Germany and is used for quality evaluation and payment for tank milk. It is recognized as official inspection method for the detection of inhibitors in tank milk and is part of the official register of inspection procedures according to § 64 LFGB (German Food, Feed and Consumer Goods Code, L 01.01-5). Furthermore, it is produced according to Commission Decision 91/180/EEC.




Figure 1. BRT Inhibitor Test plates before (A) and after (B) incubation

Within the framework of this validation, the BRT Inhibitor Test was evaluated in microtiter plate format. The plates were stored refrigerated (6 - 10 °C) until use. Additional to the samples (100 µl milk volume), each plate contained four positive (raw milk spiked with 4 µg/kg Penicillin G, remaining blue after incubation) and four negative controls (inhibitor-free raw milk, turning yellow after incubation) in order to enable a correct evaluation. According to the manufacturer's instructions, the plates were incubated at 65 °C in a temperature-surveilled water bath until the complete

discoloration of the negative control (color change from blue to yellow, Figure 1) indicated the ideal reading time (2 hrs 15 ± 15 min). Thereafter, the milk was rinsed off the cavities and the plates were assessed with 2 different reading methods: Visual examination performed by 3 technical assistants trained particularly for this purpose and photometric evaluation, using 2 instruments (ELISA reader (Multiskan Ascent V1.24, Thermo Labsystems)).

The photometric measurements were evaluated conforming to the relativized absorption method described by Beer and Suhren (1993). Accordingly, the measuring wavelength of 450 nm and the reference wavelength of 620 nm were chosen for reading. The recorded absorption values of the analyzed samples were converted into relative percentage values by setting the average absorption level of the negative controls (yellow color after incubation) as 0% and that of the positive controls (blue color after incubation) as 100%, other absorption levels (samples) were set in relation to negative (0%) and positive (100%) control.

The conversion formula is as follows:

$$(S-NC)/(PC-NC) \times 100 = X \%$$

where

S is the analyzed sample's absorption level

NC is the average of the four negative controls absorption levels

PC is the average of the four positive controls absorption levels

X relative percentage value of the analyzed sample

The photometric evaluation was regarded as reference method in this validation study as it provides objective, comparable and documented results and is commonly used by large laboratories.

The interpretation of the samples reading results was carried out in two different ways, in compliance with the method L 01.01-5 (§ 64 LFGB, inspection tests for milk quality payment) all samples exhibiting at least the color of the positive control respectively exceeding the threshold value of 65% (photometric evaluation) were interpreted as positive (indicated as class A) as well as all samples displaying a color which was clearly different from the negative control or exceeding the threshold value of 40% (indicated as class B), according to L 01.00-11 (§ 64 LFGB, German Food, Feed and Consumer Goods Code, MRL Screening test). All samples gaining <40% by photometric evaluation or appeared as yellow as the negative control were categorized as negative (Table 1).

For statistical purposes, the "quantitative" relative percentage photometric results were converted to the same format as the "qualitative" visual data. Thus, the number 1 was assigned to any photometric percentage value of ≥65%, whereas results with percentages in the range of 40% - <65% were referred to with 2 and negative results with 0, equaling <40% (Table 1).

Table 1. Relation of reading systems and classes of results

| Reading System | Classes of Results | | |
|----------------|--------------------|------------------|----------|
| | Positive Class A | Positive Class B | Negative |
| Visual (V) | 1 | 2 | 0 |
| ELISA (E) | ≥65% | 40% - <65% | <40% |

60,340 data results were obtained from the evaluation of 154 BRT Inhibitor Test plates and treated statistically using "R" software (Version 3.5.0 (2018-04-23)). The confidence interval (CI) was calculated according to the AOAC approach for qualitative data.

For the validation, 7 batches of plates (Table 2) were provided by the manufacturer.

Table 2. BRT Inhibitor Test plate batches provided for the validation

| Batch | Range of Batch Numbers |
|-------|------------------------|
| A | 20709235 - 20713911 |
| B | 20516031 - 20524980 |
| C | 20801052 - 20812126 |
| D | 21301001 - 21308901 |
| E | 21409615 - 21410635 |
| F | 21601002 - 21610752 |
| G | 22801005 - 22814753 |

3) Raw Milk Samples

A large quantity of high quality raw ex-farm bulk milk was collected, analyzed for milk quality and components (Table 3) and proven to be free of antibiotic residues by analysis with highly sensitive microbial inhibitor tests (BRT hi-sense and BRT ultra-sense, AiM GmbH, Munich, Germany) and receptor tests (BetaStar® 100, Neogen Corporation, Lansing, USA; Charm® MRL Beta-lactam Test, Charm Sciences Inc., Lawrence, USA; SNAP® Beta-Lactam ST-Test, IDEXX GmbH, Ludwigsburg, Germany). Additionally, the raw milk was tested with the AiM Penase Test (AiM GmbH, Munich, Germany) and proven to be free of penicillinase. Thereafter, the raw milk was aliquoted, frozen and stored until use. For the establishment of the rate of positive results not caused by residues of veterinary drugs, 704 ex-farm bulk milk samples, originating from routine milk quality payment testing, were analyzed with the BRT Inhibitor Test.

Table 3. Analysis results of the raw milk batch used for the validation samples

| Type of Milk | FC [g/100 ml] ^a | PC [g/100 ml] ^b | pH | SCC/ml ^c | CFU/ml ^d |
|----------------|----------------------------|----------------------------|------|---------------------|---------------------|
| Blank raw Milk | 4.17 | 3.51 | 6.65 | 77,000 | 5,000 |

^a Fat content; ^b Protein content; ^c Somatic cell count; ^d Colony forming units

For the preparation of positive samples, blank raw cow milk was defrosted, spiked with a highly concentrated stock solution to obtain the desired level of antibiotic residue and frozen again. When required, the milk samples were defrosted overnight at 6 - 8 °C and used the next day. To verify the correct concentration of the stock solutions and the spiked raw milk samples, serial dilutions of the prepared positive samples were analyzed with microbiological inhibitor and - if available for a certain substance - receptor tests, then the obtained results were compared with the detection limits of the individual tests. No receptor tests were available for Erythromycin, Tylosin, Neomycin and Gentamicin, therefore the correct concentrations of the individual stock solutions were verified with LC - MS/MS analysis.

The approach of using a single batch of raw milk as base for the preparation of the spiked milk samples enhances the comparability of results obtained on different validation days and thus objectifies the assessment of the validation results, as irregularities are not attributable to deviating milk qualities. Ex-farm tank milk was chosen as basic matrix for the validation as this is the target product of the BRT Inhibitor Test.

4) Detection Capability

Materials and Methods

Involved in the validation study were 30 antibiotic compounds (Table 6), the concentrations of the samples to analyze were chosen according to the manufacturer's specification. The choice of increment from concentration to concentration depended on the spiked standards' concentrations (Table 4) as well as on practical aspects as two classes of results had to be considered, leading to two different detection limits (CC β A and CC β B).

Table 4. Correlation of concentration and increment of the spiked raw milk samples

| Concentration [$\mu\text{g}/\text{kg}$] | Increment [$\mu\text{g}/\text{kg}$] |
|---|---|
| 1-10 | 1 |
| 11-20 | 2 |
| 21-50 | 5 |
| 51-100 | 10 |
| 101-250 | 25 |
| 251-500 | 50 |
| 501-1,000 | 100 |
| 1,000-5,000 | 500 |

Correlated with the proximity to the respective EU Maximum Residue Limit (MRL) for antibiotic residues in milk, the standards were measured with 20, 40 or 60 replicates (Table 5).

Table 5. Number of replicates depending on the proximity to the respective MRL

| Closeness to MRL | No. of Replicates |
|-----------------------|-------------------|
| ≤0.5 MRL | 20 |
| >0.5 MRL and <0.9 MRL | 40 |
| ≥0.9 MRL and ≤ MRL | 60 |
| > MRL | 20 |

For the determination of the detection capability, three different batches of plates were used at all times. The lowest concentration obtaining a minimum of 95% positive results was considered as detection limit (CC β). Based on the different interpretation methods, CC β A and CC β B (Section 2) were established in parallel for each substance. The detection limits determined with photometric evaluation were considered as reference values.

Results and Discussion

Table 6. Established detection limits (photometric reading) compared with the EU MRL levels. Marked in red are the substances exceeding the EU MRLs.

| Group of Antibiotics | Substance | MRL EU [$\mu\text{g}/\text{kg}$] | CC β A [$\mu\text{g}/\text{kg}$] | CC β B [$\mu\text{g}/\text{kg}$] |
|------------------------|------------------------|------------------------------------|--|--|
| Penicillins | Benzylpenicillin | 4 | 2.5 | 2 |
| | Ampicillin | 4 | 3.5 | 3 |
| | Amoxicillin | 4 | 3 | 2.5 |
| | Cloxacillin | 30 | 25 | 20 |
| | Dicloxacillin | 30 | 15 | 12.5 |
| | Nafcillin | 30 | 15 | 10 |
| | Oxacillin | 30 | 10 | 8 |
| Cephalosporins | Cefalexin | 100 | 400 | 300 |
| | Cefapirin | 60 | 6 | 5 |
| | Cefoperazone | 50 | 35 | 25 |
| | Cefazolin | 50 | 9 | 7 |
| | Cefquinome | 20 | 500 | 300 |
| | Ceftiofur | 100 | 200 | 150 |
| | Cefalonium | 20 | 14 | 12 |
| Macrolides | Erythromycin | 40 | 100 | 50 |
| | Tylosin | 50 | 75 | 40 |
| Sulfonamides | Sulfadiazine | 100 | >800 | 100 |
| | Sulfadimethoxin | 100 | >800 | 200 |
| | Sulfamethazine | 100 | 1,000 | 300 |
| | Sulfathiazol | 100 | 400 | 60 |
| | Sulfadoxin | 100 | >1,500 | 400 |
| | Sulfamethoxypyridazine | 100 | 500 | 100 |
| Tetracyclines | Chlortetracycline | 100 | >1,000 | 800 |
| | Oxytetracycline | 100 | 800 | 400 |
| | Tetracycline | 100 | 1,000 | 600 |
| Aminoglycosides | Dihydrostreptomycin | 200 | 600 | 400 |
| | Streptomycin | 200 | 1,500 | 600 |
| | Gentamicin | 100 | 200 | 100 |
| | Neomycin | 1,500 | 400 | 200 |
| Fenicol | Chloramphenicol | - | 7,000 | 4,000 |

The particular sensitivity of *G. stearothermophilus* for beta-lactams and especially for penicillins is reflected in the detection limits of the different groups of antibiotics. All penicillins were detected below MRL as well as 4 out of 7 cephalosporins. Out of the groups of the macrolides, sulfonamides and aminoglycosides Tylosin, Sulfadiazine, Sulfathiazol, Sulfamethoxyipyridazine and Gentamicin conformed with the regulatory limits with CC β B, but not with CC β A, whereas for Neomycin CC β A and CC β B were defined to be below MRL. The detection limits of other tested substances exceeded the respective MRLs. Additionally, for a low number of substances (Sulfadiazine, Sulfadimethoxin, Sulfadoxin and Chlortetracycline) CC β A could not be determined as the positive response was below 65% relative absorption at the highest concentrations tested.

Chloramphenicol, for which no MRL is established – it is prohibited for use in food producing animals (Commission Regulation (EU) No 37/2010) – can be tested positive at 4,000 $\mu\text{g}/\text{kg}$ (CC β B) or 7,000 $\mu\text{g}/\text{kg}$ (CC β A). The detection limits for the BRT Inhibitor Test established with the reference method (photometric evaluation) are reported in Table 6, detection limits established with visual reading are reported in Annex Table 1.

In conclusion, the most important antibiotics used in Germany for the treatment of dairy cows (penicillins and cephalosporins), are detected predominantly below EU MRL. A broad range of other inhibitors can be identified as well, however, mostly in concentrations exceeding the regulatory limit.

5) Dose-Response Curves




Figure 2. Incubated BRT Inhibitor Test plate inoculated with four positive and four negative controls as well as raw milk samples spiked with 7 different concentrations of an antibiotic substance

Materials and Methods

Dose-response curves were established for all antibiotics analyzed in the validation based on the class A results (Section 2) obtained within the framework of the detection capability study with both photometric and visual evaluation. For this purpose, 7 samples containing increasing concentrations were examined for each substance, with the aim of identifying the concentrations resulting in approximately 25%, 50%, 75% and 100% positive rates and to determine the highest concentration with 0% positive results. Furthermore, lower and upper CIs were calculated for the class A results under consideration of both reading systems and included in the dose-response curves (Figure 2 and Annex Table 2).

Results and Discussion

Figure 3 and Annex Figure 1 depict dose-response curves of all substances included in the validation of the BRT Inhibitor Test. The response rates generated with the respective concentrations of each substance are specified in Annex Table 2. It was not always possible to obtain dose-response curves entirely corresponding to the requirements of 0%, 25%, 50%, 75% and 100% positive results. Bactericidal substances like beta-lactams mostly exhibited steeply increasing dose-response curves. For Benzylpenicillin, e. g., the positive response rate was 0% at 1.5 µg/kg, 76% at 2 µg/kg already and 100% of samples were detected positive at 2.5 µg/kg. Substances like the sulfonamides and tetracyclines displayed more consistent curve increments, probably due to their bacteriostatic character. Sulfadoxin obtained 0% positive results at 100 µg/kg, 7% at 400 µg/kg, 31% respectively 39% at 600 µg/kg and 800 µg/kg. At 1,000 µg/kg, the positive response was 47% and with the highest concentration analyzed (1,500 µg/kg) 63% - no CCB A was established for this substance.

Principally, the confidence interval is narrow at the concentrations of the CCB and at concentrations close to 0% of positive results. Bactericidal substances tend to exhibit narrow CIs also at concentrations in between 0% and CCB, which indicates that most results of samples with different concentrations are interpreted in the same way with the different reading systems (photometric and visual) and individual readers.

In contrast, bacteriostatic substances often show bigger variations in the results at the concentrations below the CCB. The bacteriostatic activity causes different degrees of inhibition and consequently of color development, which can be more difficult to interpret by human eye. While the interpretation with photometric reading systems is well standardized, the visual interpretation leads to bigger variances in the results and thus to wider CIs.




Figure 3. Dose-response curves of the bactericidal antibiotics Benzylpenicillin and Cefalonium and of the bacteriostatic substances Sulfadoxin and Tetracycline.

Red line = dose-response curve; red shade = CI; Black line = CC₅₀ A (photometric reading); Dotted line = highest concentration analyzed

6) Selectivity

Materials and Methods

Marker substances of commonly used classes of veterinary drugs other than antibiotics were analyzed with photometric reading in order to determine the selectivity of the BRT Inhibitor Test. The investigated compounds included the anti-inflammatories Flunixin, Metamizole (NSAIDs) and Prednisolone (glucocorticoid) as well as antiparasitic substances (Triclabendazole and Deltamethrin). Furthermore, the polyether-antibiotic Monensin, used for ketosis treatment in dairy cows, was tested. The substances were spiked at a concentration of 100 x EU MRL and inoculated with 6 replicates (Table 7).

Table 7. Selectivity: Concentrations of analyzed substances and test results

| Use | Drug Class | Substance | MRL [$\mu\text{g}/\text{kg}$] | Concentration [$\mu\text{g}/\text{kg}$] | False positive Results |
|------------------------------|----------------------|-----------------|---------------------------------|---|------------------------|
| Anti-inflammatory Substances | NSAID | Flunixin | 40 | 4,000 | 0/6 |
| | NSAID | Metamizole | 50 | 5,000 | 0/6 |
| | Glucocorticoid | Prednisolone | 6 | 600 | 0/6 |
| Antiparasitics | Anthelmintic | Triclabendazole | 10 | 1,000 | 0/6 |
| | Ectoparasite | Deltamethrin | 20 | 2,000 | 0/6 |
| Ketosis Treatment | Polyether-Antibiotic | Monensin | 2 | 200 | 0/6 |

Results and Discussion

Highly concentrated samples of Flunixin, Metamizole, Prednisolone, Triclabendazole, Deltamethrin and Monensin did not inhibit the growth of the test germs, leading to negative results (both class A and class B). Thus, no false positive results were observed, signifying a high specificity of the BRT Inhibitor Test for the detection of antibiotics opposed to other classes of veterinary drugs.

7) Batch-to-Batch Variability

Materials and Methods

In order to evaluate potential deviations in the detection capabilities of different plate batches statistically, Fisher's exact tests (method: two-sided) were applied at the concentration of the CCB A obtained with photometric reading. Contingency tables were created for the datasets of ELISA reader 1 and ELISA reader 2 to provide a basic picture of the interrelation between the two variables plate batches and number of results (class A) per batch. Due to the duration of the validation study and the limited shelf-life of the BRT Inhibitor Test plates, two sets of plate batches (A, B, C and D, E, F) had to be used.

The Fisher's test was selected because the test is more precise than Chi square for this number of observations, the null hypothesis is based on the batches independence (the probability of the results is the same for the different batches). The Fisher's exact test was applied only to the analytes for which a CCB A could be

determined. If the significance level is $\alpha = 0.05$ and the p-value <0.05 , the null hypothesis is rejected, which would mean that there is a probability for batch-to-batch differences concerning the detection capability at the CC β A.

Results and Discussion

The Fisher's test examinations for the concentrations at CC β A indicate that there are no significant differences in between the detection sensitivities of the different plate batches used in the validation. Most substances realized p-value = 1, for Cloxacillin, Oxacillin, Ceftiofur and Sulfathiazol the p values were $0.05 \leq p < 1$ (Table 8). In addition to the p-values (CC β A), Annex Table 3 comprises the numbers of results per class (1-2-0), plate batch and individual ELISA reader at the concentration of the CC β A.

Table 8. Contingency table created with the Fisher Test for the concentration at CC β A obtained with photometric reading

| Group of Antibiotics | Substance | MRL | CC β A [μ g/kg] | p value | | Group of Antibiotics | Substance | MRL | CC β A [μ g/kg] | p value | |
|----------------------|------------------|-----|----------------------------|---------|---------|----------------------|-------------------------|-------|----------------------------|---------|---------|
| | | | | ELISA 1 | ELISA 2 | | | | | ELISA 1 | ELISA 2 |
| Penicillins | Benzylpenicillin | 4 | 2.5 | 1 | 1 | Sulfonamides | Sulfadiazine | 100 | NA | - | - |
| | Ampicillin | 4 | 3.5 | 1 | 1 | | Sulfadimethoxin | 100 | NA | - | - |
| | Amoxicillin | 4 | 3 | 1 | 1 | | Sulphamethazine | 100 | 1,000 | 1 | 1 |
| | Cloxacillin | 30 | 25 | 0.33 | 1 | | Sulfathiazol | 100 | 400 | 1 | 0.06 |
| | Dicloxacillin | 30 | 15 | 1 | 1 | | Sulfadoxin | 100 | NA | - | - |
| | Nafcillin | 30 | 15 | 1 | 1 | | Sulfamethoxy-pyridazine | 100 | 500 | 1 | 1 |
| Cephalosporines | Oxacillin | 30 | 10 | 0.20 | 1 | Tetracyclines | Chlortetracycline | 100 | NA | - | - |
| | Cefalexin | 100 | 400 | 1 | 1 | | Oxytetracycline | 100 | 800 | 1 | 1 |
| | Cefapirin | 60 | 6 | 1 | 1 | | Tetracycline | 100 | 1,000 | 1 | 1 |
| | Cefoperazone | 50 | 35 | 1 | 1 | Aminoglycosides | Dihydrostreptomycin | 200 | 600 | 1 | 1 |
| | Cefazolin | 50 | 9 | 1 | 1 | | Streptomycin | 200 | 1,500 | 1 | 1 |
| | Cefquinome | 20 | 500 | 1 | 1 | | Gentamicin | 100 | 200 | 1 | 1 |
| Macrolides | Ceftiofur | 100 | 200 | 0.11 | 0.11 | Fenicols | Neomycin | 1,500 | 400 | 1 | 1 |
| | Cefalonium | 20 | 14 | 1 | 1 | | Chloramphenicol | - | 7,000 | 1 | 1 |
| | Erythromycin | 40 | 100 | 1 | 1 | | | | | | |
| | Tylosin | 50 | 75 | 1 | 1 | | | | | | |

Significance levels: Low: $p < 0.05$; Medium: $p < 0.01$; High: $p < 0.001$

8) False-Positive and False-Negative Rate

Materials and Methods

With each BRT Inhibitor Test plate used during the validation study, 4 positive and negative control samples (Section 2) as well as additional 16 negative raw milk samples, adding up to 20 negative milk samples, were inoculated. By means of these samples, the rates of false-positive and false-negative results were established. Within the framework of this validation, 154 test plates were analyzed, including 616 positive control samples and 3,080 samples of negative raw milk in total. Thus, 3,080 (positive control) respectively 15,400 (negative milk) results were obtained with photometric evaluation (2 readers) and visual reading (3 technicians, Table 9).

Table 9. Numbers of positive and negative samples and obtained results used for the establishment of the false-negative and false-positive rates

| Type of Milk Sample | No. Plates | No. Samples | No. Results ELISA Readers | No. Results Visual | Total No. Results |
|---------------------|------------|-------------|---------------------------|--------------------|-------------------|
| Positive Control | 154 | 616 | 1,232 | 1,848 | 3,080 |
| Negative Milk | | 3,080 | 6,160 | 9,240 | 15,400 |

Results and Discussion

No false-positive results were observed when analyzing the results of the negative milk samples by photometric evaluation or visual reading, indicating a false-positive rate of 0%.

With photometric evaluation no false-negative result was obtained out of 3,080 results for the positive control samples. Only 1 sample was classified false-negative by 1 out of 3 examining technicians, leading to a false-negative rate of 0.2% for this person (Table 10). As none of the other readers (technicians and ELISA readers) assessed this sample as positive, the negative result is considered as outlier and might have been caused by a typing error.

Table 10. Rates of false-negative and false-positive results of all applied reading methods and readers

| Type of Milk Sample | Rate of false Results [%] | | | | |
|---------------------|---------------------------|---------|----------|----------|----------|
| | ELISA 1 | ELISA 2 | Visual 1 | Visual 2 | Visual 3 |
| Positive Control | 0 | 0 | 0 | 0 | 0.2 |
| Negative Milk | 0 | 0 | 0 | 0 | 0 |

The maximum relative percentage value (Section 2) obtained with photometric reading for negative samples was 33%, whereas the minimum relative percentage value for positive samples was 93% (Table 11). These values demonstrate that with the chosen thresholds for photometric reading (65% class A; 40% class B; Table 1) the false interpretation of positive as well as negative samples can be avoided.

Table 11. Minimum and maximum photometric percentage results obtained with two photometric instruments

| Type of Milk Sample | No. Results ELISA Readers | Photometric Values Min/Max [%] |
|---------------------|---------------------------|--------------------------------|
| Positive Control | 1,232 | 93 |
| Negative Milk | 6,160 | 33 |

In conclusion, the absence of false-negative and false-positive results indicates that the validity of positive as well as negative results obtained for raw milk samples by analysis with the BRT Inhibitor Test is very high.

9) Rate of Positive Results not caused by Residues of Veterinary Drugs

Materials and Methods

In order to demonstrate that the BRT Inhibitor Test performs properly with a broad range of samples, the rate of positive results not caused by residues of veterinary drugs was established by analyzing 704 ex-farm bulk milk samples, originating from routine inhibitor analysis (milk quality payment testing at MPR Bayern). In order to verify the correct performance of the test all samples were examined in parallel on two different microbiological inhibitor tests (BRT MRL Screening Test and BRT hi-sense). To confirm detected inhibitors, screening-positive samples were tested a second time on the BRT Inhibitor Test, then evaluated with receptor tests (BetaStar® 100, Neogen Corporation, Lansing, USA; Charm MRL Beta-lactam 1-Minute Test, Charm Sciences Inc., Lawrence, USA; SNAP Beta-Lactam ST Plus, IDEXX GmbH, Ludwigsburg, Germany) and identified and quantified by analysis with the biosensor MCR-3 (GWK Präzisionstechnik GmbH, Munich, Germany). The MCR-3 is an antibody-based rapid micro-array chip reader, which is capable of the simultaneous detection and quantification of 13 antibiotic substances. Furthermore, confirmed inhibitor-positive samples were quantified by LC-MS/MS analysis.

Results and Discussion

2 out of 704 samples (0.28%, Table 12) were detected positive by the BRT Inhibitor Test. Both results were confirmed positive by evaluation with other inhibitor tests and receptor tests, the causative substance was identified as Cloxacillin by MCR-3- as well as LC-MS/MS-analysis. Cloxacillin was present in the samples at 64.8 µg/kg respectively 50.6 µg/kg. Thus, the rate of positive results not caused by residues of veterinary drugs was 0%, as all positive samples detected were confirmed to contain antibiotic inhibitors. The correct analysis of routine samples demonstrates the robust performance of the BRT Inhibitor Test with a broad range of samples and it's applicability for real-life laboratory use.

Table 12. Routine samples analysis results

| Total No. Samples | Negative Samples | | Positive Samples | | | |
|-------------------|------------------|--------|------------------|-------|----------------|--------------------|
| | No. | Rate | No. | Rate | False positive | Confirmed positive |
| 704 | 702 | 99.72% | 2 | 0.28% | 0% | 100% |

10) Participation in an international interlaboratory study and comparability

Materials and Methods

The BRT Inhibitor Test was validated in an international interlaboratory study in order to demonstrate its robust performance and suitability for real-life laboratory applications. This interlaboratory study was conducted in parallel with the international 10th proficiency test for inhibitors, organized by the QSE GmbH. 61

laboratories belonging to 55 companies - originating from 10 countries - out of 148 laboratories taking part in the 10th proficiency test, assisted with the examination of provided BRT Inhibitor Test plates for the interlaboratory study as a part of the validation.

Within the framework of the 10th proficiency test, 15 randomized and coded lyophilized UHT-milk samples were analyzed - 8 samples contained antibiotics, 7 samples consisted of inhibitor-free milk (Table 13). The antibiotics Penicillin G, Cloxacillin, Ampicillin and Cefapirin, which are often used for treatment of lactating cows, had to be detected at MRL level. These proficiency test sets were used for the interlaboratory study of the BRT Inhibitor Test, too.

The reported results of the interlaboratory study of the BRT Inhibitor Test and the 10th proficiency test were evaluated in parallel and compared in order to assess the performance of the validated test in correlation with other commonly used inhibitor tests (both microbiological and receptor tests).

Table 13. Composition of the proficiency test sets

| Substance | Concentration [$\mu\text{g}/\text{kg}$] | No. Samples |
|------------------|---|-------------|
| Benzympenicillin | 4 | 2 |
| Ampicillin | 4 | 2 |
| Cefapirin | 60 | 2 |
| Cloxacillin | 30 | 2 |
| - | - | 7 |

The participants of the interlaboratory study analyzed the coded samples with the BRT Inhibitor Test, reported the observed results in a supplied evaluation sheet and returned these sheets to the QSE GmbH, where the results were decoded. It was not reported by the laboratories which reading system was used for the examination of the test plates.

Results and Discussion

In total, 945 results were reported for the BRT Inhibitor Test by the interlaboratory study participants, 100% of these results were correct. No false-positive or false-negative results were observed (Figure 4).

This high rate of correct results obtained in different laboratories signifies once more that the BRT Inhibitor Test is suitable for routine analyses as all positive and negative samples were identified properly and all examined substances were detected at MRL level.




Figure 4. Rates of correct and false results (%) obtained by the interlaboratory study within the framework of the validation of the BRT Inhibitor Test

As part of a comparability study, the results obtained in the framework of the 10th proficiency test were contrasted with the results of the interlaboratory study of the BRT Inhibitor Test. 2,513 results for inhibitor-free milk and 2,872 results for inhibitor-positive samples were forwarded by the 10th proficiency test participants in total. The participating laboratories indicated if microbiological test systems or receptor tests had been used for the examination of the samples. Taking into account both types of test systems, 0.7% of the inhibitor-free milk samples were detected false-positive (Figure 5). Only 0.5% of the samples analyzed with microbiological test systems were reported false-positive (Figure 6), compared with 1.0% of the samples examined with receptor tests (Figure 7). Regarding the inhibitor-positive samples, 5% in total were identified as false-negative. Especially Cloxacillin (14.3%) and Ampicillin (3.3%), but also a few samples of Benzylpenicillin (1.7%) and Cefapirin (0.7%) were not identified correctly (Figure 5). The false-negative rate was higher for receptor test systems (6.9%) than for microbiological test systems (3.7%).




Figure 5. Rates of correct and false results (%) of all test systems (microbiological and receptor tests, 10th proficiency test)

Compared with other tests evaluated in the context of the 10th proficiency test, the BRT Inhibitor Test demonstrated an excellent performance, as no false results were observed within the interlaboratory study.




Figure 6. Rates of correct and false results (%) of microbiological test systems (10th proficiency test)




Figure 7. Rates of correct and false results (%) of receptor test systems (10th proficiency test)

11) Conclusions

The BRT Inhibitor Test is capable of the detection of all of the 7 penicillins and 4 out of 7 cephalosporins as well as 6 out of 15 compounds belonging to other antibiotic groups investigated in this study at or below MRL level – depending on the interpretation method. This means that the most important antibiotic compounds used in Germany for the treatment of dairy cows are detected predominantly below MRL. A broad range of other inhibitors can be identified above MRL as well. The BRT Inhibitor Test displays a high selectivity for antibiotic residues, marker substances of other veterinary classes were not detected at high concentrations. The Batch-to-Batch-Variability proved to be low, no significant differences were observed for positive result rates obtained with different plate batches. The validity of obtained results is high as no false-positive and an extremely low rate of false-negative results were observed in the analysis of positive and negative control samples. With the correct analysis of a broad range of routine milk quality payment samples, the good performance of the BRT Inhibitor Test in an international interlaboratory study (100% correct results) and in comparison with other inhibitor tests used by laboratories participating in an international proficiency test, which was organized in parallel, it could be demonstrated that the test is fit for routine laboratory use.

12) References

COMMISSION DECISION C1 14 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results (notified under document number C (2002) 3044) (Text with EEA relevance) (2002/657/EC) OJ L 221, 17.8.2002, p. 8

COMMUNITY REFERENCE LABORATORIES RESIDUES (CRLs) 20/1/2010 - Guidelines for the validation of screening methods for residues of veterinary medicines (initial validation and transfer)

ISO 13969 IDF 183 Milk and Milk products - Guidelines for a standardized description of microbial inhibitor tests

ISO 18330 IDF 188 Milk and milk products - Guidelines for the standardized description of immunoassays or receptor assays for the detection of antimicrobial residues

German Federal Office of Consumer Protection and Food Safety
Amtliche Sammlung von Untersuchungsverfahren nach § 64 LFGB (vormals §35 LMBG) Band 1 (L), L 01.01-5: Nachweis von Hemmstoffen in Sammelmilch, Agar-Diffusions-Verfahren (Brillantschwarz-Reduktionstest), Januar 2012

German Federal Office of Consumer Protection and Food Safety
Amtliche Sammlung von Untersuchungsverfahren nach § 64 LFGB (vormals §35 LMBG) Band 1 (L), L 01.00-11: Suchverfahren auf das Vorhandensein von Antiinfektiva in Milch, Agar-Diffusions-Verfahren mit *Bacillus stearothermophilus* (Brillantschwarz-Reduktionstest), Februar 1996

BEER, P. and G. SUHREN (1993): Approach for an inhibitor test kit validation program, IDF-Workshop on Residues of Antibiotics and Other Antimicrobial Inhibitors in Raw and Heat-Treated Milk, Copenhagen, collected abstracts

R Core Team, 2018. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>

AOAC Binary Data Interlaboratory Study Workbook Version 2.3

QSE GmbH, 2017: 10th proficiency test for inhibitors, Final report

13) Acknowledgements

Authors and responsible persons:

Dr. Christian Baumgartner (Milchprüfing Bayern e. V.) and Dr. Silvia Orlandini (AEOS)

The authors acknowledge the manufacturer's staff for providing all the necessary equipment and the initial training in the preliminary phase of the validation study as well as the staff of MPR Bayern, who were involved in the validation study, Christine Habel and Kerstin Karl.



Accredited laboratory according to ISO/IEC 17025



COPYRIGHT

No part of the publication (scientific data, graphs, images, etc.) protected by this copyright notice may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage and retrieval system, without written permission from the copyright owner.
All rights reserved.





© Milchprüfing Bayern e. V.
Hochstatt 2, 85283 Wolnzach, Germany
Tel: +49 8442 210, Fax: +49 8444 5210
E-Mail: validation@mpr-bayern.de





Date of publication: 09.11.2018





ANNEX





Annex Table 1. Established detection limits (visual reading) compared with the EU MRL levels. Marked in red are the substances exceeding the EU MRLs.





| Group of Antibiotics | Substance | MRL EU [$\mu\text{g}/\text{kg}$] | CC β A [$\mu\text{g}/\text{kg}$] | CC β B [$\mu\text{g}/\text{kg}$] |
|------------------------|------------------------|------------------------------------|--|--|
| Penicillins | Benzylpenicillin | 4 | 2.5 | 2 |
| | Ampicillin | 4 | 3.5 | 3 |
| | Amoxicillin | 4 | 3.5 | 3 |
| | Cloxacillin | 30 | 30 | 25 |
| | Dicloxacillin | 30 | 15 | 12.5 |
| | Nafcillin | 30 | 15 | 8 |
| | Oxacillin | 30 | 12 | 10 |
| Cephalosporins | Cefalexin | 100 | 500 | 400 |
| | Cefapirin | 60 | 8 | 5 |
| | Cefoperazone | 50 | 35 | 25 |
| | Cefazolin | 50 | 9 | 7 |
| | Cefquinome | 20 | 600 | 300 |
| | Ceftiofur | 100 | 250 | 200 |
| | Cefalonium | 20 | 16 | 12 |
| Macrolides | Erythromycin | 40 | 100 | 60 |
| | Tylosin | 50 | 100 | 30 |
| Sulfonamides | Sulfadiazine | 100 | >800 | 100 |
| | Sulfadimethoxin | 100 | >800 | 200 |
| | Sulfamethazine | 100 | >1,000 | 200 |
| | Sulfathiazol | 100 | 400 | 60 |
| | Sulfadoxin | 100 | >1,500 | 400 |
| | Sulfamethoxypyridazine | 100 | 500 | 100 |
| Tetracyclines | Chlortetracycline | 100 | >1,000 | 800 |
| | Oxytetracycline | 100 | 800 | 400 |
| | Tetracycline | 100 | 1,000 | 600 |
| Aminoglycosides | Dihydrostreptomycin | 200 | 500 | 400 |
| | Streptomycin | 200 | 1,500 | 600 |
| | Gentamicin | 100 | 150 | 80 |
| | Neomycin | 1,500 | 300 | 200 |
| Fenicol | Chloramphenicol | - | 5,000 | 3,500 |




















Annex Figure 1. Dose-response curves of antibiotic substances included in the validation of the BRT Inhibitor Test. Red line = dose-response curve; red shade = CI; Black line = CCβA (photometric reading); Dotted line = highest concentration analyzed

Annex Table 2. Numbers and percentages of results per concentrations of samples for each class of results (1-2-0) and both reading systems (photometric and visual) separately as well as joint for both reading systems including the CI for class A results.

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC β A | Lower 95%-CI (CC β A) | Upper 95%-CI (CC β A) | No. of Results (pos. Class B) | Percentage of CC β B | No. of Results (negative) |
|------------------|----------------------|---------------|----------------------|-------------------------------|----------------------------|-----------------------------|-----------------------------|-------------------------------|----------------------------|---------------------------|
| Benzylpenicillin | Photometric | 0.5 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 0.75 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 1 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 1.5 | 80 | 0 | 0.00 | - | - | 26 | 0.33 | 54 |
| | | 2 | 80 | 68 | 0.85 | - | - | 12 | 1.00 | 0 |
| | | 2.5 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 3 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 0.5 | 120 | 0 | 0.00 | - | - | 2 | 0.02 | 118 |
| | | 0.75 | 120 | 0 | 0.00 | - | - | 1 | 0.01 | 119 |
| | | 1 | 120 | 0 | 0.00 | - | - | 6 | 0.05 | 114 |
| | | 1.5 | 120 | 0 | 0.00 | - | - | 60 | 0.50 | 60 |
| | | 2 | 120 | 83 | 0.69 | - | - | 37 | 1.00 | 0 |
| | | 2.5 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 3 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 0.5 | 200 | 0 | 0.00 | 0.00 | 0.02 | 2 | - | 198 |
| | | 0.75 | 200 | 0 | 0.00 | 0.00 | 0.02 | 1 | - | 199 |
| | | 1 | 200 | 0 | 0.00 | 0.00 | 0.02 | 6 | - | 194 |
| | | 1.5 | 200 | 0 | 0.00 | 0.00 | 0.02 | 86 | - | 114 |
| 2 | | 200 | 151 | 0.76 | 0.42 | 1.00 | 49 | - | 0 | |
| 2.5 | | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| 3 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| Ampicillin | Photometric | 1 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 1.5 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 2 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 2.5 | 80 | 0 | 0.00 | - | - | 17 | 0.21 | 63 |
| | | 3 | 80 | 3 | 0.04 | - | - | 77 | 1.00 | 0 |
| | | 3.5 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 4 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 1 | 120 | 0 | 0.00 | - | - | 0 | 0.00 | 120 |
| | | 1.5 | 120 | 0 | 0.00 | - | - | 0 | 0.00 | 120 |
| | | 2 | 120 | 0 | 0.00 | - | - | 1 | 0.01 | 119 |
| | | 2.5 | 120 | 0 | 0.00 | - | - | 32 | 0.27 | 88 |
| | | 3 | 120 | 27 | 0.23 | - | - | 90 | 0.98 | 3 |
| | | 3.5 | 120 | 119 | 0.99 | - | - | 1 | 1.00 | 0 |
| | 4 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 1 | 200 | 0 | 0.00 | 0.00 | 0.02 | 0 | - | 200 |
| | | 1.5 | 200 | 0 | 0.00 | 0.00 | 0.02 | 0 | - | 200 |
| | | 2 | 200 | 0 | 0.00 | 0.00 | 0.02 | 1 | - | 199 |
| | | 2.5 | 200 | 0 | 0.00 | 0.00 | 0.02 | 49 | - | 151 |
| 3 | | 200 | 30 | 0.15 | 0.00 | 0.44 | 167 | - | 3 | |
| 3.5 | | 200 | 199 | 1.00 | 0.97 | 1.00 | 1 | - | 0 | |
| 4 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| Amoxicillin | Photometric | 1.5 | 128 | 0 | 0.00 | - | - | 0 | 0.00 | 128 |
| | | 2 | 128 | 0 | 0.00 | - | - | 6 | 0.05 | 122 |
| | | 2.5 | 128 | 0 | 0.00 | - | - | 126 | 0.98 | 2 |
| | | 3 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 3.5 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 4 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 4.5 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 1.5 | 192 | 0 | 0.00 | - | - | 0 | 0.00 | 192 |
| | | 2 | 192 | 0 | 0.00 | - | - | 0 | 0.00 | 192 |
| | | 2.5 | 192 | 0 | 0.00 | - | - | 142 | 0.74 | 50 |
| | | 3 | 192 | 179 | 0.93 | - | - | 13 | 1.00 | 0 |
| | | 3.5 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 4 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 4.5 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 1.5 | 320 | 0 | 0.00 | 0.00 | 0.01 | 0 | - | 320 |
| | | 2 | 320 | 0 | 0.00 | 0.00 | 0.01 | 6 | - | 314 |
| | | 2.5 | 320 | 0 | 0.00 | 0.00 | 0.01 | 268 | - | 52 |
| | | 3 | 320 | 307 | 0.96 | 0.93 | 0.98 | 13 | - | 0 |
| 3.5 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 4 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 4.5 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | |
| Cloxacillin | Photometric | 16 | 128 | 0 | 0.00 | - | - | 0 | 0.00 | 128 |
| | | 18 | 128 | 2 | 0.02 | - | - | 85 | 0.68 | 41 |
| | | 20 | 128 | 0 | 0.00 | - | - | 124 | 0.97 | 4 |
| | | 25 | 128 | 126 | 0.98 | - | - | 2 | 1.00 | 0 |
| | | 30 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 35 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 40 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 16 | 192 | 0 | 0.00 | - | - | 1 | 0.01 | 191 |
| | | 18 | 192 | 3 | 0.02 | - | - | 42 | 0.23 | 147 |
| | | 20 | 192 | 1 | 0.01 | - | - | 167 | 0.88 | 24 |
| | | 25 | 192 | 161 | 0.84 | - | - | 31 | 1.00 | 0 |
| | | 30 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 35 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 40 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 16 | 320 | 0 | 0.00 | 0.00 | 0.01 | 1 | - | 319 |
| | | 18 | 320 | 5 | 0.02 | 0.01 | 0.04 | 127 | - | 188 |
| | | 20 | 320 | 1 | 0.00 | 0.00 | 0.02 | 291 | - | 28 |
| | | 25 | 320 | 287 | 0.90 | 0.86 | 0.93 | 33 | - | 0 |
| 30 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 35 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 40 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC β A | Lower 95%- CI (CC β A) | Upper 95%- CI (CC β A) | No. of Results (pos. Class B) | Percentage of CC β B | No. of Results (negative) |
|---------------|----------------------|---------------|----------------------|-------------------------------|----------------------------|------------------------------|------------------------------|-------------------------------|----------------------------|---------------------------|
| Dicloxacillin | Photometric | 6 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 8 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 10 | 80 | 0 | 0.00 | - | - | 12 | 0.15 | 68 |
| | | 12.5 | 80 | 17 | 0.21 | - | - | 63 | 1.00 | 0 |
| | | 15 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 17.5 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 20 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 6 | 120 | 0 | 0.00 | - | - | 8 | 0.07 | 112 |
| | | 8 | 120 | 0 | 0.00 | - | - | 10 | 0.08 | 110 |
| | | 10 | 120 | 0 | 0.00 | - | - | 36 | 0.30 | 84 |
| | | 12.5 | 120 | 33 | 0.28 | - | - | 86 | 0.99 | 1 |
| | | 15 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 17.5 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 20 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 6 | 200 | 0 | 0.00 | 0.00 | 0.02 | 8 | - | 192 |
| | | 8 | 200 | 0 | 0.00 | 0.00 | 0.02 | 10 | - | 190 |
| | | 10 | 200 | 0 | 0.00 | 0.00 | 0.02 | 48 | - | 152 |
| | | 12.5 | 200 | 50 | 0.25 | 0.18 | 0.32 | 149 | - | 1 |
| 15 | | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| 17.5 | | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| 20 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| Nafcillin | Photometric | 3 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 4 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 5 | 80 | 0 | 0.00 | - | - | 1 | 0.01 | 79 |
| | | 6 | 80 | 0 | 0.00 | - | - | 2 | 0.03 | 78 |
| | | 8 | 80 | 0 | 0.00 | - | - | 61 | 0.76 | 19 |
| | | 10 | 80 | 30 | 0.38 | - | - | 50 | 1.00 | 0 |
| | 15 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 3 | 120 | 0 | 0.00 | - | - | 6 | 0.05 | 114 |
| | | 4 | 120 | 0 | 0.00 | - | - | 15 | 0.13 | 105 |
| | | 5 | 120 | 1 | 0.01 | - | - | 34 | 0.29 | 85 |
| | | 6 | 120 | 0 | 0.00 | - | - | 59 | 0.49 | 61 |
| | | 8 | 120 | 12 | 0.10 | - | - | 102 | 0.95 | 6 |
| | | 10 | 120 | 79 | 0.66 | - | - | 41 | 1.00 | 0 |
| | 15 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 3 | 200 | 0 | 0.00 | 0.00 | 0.02 | 6 | - | 194 |
| | | 4 | 200 | 0 | 0.00 | 0.00 | 0.02 | 15 | - | 185 |
| | | 5 | 200 | 1 | 0.01 | 0.00 | 0.03 | 35 | - | 164 |
| | | 6 | 200 | 0 | 0.00 | 0.00 | 0.02 | 61 | - | 139 |
| 8 | | 200 | 12 | 0.06 | 0.03 | 0.10 | 163 | - | 25 | |
| 10 | | 200 | 109 | 0.55 | 0.01 | 1.00 | 91 | - | 0 | |
| 15 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| Oxacillin | Photometric | 2 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 4 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 6 | 80 | 0 | 0.00 | - | - | 2 | 0.03 | 78 |
| | | 8 | 80 | 0 | 0.00 | - | - | 80 | 1.00 | 0 |
| | | 10 | 80 | 79 | 0.99 | - | - | 1 | 1.00 | 0 |
| | | 12 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 15 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 2 | 120 | 0 | 0.00 | - | - | 4 | 0.03 | 116 |
| | | 4 | 120 | 0 | 0.00 | - | - | 3 | 0.03 | 117 |
| | | 6 | 120 | 0 | 0.00 | - | - | 41 | 0.34 | 79 |
| | | 8 | 120 | 9 | 0.08 | - | - | 102 | 0.93 | 9 |
| | | 10 | 120 | 112 | 0.93 | - | - | 8 | 1.00 | 0 |
| | | 12 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 15 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 2 | 200 | 0 | 0.00 | 0.00 | 0.02 | 4 | - | 196 |
| | | 4 | 200 | 0 | 0.00 | 0.00 | 0.02 | 3 | - | 197 |
| | | 6 | 200 | 0 | 0.00 | 0.00 | 0.02 | 43 | - | 157 |
| | | 8 | 200 | 9 | 0.05 | 0.02 | 0.08 | 182 | - | 9 |
| 10 | | 200 | 191 | 0.96 | 0.92 | 0.98 | 9 | - | 0 | |
| 12 | | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| 15 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| Cefalexin | Photometric | 100 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 150 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 200 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 250 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 300 | 48 | 0 | 0.00 | - | - | 48 | 1.00 | 0 |
| | | 400 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 500 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 100 | 72 | 0 | 0.00 | - | - | 1 | 0.01 | 71 |
| | | 150 | 72 | 0 | 0.00 | - | - | 1 | 0.01 | 71 |
| | | 200 | 72 | 0 | 0.00 | - | - | 7 | 0.10 | 65 |
| | | 250 | 72 | 0 | 0.00 | - | - | 10 | 0.14 | 62 |
| | | 300 | 72 | 0 | 0.00 | - | - | 39 | 0.54 | 33 |
| | | 400 | 72 | 42 | 0.58 | - | - | 30 | 1.00 | 0 |
| | 500 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 100 | 120 | 0 | 0.00 | 0.00 | 0.03 | 1 | - | 119 |
| | | 150 | 120 | 0 | 0.00 | 0.00 | 0.03 | 1 | - | 119 |
| | | 200 | 120 | 0 | 0.00 | 0.00 | 0.03 | 7 | - | 113 |
| | | 250 | 120 | 0 | 0.00 | 0.00 | 0.03 | 10 | - | 110 |
| 300 | | 120 | 0 | 0.00 | 0.00 | 0.03 | 87 | - | 33 | |
| 400 | | 120 | 90 | 0.75 | 0.24 | 1.00 | 30 | - | 0 | |
| 500 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC&A | Lower 95%- CI (CC&A) | Upper 95%- CI (CC&A) | No. of Results (pos. Class B) | Percentage of CC&B | No. of Results (negative) | | |
|--------------|----------------------|---------------|----------------------|-------------------------------|--------------------|----------------------|----------------------|-------------------------------|--------------------|---------------------------|------|-----|
| | Photometric | 2 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 | | |
| | | 3 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 | | |
| | | 4 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 | | |
| | | 5 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 | | |
| | | 6 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | 8 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | 10 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | Cefapirin | Visual | 2 | 63 | 0 | 0.00 | - | - | 1 | 0.02 | 62 |
| | | | | 3 | 63 | 0 | 0.00 | - | - | 9 | 0.14 | 54 |
| | | | | 4 | 63 | 0 | 0.00 | - | - | 9 | 0.14 | 54 |
| 5 | 63 | | | 14 | 0.22 | - | - | 49 | 1.00 | 0 | | |
| 6 | 63 | | | 56 | 0.89 | - | - | 7 | 1.00 | 0 | | |
| 8 | 63 | | | 63 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 10 | 63 | | | 63 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Photometric + Visual | | | 2 | 105 | 0 | 0.00 | 0.00 | 0.04 | 1 | - | 104 |
| | | | | 3 | 105 | 0 | 0.00 | 0.00 | 0.04 | 9 | - | 96 |
| | | | | 4 | 105 | 0 | 0.00 | 0.00 | 0.04 | 9 | - | 96 |
| | | 5 | 105 | 14 | 0.13 | 0.08 | 0.21 | 91 | - | 0 | | |
| | | 6 | 105 | 98 | 0.93 | 0.87 | 0.97 | 7 | - | 0 | | |
| | | 8 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| | | 10 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| | | | Photometric | 10 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | | | 15 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | | | 20 | 80 | 0 | 0.00 | - | - | 11 | 0.14 | 69 |
| 25 | 80 | | | 0 | 0.00 | - | - | 80 | 1.00 | 0 | | |
| 30 | 80 | | | 52 | 0.65 | - | - | 28 | 1.00 | 0 | | |
| 35 | 80 | | | 80 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 40 | 80 | | | 80 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Cefoperazone | Visual | | | 10 | 120 | 0 | 0.00 | - | - | 5 | 0.04 | 115 |
| | | | | 15 | 120 | 0 | 0.00 | - | - | 16 | 0.13 | 104 |
| | | | | 20 | 120 | 1 | 0.01 | - | - | 74 | 0.63 | 45 |
| | | 25 | 120 | 35 | 0.29 | - | - | 83 | 0.98 | 2 | | |
| | | 30 | 120 | 89 | 0.74 | - | - | 31 | 1.00 | 0 | | |
| | | 35 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | 40 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | | Photometric + Visual | 10 | 200 | 0 | 0.00 | 0.00 | 0.02 | 5 | - | 195 |
| | | | | 15 | 200 | 0 | 0.00 | 0.00 | 0.02 | 16 | - | 184 |
| | | | | 20 | 200 | 1 | 0.01 | 0.00 | 0.03 | 85 | - | 114 |
| 25 | 200 | | | 35 | 0.18 | 0.00 | 0.64 | 163 | - | 2 | | |
| 30 | 200 | | | 141 | 0.71 | 0.34 | 1.00 | 59 | - | 0 | | |
| 35 | 200 | | | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| 40 | 200 | | | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| | Photometric | | | 4 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | | | 5 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | | | 6 | 42 | 0 | 0.00 | - | - | 4 | 0.10 | 38 |
| | | 7 | 42 | 1 | 0.02 | - | - | 41 | 1.00 | 0 | | |
| | | 8 | 42 | 28 | 0.67 | - | - | 14 | 1.00 | 0 | | |
| | | 9 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | 10 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | Cefazolin | Visual | 4 | 63 | 0 | 0.00 | - | - | 2 | 0.03 | 61 |
| | | | | 5 | 63 | 0 | 0.00 | - | - | 6 | 0.10 | 57 |
| | | | | 6 | 63 | 0 | 0.00 | - | - | 16 | 0.25 | 47 |
| 7 | 63 | | | 4 | 0.06 | - | - | 58 | 0.98 | 1 | | |
| 8 | 63 | | | 35 | 0.56 | - | - | 28 | 1.00 | 0 | | |
| 9 | 63 | | | 63 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 10 | 63 | | | 63 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Photometric + Visual | | | 4 | 105 | 0 | 0.00 | 0.00 | 0.04 | 2 | - | 103 |
| | | | | 5 | 105 | 0 | 0.00 | 0.00 | 0.04 | 6 | - | 99 |
| | | | | 6 | 105 | 0 | 0.00 | 0.00 | 0.04 | 20 | - | 85 |
| | | 7 | 105 | 5 | 0.05 | 0.02 | 0.11 | 99 | - | 1 | | |
| | | 8 | 105 | 63 | 0.60 | 0.16 | 1.00 | 42 | - | 0 | | |
| | | 9 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| | | 10 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| | | | Photometric | 100 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | | | 200 | 42 | 0 | 0.00 | - | - | 7 | 0.17 | 35 |
| | | | | 300 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| 400 | 42 | | | 14 | 0.33 | - | - | 28 | 1.00 | 0 | | |
| 500 | 42 | | | 42 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 600 | 42 | | | 42 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 700 | 42 | | | 42 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Cefquinome | Visual | | | 100 | 63 | 0 | 0.00 | - | - | 5 | 0.08 | 58 |
| | | | | 200 | 63 | 0 | 0.00 | - | - | 40 | 0.63 | 23 |
| | | | | 300 | 63 | 8 | 0.13 | - | - | 55 | 1.00 | 0 |
| | | 400 | 63 | 41 | 0.65 | - | - | 22 | 1.00 | 0 | | |
| | | 500 | 63 | 49 | 0.78 | - | - | 14 | 1.00 | 0 | | |
| | | 600 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | 700 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | | Photometric + Visual | 100 | 105 | 0 | 0.00 | 0.00 | 0.04 | 5 | - | 100 |
| | | | | 200 | 105 | 0 | 0.00 | 0.00 | 0.04 | 47 | - | 58 |
| | | | | 300 | 105 | 8 | 0.08 | 0.04 | 0.14 | 97 | - | 0 |
| 400 | 105 | | | 55 | 0.52 | 0.00 | 1.00 | 50 | - | 0 | | |
| 500 | 105 | | | 91 | 0.87 | 0.79 | 0.92 | 14 | - | 0 | | |
| 600 | 105 | | | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| 700 | 105 | | | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC&A | Lower 95%- CI (CC&A) | Upper 95%- CI (CC&A) | No. of Results (pos. Class B) | Percentage of CC&B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|--------------------|----------------------|----------------------|-------------------------------|--------------------|---------------------------|
| Ceftiofur | Photometric | 100 | 128 | 7 | 0.05 | - | - | 101 | 0.84 | 20 |
| | | 150 | 128 | 64 | 0.50 | - | - | 62 | 0.98 | 2 |
| | | 200 | 128 | 122 | 0.95 | - | - | 6 | 1.00 | 0 |
| | | 250 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 300 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 360 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 460 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 100 | 192 | 2 | 0.01 | - | - | 118 | 0.63 | 72 |
| | | 150 | 192 | 80 | 0.42 | - | - | 81 | 0.84 | 31 |
| | | 200 | 192 | 175 | 0.91 | - | - | 17 | 1.00 | 0 |
| | | 250 | 192 | 186 | 0.97 | - | - | 6 | 1.00 | 0 |
| | | 300 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 360 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 460 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 100 | 320 | 9 | 0.03 | 0.01 | 0.05 | 219 | - | 92 |
| | | 150 | 320 | 144 | 0.45 | 0.26 | 0.64 | 143 | - | 33 |
| | | 200 | 320 | 297 | 0.93 | 0.89 | 0.95 | 23 | - | 0 |
| | | 250 | 320 | 314 | 0.98 | 0.96 | 0.99 | 6 | - | 0 |
| | | 300 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 |
| | | 360 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 |
| | 460 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Cefalonium | Photometric | 6 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 8 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 10 | 80 | 0 | 0.00 | - | - | 6 | 0.08 | 74 |
| | | 12 | 80 | 1 | 0.01 | - | - | 79 | 1.00 | 0 |
| | | 14 | 80 | 79 | 0.99 | - | - | 1 | 1.00 | 0 |
| | | 16 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 20 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 6 | 120 | 0 | 0.00 | - | - | 1 | 0.01 | 119 |
| | | 8 | 120 | 0 | 0.00 | - | - | 10 | 0.08 | 110 |
| | | 10 | 120 | 0 | 0.00 | - | - | 43 | 0.36 | 77 |
| | | 12 | 120 | 25 | 0.21 | - | - | 93 | 0.98 | 2 |
| | | 14 | 120 | 103 | 0.86 | - | - | 17 | 1.00 | 0 |
| 16 | | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 20 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Photometric + Visual | 6 | 200 | 0 | 0.00 | 0.00 | 0.02 | 1 | - | 199 | |
| | 8 | 200 | 0 | 0.00 | 0.00 | 0.02 | 10 | - | 190 | |
| | 10 | 200 | 0 | 0.00 | 0.00 | 0.02 | 49 | - | 151 | |
| | 12 | 200 | 26 | 0.13 | 0.09 | 0.18 | 172 | - | 2 | |
| | 14 | 200 | 182 | 0.91 | 0.86 | 0.94 | 18 | - | 0 | |
| | 16 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| 20 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| Erythromycin | Photometric | 30 | 128 | 0 | 0.00 | - | - | 32 | 0.25 | 96 |
| | | 40 | 128 | 0 | 0.00 | - | - | 93 | 0.73 | 35 |
| | | 50 | 128 | 5 | 0.04 | - | - | 123 | 1.00 | 0 |
| | | 60 | 128 | 13 | 0.10 | - | - | 115 | 1.00 | 0 |
| | | 80 | 128 | 119 | 0.93 | - | - | 9 | 1.00 | 0 |
| | | 100 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 120 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 30 | 192 | 2 | 0.01 | - | - | 30 | 0.17 | 160 |
| | | 40 | 192 | 6 | 0.03 | - | - | 142 | 0.77 | 44 |
| | | 50 | 192 | 22 | 0.11 | - | - | 154 | 0.92 | 16 |
| | | 60 | 192 | 40 | 0.21 | - | - | 151 | 0.99 | 1 |
| | | 80 | 192 | 162 | 0.84 | - | - | 30 | 1.00 | 0 |
| 100 | | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 120 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Photometric + Visual | 30 | 320 | 2 | 0.01 | 0.00 | 0.02 | 62 | - | 256 | |
| | 40 | 320 | 6 | 0.02 | 0.01 | 0.04 | 235 | - | 79 | |
| | 50 | 320 | 27 | 0.08 | 0.06 | 0.12 | 277 | - | 16 | |
| | 60 | 320 | 53 | 0.17 | 0.00 | 0.42 | 266 | - | 1 | |
| | 80 | 320 | 281 | 0.88 | 0.84 | 0.91 | 39 | - | 0 | |
| | 100 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 120 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | |
| Tylosin | Photometric | 20 | 128 | 0 | 0.00 | - | - | 0 | 0.00 | 128 |
| | | 30 | 128 | 0 | 0.00 | - | - | 106 | 0.83 | 22 |
| | | 40 | 128 | 2 | 0.02 | - | - | 126 | 1.00 | 0 |
| | | 50 | 128 | 1 | 0.01 | - | - | 127 | 1.00 | 0 |
| | | 75 | 128 | 126 | 0.98 | - | - | 2 | 1.00 | 0 |
| | | 100 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 120 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 20 | 192 | 0 | 0.00 | - | - | 25 | 0.13 | 167 |
| | | 30 | 192 | 1 | 0.01 | - | - | 189 | 0.99 | 2 |
| | | 40 | 192 | 24 | 0.13 | - | - | 168 | 1.00 | 0 |
| | | 50 | 192 | 59 | 0.31 | - | - | 133 | 1.00 | 0 |
| | | 75 | 192 | 147 | 0.77 | - | - | 45 | 1.00 | 0 |
| 100 | | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 120 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Photometric + Visual | 20 | 320 | 0 | 0.00 | 0.00 | 0.01 | 25 | - | 295 | |
| | 30 | 320 | 1 | 0.00 | 0.00 | 0.02 | 295 | - | 24 | |
| | 40 | 320 | 26 | 0.08 | 0.06 | 0.12 | 294 | - | 0 | |
| | 50 | 320 | 60 | 0.19 | 0.00 | 0.70 | 260 | - | 0 | |
| | 75 | 320 | 273 | 0.85 | 0.81 | 0.89 | 47 | - | 0 | |
| | 100 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 120 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC&A | Lower 95%- CI (CC&A) | Upper 95%- CI (CC&A) | No. of Results (pos. Class B) | Percentage of CC&B | No. of Results (negative) | |
|----------------------|----------------------|------------------|----------------------|-------------------------------|--------------------|----------------------|----------------------|-------------------------------|--------------------|---------------------------|------|
| Sulfadiazine | Photometric | 50 | 128 | 0 | 0.00 | - | - | 12 | 0.09 | 116 | |
| | | 100 | 128 | 0 | 0.00 | - | - | 123 | 0.96 | 5 | |
| | | 200 | 128 | 3 | 0.02 | - | - | 125 | 1.00 | 0 | |
| | | 300 | 128 | 0 | 0.00 | - | - | 128 | 1.00 | 0 | |
| | | 400 | 128 | 12 | 0.09 | - | - | 116 | 1.00 | 0 | |
| | | 600 | 128 | 49 | 0.38 | - | - | 79 | 1.00 | 0 | |
| | | 800 | 128 | 95 | 0.74 | - | - | 33 | 1.00 | 0 | |
| | | 50 | 192 | 0 | 0.00 | - | - | 44 | 0.23 | 148 | |
| | 100 | 192 | 10 | 0.05 | - | - | 176 | 0.97 | 6 | | |
| | 200 | 192 | 77 | 0.40 | - | - | 115 | 1.00 | 0 | | |
| | 300 | 192 | 109 | 0.57 | - | - | 83 | 1.00 | 0 | | |
| | 400 | 192 | 128 | 0.67 | - | - | 64 | 1.00 | 0 | | |
| | 600 | 192 | 128 | 0.67 | - | - | 64 | 1.00 | 0 | | |
| | 800 | 192 | 130 | 0.68 | - | - | 62 | 1.00 | 0 | | |
| | Photometric + Visual | 50 | 320 | 0 | 0.00 | 0.00 | 0.01 | 56 | - | 264 | |
| | | 100 | 320 | 10 | 0.03 | 0.02 | 0.06 | 299 | - | 11 | |
| | | 200 | 320 | 80 | 0.25 | 0.00 | 0.65 | 240 | - | 0 | |
| | | 300 | 320 | 109 | 0.34 | 0.00 | 0.92 | 211 | - | 0 | |
| | | 400 | 320 | 140 | 0.44 | 0.00 | 1.00 | 180 | - | 0 | |
| | | 600 | 320 | 177 | 0.55 | 0.01 | 1.00 | 143 | - | 0 | |
| | | 800 | 320 | 225 | 0.70 | 0.21 | 1.00 | 95 | - | 0 | |
| | | Sulfadi-methoxin | Photometric | 50 | 128 | 0 | 0.00 | - | - | 8 | 0.06 |
| | 100 | | | 128 | 0 | 0.00 | - | - | 116 | 0.91 | 12 |
| | 200 | | | 128 | 0 | 0.00 | - | - | 128 | 1.00 | 0 |
| 300 | 128 | | | 13 | 0.10 | - | - | 115 | 1.00 | 0 | |
| 400 | 128 | | | 27 | 0.21 | - | - | 101 | 1.00 | 0 | |
| 600 | 128 | | | 73 | 0.57 | - | - | 55 | 1.00 | 0 | |
| 800 | 128 | | | 102 | 0.80 | - | - | 26 | 1.00 | 0 | |
| 50 | 192 | | | 0 | 0.00 | - | - | 53 | 0.28 | 139 | |
| 100 | 192 | 4 | 0.02 | - | - | 173 | 0.92 | 15 | | | |
| 200 | 192 | 68 | 0.35 | - | - | 122 | 0.99 | 2 | | | |
| 300 | 192 | 126 | 0.66 | - | - | 66 | 1.00 | 0 | | | |
| 400 | 192 | 128 | 0.67 | - | - | 64 | 1.00 | 0 | | | |
| 600 | 192 | 127 | 0.66 | - | - | 65 | 1.00 | 0 | | | |
| 800 | 192 | 128 | 0.67 | - | - | 64 | 1.00 | 0 | | | |
| Photometric + Visual | 50 | 320 | 0 | 0.00 | 0.00 | 0.01 | 61 | - | 259 | | |
| | 100 | 320 | 4 | 0.01 | 0.00 | 0.03 | 289 | - | 27 | | |
| | 200 | 320 | 68 | 0.21 | 0.00 | 0.58 | 250 | - | 2 | | |
| | 300 | 320 | 139 | 0.43 | 0.00 | 1.00 | 181 | - | 0 | | |
| | 400 | 320 | 155 | 0.48 | 0.00 | 1.00 | 165 | - | 0 | | |
| | 600 | 320 | 200 | 0.63 | 0.11 | 1.00 | 120 | - | 0 | | |
| | 800 | 320 | 230 | 0.72 | 0.20 | 1.00 | 90 | - | 0 | | |
| | Sulfametha-zine | Photometric | 50 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| 100 | | | 42 | 0 | 0.00 | - | - | 8 | 0.19 | 34 | |
| 200 | | | 42 | 0 | 0.00 | - | - | 39 | 0.93 | 3 | |
| 300 | | | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 | |
| 500 | | | 42 | 5 | 0.12 | - | - | 37 | 1.00 | 0 | |
| 750 | | | 42 | 14 | 0.33 | - | - | 28 | 1.00 | 0 | |
| 1,000 | | | 42 | 41 | 0.98 | - | - | 1 | 1.00 | 0 | |
| 50 | | 63 | 0 | 0.00 | - | - | 6 | 0.10 | 57 | | |
| 100 | | 63 | 0 | 0.00 | - | - | 54 | 0.86 | 9 | | |
| 200 | | 63 | 7 | 0.11 | - | - | 55 | 0.98 | 1 | | |
| 300 | 63 | 16 | 0.25 | - | - | 47 | 1.00 | 0 | | | |
| 500 | 63 | 44 | 0.70 | - | - | 19 | 1.00 | 0 | | | |
| 750 | 63 | 42 | 0.67 | - | - | 21 | 1.00 | 0 | | | |
| 1,000 | 63 | 42 | 0.67 | - | - | 21 | 1.00 | 0 | | | |
| Photometric + Visual | 50 | 105 | 0 | 0.00 | 0.00 | 0.04 | 6 | - | 99 | | |
| | 100 | 105 | 0 | 0.00 | 0.00 | 0.04 | 62 | - | 43 | | |
| | 200 | 105 | 7 | 0.07 | 0.03 | 0.13 | 94 | - | 4 | | |
| | 300 | 105 | 16 | 0.15 | 0.00 | 0.47 | 89 | - | 0 | | |
| | 500 | 105 | 49 | 0.47 | 0.00 | 1.00 | 56 | - | 0 | | |
| | 750 | 105 | 56 | 0.53 | 0.00 | 1.00 | 49 | - | 0 | | |
| | 1,000 | 105 | 83 | 0.79 | 0.24 | 1.00 | 22 | - | 0 | | |
| Sulfathiazol | Photometric | 40 | 128 | 0 | 0.00 | - | - | 86 | 0.67 | 42 | |
| | | 60 | 128 | 0 | 0.00 | - | - | 126 | 0.98 | 2 | |
| | | 80 | 128 | 1 | 0.01 | - | - | 127 | 1.00 | 0 | |
| | | 100 | 128 | 5 | 0.04 | - | - | 123 | 1.00 | 0 | |
| | | 200 | 128 | 106 | 0.83 | - | - | 22 | 1.00 | 0 | |
| | | 400 | 128 | 126 | 0.98 | - | - | 2 | 1.00 | 0 | |
| | 600 | 128 | 125 | 0.98 | - | - | 3 | 1.00 | 0 | | |
| | 40 | 192 | 1 | 0.01 | - | - | 147 | 0.77 | 44 | | |
| | 60 | 192 | 13 | 0.07 | - | - | 178 | 0.99 | 1 | | |
| | 80 | 192 | 35 | 0.18 | - | - | 157 | 1.00 | 0 | | |
| | 100 | 192 | 67 | 0.35 | - | - | 125 | 1.00 | 0 | | |
| | 200 | 192 | 180 | 0.94 | - | - | 12 | 1.00 | 0 | | |
| 400 | 192 | 189 | 0.98 | - | - | 3 | 1.00 | 0 | | | |
| 600 | 192 | 187 | 0.97 | - | - | 5 | 1.00 | 0 | | | |
| Photometric + Visual | 40 | 320 | 1 | 0.00 | 0.00 | 0.02 | 233 | - | 86 | | |
| | 60 | 320 | 13 | 0.04 | 0.02 | 0.07 | 304 | - | 3 | | |
| | 80 | 320 | 36 | 0.11 | 0.08 | 0.15 | 284 | - | 0 | | |
| | 100 | 320 | 72 | 0.23 | 0.00 | 0.61 | 248 | - | 0 | | |
| | 200 | 320 | 286 | 0.89 | 0.86 | 0.92 | 34 | - | 0 | | |
| | 400 | 320 | 315 | 0.98 | 0.96 | 0.99 | 5 | - | 0 | | |
| 600 | 320 | 312 | 0.98 | 0.95 | 0.99 | 8 | - | 0 | | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC β A | Lower 95%- CI (CC β A) | Upper 95%- CI (CC β A) | No. of Results (pos. Class B) | Percentage of CC β B | No. of Results (negative) |
|-------------------------|----------------------|---------------|----------------------|-------------------------------|----------------------------|------------------------------|------------------------------|-------------------------------|----------------------------|---------------------------|
| Sulfadoxin | Photometric | 100 | 42 | 0 | 0.00 | - | - | 5 | 0.12 | 37 |
| | | 200 | 42 | 0 | 0.00 | - | - | 23 | 0.55 | 19 |
| | | 400 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| | | 600 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| | | 800 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| | | 1,000 | 42 | 9 | 0.21 | - | - | 33 | 1.00 | 0 |
| | 1,500 | 42 | 25 | 0.60 | - | - | 17 | 1.00 | 0 | |
| | Visual | 100 | 63 | 0 | 0.00 | - | - | 41 | 0.65 | 22 |
| | | 200 | 63 | 1 | 0.02 | - | - | 56 | 0.90 | 6 |
| | | 400 | 63 | 7 | 0.11 | - | - | 56 | 1.00 | 0 |
| | | 600 | 63 | 33 | 0.52 | - | - | 30 | 1.00 | 0 |
| | | 800 | 63 | 41 | 0.65 | - | - | 22 | 1.00 | 0 |
| | | 1,000 | 63 | 40 | 0.63 | - | - | 23 | 1.00 | 0 |
| | 1,500 | 63 | 41 | 0.65 | - | - | 22 | 1.00 | 0 | |
| | Photometric + Visual | 100 | 105 | 0 | 0.00 | 0.00 | 0.04 | 46 | - | 59 |
| | | 200 | 105 | 1 | 0.01 | 0.00 | 0.05 | 79 | - | 25 |
| | | 400 | 105 | 7 | 0.07 | 0.03 | 0.13 | 98 | - | 0 |
| | | 600 | 105 | 33 | 0.31 | 0.00 | 0.85 | 72 | - | 0 |
| 800 | | 105 | 41 | 0.39 | 0.00 | 1.00 | 64 | - | 0 | |
| 1,000 | | 105 | 49 | 0.47 | 0.00 | 1.00 | 56 | - | 0 | |
| 1,500 | 105 | 66 | 0.63 | 0.14 | 1.00 | 39 | - | 0 | | |
| Sulfamethoxy-pyridazine | Photometric | 50 | 128 | 1 | 0.01 | - | - | 99 | 0.78 | 28 |
| | | 100 | 128 | 0 | 0.00 | - | - | 126 | 0.98 | 2 |
| | | 200 | 128 | 24 | 0.19 | - | - | 104 | 1.00 | 0 |
| | | 300 | 128 | 107 | 0.84 | - | - | 21 | 1.00 | 0 |
| | | 500 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 750 | 128 | 127 | 0.99 | - | - | 0 | 0.99 | 1 |
| | 1,000 | 128 | 127 | 0.99 | - | - | 1 | 1.00 | 0 | |
| | Visual | 50 | 192 | 2 | 0.01 | - | - | 119 | 0.63 | 71 |
| | | 100 | 192 | 9 | 0.05 | - | - | 177 | 0.97 | 6 |
| | | 200 | 192 | 107 | 0.56 | - | - | 85 | 1.00 | 0 |
| | | 300 | 192 | 176 | 0.92 | - | - | 16 | 1.00 | 0 |
| | | 500 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 750 | 192 | 191 | 0.99 | - | - | 1 | 1.00 | 0 |
| | 1,000 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 50 | 320 | 3 | 0.01 | 0.00 | 0.03 | 218 | - | 99 |
| | | 100 | 320 | 9 | 0.03 | 0.01 | 0.05 | 303 | - | 8 |
| | | 200 | 320 | 131 | 0.41 | 0.01 | 0.80 | 189 | - | 0 |
| | | 300 | 320 | 283 | 0.88 | 0.84 | 0.92 | 37 | - | 0 |
| 500 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 750 | | 320 | 318 | 0.99 | 0.98 | 1.00 | 1 | - | 1 | |
| 1,000 | 320 | 319 | 1.00 | 0.98 | 1.00 | 1 | - | 0 | | |
| Chlortetra-cycline | Photometric | 100 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | 200 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | 300 | 42 | 0 | 0.00 | - | - | 4 | 0.10 | 38 |
| | | 400 | 42 | 0 | 0.00 | - | - | 17 | 0.40 | 25 |
| | | 600 | 42 | 0 | 0.00 | - | - | 32 | 0.76 | 10 |
| | | 800 | 42 | 2 | 0.05 | - | - | 38 | 0.95 | 2 |
| | 1,000 | 42 | 28 | 0.67 | - | - | 14 | 1.00 | 0 | |
| | Visual | 100 | 63 | 0 | 0.00 | - | - | 12 | 0.19 | 51 |
| | | 200 | 63 | 0 | 0.00 | - | - | 12 | 0.19 | 51 |
| | | 300 | 63 | 0 | 0.00 | - | - | 23 | 0.37 | 40 |
| | | 400 | 63 | 0 | 0.00 | - | - | 36 | 0.57 | 27 |
| | | 600 | 63 | 25 | 0.40 | - | - | 31 | 0.89 | 7 |
| | | 800 | 63 | 27 | 0.43 | - | - | 36 | 1.00 | 0 |
| | 1,000 | 63 | 49 | 0.78 | - | - | 14 | 1.00 | 0 | |
| | Photometric + Visual | 100 | 105 | 0 | 0.00 | 0.00 | 0.04 | 12 | - | 93 |
| | | 200 | 105 | 0 | 0.00 | 0.00 | 0.04 | 12 | - | 93 |
| | | 300 | 105 | 0 | 0.00 | 0.00 | 0.04 | 27 | - | 78 |
| | | 400 | 105 | 0 | 0.00 | 0.00 | 0.04 | 53 | - | 52 |
| 600 | | 105 | 25 | 0.24 | 0.00 | 0.63 | 63 | - | 17 | |
| 800 | | 105 | 29 | 0.28 | 0.00 | 0.68 | 74 | - | 2 | |
| 1,000 | 105 | 77 | 0.73 | 0.41 | 1.00 | 28 | - | 0 | | |
| Oxytetra-cycline | Photometric | 100 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | 200 | 42 | 0 | 0.00 | - | - | 9 | 0.21 | 33 |
| | | 300 | 42 | 1 | 0.02 | - | - | 28 | 0.69 | 13 |
| | | 400 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| | | 600 | 42 | 29 | 0.69 | - | - | 13 | 1.00 | 0 |
| | | 800 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 1,000 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 100 | 63 | 0 | 0.00 | - | - | 3 | 0.05 | 60 |
| | | 200 | 63 | 0 | 0.00 | - | - | 34 | 0.54 | 29 |
| | | 300 | 63 | 3 | 0.05 | - | - | 51 | 0.86 | 9 |
| | | 400 | 63 | 13 | 0.21 | - | - | 50 | 1.00 | 0 |
| | | 600 | 63 | 52 | 0.83 | - | - | 11 | 1.00 | 0 |
| | | 800 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 1,000 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 100 | 105 | 0 | 0.00 | 0.00 | 0.04 | 3 | - | 102 |
| | | 200 | 105 | 0 | 0.00 | 0.00 | 0.04 | 43 | - | 62 |
| | | 300 | 105 | 4 | 0.04 | 0.01 | 0.09 | 79 | - | 22 |
| | | 400 | 105 | 13 | 0.12 | 0.07 | 0.20 | 92 | - | 0 |
| 600 | | 105 | 81 | 0.77 | 0.64 | 0.90 | 24 | - | 0 | |
| 800 | | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 1,000 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC β A | Lower 95%- CI (CC β A) | Upper 95%- CI (CC β A) | No. of Results (pos. Class B) | Percentage of CC β B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|----------------------------|------------------------------|------------------------------|-------------------------------|----------------------------|---------------------------|
| Tetracycline | Photometric | 100 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | 200 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | 300 | 42 | 0 | 0.00 | - | - | 5 | 0.12 | 37 |
| | | 400 | 42 | 0 | 0.00 | - | - | 15 | 0.36 | 27 |
| | | 600 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| | | 800 | 42 | 21 | 0.50 | - | - | 21 | 1.00 | 0 |
| | 1,000 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 100 | 63 | 0 | 0.00 | - | - | 6 | 0.10 | 57 |
| | | 200 | 63 | 0 | 0.00 | - | - | 16 | 0.25 | 47 |
| | | 300 | 63 | 0 | 0.00 | - | - | 39 | 0.62 | 24 |
| | | 400 | 63 | 0 | 0.00 | - | - | 49 | 0.78 | 14 |
| | | 600 | 63 | 29 | 0.46 | - | - | 34 | 1.00 | 0 |
| | | 800 | 63 | 49 | 0.78 | - | - | 14 | 1.00 | 0 |
| | 1,000 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 100 | 105 | 0 | 0.00 | 0.00 | 0.04 | 6 | - | 99 |
| | | 200 | 105 | 0 | 0.00 | 0.00 | 0.04 | 16 | - | 89 |
| | | 300 | 105 | 0 | 0.00 | 0.00 | 0.04 | 44 | - | 61 |
| | | 400 | 105 | 0 | 0.00 | 0.00 | 0.04 | 64 | - | 41 |
| 600 | | 105 | 29 | 0.28 | 0.00 | 0.76 | 76 | - | 0 | |
| 800 | | 105 | 70 | 0.67 | 0.27 | 1.00 | 35 | - | 0 | |
| 1,000 | | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| Dihydro-streptomycin | | Photometric | 200 | 42 | 0 | 0.00 | - | - | 1 | 0.02 |
| | 300 | | 42 | 0 | 0.00 | - | - | 11 | 0.26 | 31 |
| | 400 | | 42 | 7 | 0.17 | - | - | 35 | 1.00 | 0 |
| | 500 | | 42 | 13 | 0.31 | - | - | 29 | 1.00 | 0 |
| | 600 | | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 700 | | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 800 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 200 | 63 | 0 | 0.00 | - | - | 26 | 0.41 | 37 |
| | | 300 | 63 | 0 | 0.00 | - | - | 55 | 0.87 | 8 |
| | | 400 | 63 | 33 | 0.52 | - | - | 30 | 1.00 | 0 |
| | | 500 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 700 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 800 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 200 | 105 | 0 | 0.00 | 0.00 | 0.04 | 27 | - | 78 |
| | | 300 | 105 | 0 | 0.00 | 0.00 | 0.04 | 66 | - | 39 |
| | | 400 | 105 | 40 | 0.38 | 0.00 | 0.81 | 65 | - | 0 |
| | | 500 | 105 | 76 | 0.72 | 0.26 | 1.00 | 29 | - | 0 |
| 600 | | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 700 | | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 800 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| Streptomycin | Photometric | 300 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | 400 | 42 | 0 | 0.00 | - | - | 2 | 0.05 | 40 |
| | | 500 | 42 | 0 | 0.00 | - | - | 30 | 0.71 | 12 |
| | | 600 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| | | 800 | 42 | 2 | 0.05 | - | - | 40 | 1.00 | 0 |
| | | 1,000 | 42 | 36 | 0.86 | - | - | 6 | 1.00 | 0 |
| | 1,500 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 300 | 63 | 1 | 0.02 | - | - | 7 | 0.13 | 55 |
| | | 400 | 63 | 0 | 0.00 | - | - | 21 | 0.33 | 42 |
| | | 500 | 63 | 4 | 0.06 | - | - | 54 | 0.92 | 5 |
| | | 600 | 63 | 0 | 0.00 | - | - | 63 | 1.00 | 0 |
| | | 800 | 63 | 22 | 0.35 | - | - | 41 | 1.00 | 0 |
| | | 1,000 | 63 | 44 | 0.70 | - | - | 19 | 1.00 | 0 |
| | 1,500 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 300 | 105 | 1 | 0.01 | 0.00 | 0.05 | 7 | - | 97 |
| | | 400 | 105 | 0 | 0.00 | 0.00 | 0.04 | 23 | - | 82 |
| | | 500 | 105 | 4 | 0.04 | 0.01 | 0.09 | 84 | - | 17 |
| | | 600 | 105 | 0 | 0.00 | 0.00 | 0.04 | 105 | - | 0 |
| 800 | | 105 | 24 | 0.23 | 0.00 | 0.64 | 81 | - | 0 | |
| 1,000 | | 105 | 80 | 0.76 | 0.28 | 1.00 | 25 | - | 0 | |
| 1,500 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| Gentamicin | Photometric | 40 | 128 | 0 | 0.00 | - | - | 1 | 0.01 | 127 |
| | | 60 | 128 | 0 | 0.00 | - | - | 37 | 0.29 | 91 |
| | | 80 | 128 | 0 | 0.00 | - | - | 121 | 0.95 | 7 |
| | | 100 | 128 | 0 | 0.00 | - | - | 128 | 1.00 | 0 |
| | | 125 | 128 | 8 | 0.06 | - | - | 120 | 1.00 | 0 |
| | | 150 | 128 | 118 | 0.92 | - | - | 10 | 1.00 | 0 |
| | 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 40 | 192 | 0 | 0.00 | - | - | 31 | 0.16 | 161 |
| | | 60 | 192 | 0 | 0.00 | - | - | 159 | 0.83 | 33 |
| | | 80 | 192 | 19 | 0.10 | - | - | 173 | 1.00 | 0 |
| | | 100 | 192 | 79 | 0.41 | - | - | 113 | 1.00 | 0 |
| | | 125 | 192 | 141 | 0.73 | - | - | 51 | 1.00 | 0 |
| | | 150 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 200 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 40 | 320 | 0 | 0.00 | 0.00 | 0.01 | 32 | - | 288 |
| | | 60 | 320 | 0 | 0.00 | 0.00 | 0.01 | 196 | - | 124 |
| | | 80 | 320 | 19 | 0.06 | 0.04 | 0.09 | 294 | - | 7 |
| | | 100 | 320 | 79 | 0.25 | 0.00 | 0.74 | 241 | - | 0 |
| 125 | | 320 | 149 | 0.47 | 0.00 | 1.00 | 171 | - | 0 | |
| 150 | | 320 | 310 | 0.97 | 0.94 | 0.98 | 10 | - | 0 | |
| 200 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%- CI (CCB A) | Upper 95%- CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|---------------------|-----------------------|-----------------------|-------------------------------|---------------------|---------------------------|
| Neomycin | Photometric | 60 | 42 | 0 | 0.00 | - | - | 0 | 0.00 | 42 |
| | | 80 | 42 | 0 | 0.00 | - | - | 2 | 0.05 | 40 |
| | | 100 | 42 | 0 | 0.00 | - | - | 1 | 0.02 | 41 |
| | | 200 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| | | 300 | 42 | 32 | 0.76 | - | - | 10 | 1.00 | 0 |
| | | 400 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 500 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 60 | 63 | 0 | 0.00 | - | - | 9 | 0.14 | 54 |
| | | 80 | 63 | 0 | 0.00 | - | - | 34 | 0.54 | 29 |
| | | 100 | 63 | 0 | 0.00 | - | - | 24 | 0.38 | 39 |
| | | 200 | 63 | 15 | 0.24 | - | - | 48 | 1.00 | 0 |
| | | 300 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 500 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 60 | 105 | 0 | 0.00 | 0.00 | 0.04 | 9 | - | 96 |
| | | 80 | 105 | 0 | 0.00 | 0.00 | 0.04 | 36 | - | 69 |
| | | 100 | 105 | 0 | 0.00 | 0.00 | 0.04 | 25 | - | 80 |
| | | 200 | 105 | 15 | 0.14 | 0.09 | 0.22 | 90 | - | 0 |
| | | 300 | 105 | 95 | 0.90 | 0.83 | 0.95 | 10 | - | 0 |
| | | 400 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 500 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| Chlor- amphenicol | Photometric | 3,000 | 42 | 0 | 0.00 | - | - | 17 | 0.40 | 25 |
| | | 3,500 | 42 | 0 | 0.00 | - | - | 29 | 0.69 | 13 |
| | | 4,000 | 42 | 0 | 0.00 | - | - | 42 | 1.00 | 0 |
| | | 4,500 | 42 | 2 | 0.05 | - | - | 40 | 1.00 | 0 |
| | | 5,000 | 42 | 14 | 0.33 | - | - | 28 | 1.00 | 0 |
| | | 6,000 | 42 | 39 | 0.93 | - | - | 3 | 1.00 | 0 |
| | | 7,000 | 42 | 42 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 3,000 | 63 | 1 | 0.02 | - | - | 37 | 0.60 | 25 |
| | | 3,500 | 63 | 3 | 0.05 | - | - | 60 | 1.00 | 0 |
| | | 4,000 | 63 | 20 | 0.32 | - | - | 43 | 1.00 | 0 |
| | | 4,500 | 63 | 46 | 0.73 | - | - | 17 | 1.00 | 0 |
| | | 5,000 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 6,000 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 7,000 | 63 | 63 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 3,000 | 105 | 1 | 0.01 | 0.00 | 0.05 | 54 | - | 50 | |
| | 3,500 | 105 | 3 | 0.03 | 0.01 | 0.08 | 89 | - | 13 | |
| | 4,000 | 105 | 20 | 0.19 | 0.00 | 0.59 | 85 | - | 0 | |
| | 4,500 | 105 | 48 | 0.46 | 0.00 | 0.96 | 57 | - | 0 | |
| | 5,000 | 105 | 77 | 0.73 | 0.29 | 1.00 | 28 | - | 0 | |
| | 6,000 | 105 | 102 | 0.97 | 0.92 | 0.99 | 3 | - | 0 | |
| | 7,000 | 105 | 105 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |

Annex Table 3. Contingency table created with the Fisher Test for the concentration at CCB A obtained with photometric reading, including the numbers of results of the different classes of results (1-2-0) for the different plate batches and ELISA readers

| Substance | Concentration CCB A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CCB A) |
|---------------------------|---------------------|---------------------|-------|-------------------------------|-------------------------------|---------------------------|-------------------------------------|
| Benzylo-penicillin | 2.5 | 1 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| Ampicillin | 3.5 | 2 | C | 8 | 0 | 0 | 1 |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| Amoxicillin | 3 | 2 | B | 16 | 0 | 0 | 1 |
| | | 2 | C | 16 | 0 | 0 | |
| | | 1 | D | 24 | 0 | 0 | |
| | | 1 | E | 16 | 0 | 0 | |
| | | 1 | F | 24 | 0 | 0 | |
| Cloxacillin | 25 | 2 | D | 24 | 0 | 0 | 1 |
| | | 2 | E | 16 | 0 | 0 | |
| | | 1 | D | 16 | 0 | 0 | |
| | | 1 | E | 22 | 2 | 0 | |
| | | 1 | F | 24 | 0 | 0 | |
| Dicloxacillin | 15 | 2 | D | 16 | 0 | 0 | 1 |
| | | 2 | E | 24 | 0 | 0 | |
| | | 2 | F | 24 | 0 | 0 | |
| | | 1 | A | 16 | 0 | 0 | |
| | | 1 | B | 16 | 0 | 0 | |
| Nafcillin | 15 | 1 | C | 8 | 0 | 0 | 1 |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| Oxacillin | 10 | 1 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 7 | 1 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| Cefalexin | 400 | 2 | C | 16 | 0 | 0 | 1 |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| Cefapirin | 6 | 2 | B | 8 | 0 | 0 | 1 |
| | | 2 | C | 8 | 0 | 0 | |
| | | 1 | A | 7 | 0 | 0 | |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| Cefoperazone | 35 | 2 | A | 7 | 0 | 0 | 1 |
| | | 2 | B | 7 | 0 | 0 | |
| | | 1 | A | 16 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |

Continuation Annex Table 3

| Substance | Concentration CCB A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CCB A) |
|------------------|------------------------|------------------------|-------|----------------------------------|----------------------------------|------------------------------|---|
| Cefazolin | 9 | 1 | A | 7 | 0 | 0 | 1 |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| | | 2 | B | 7 | 0 | 0 | |
| Cefquinome | 500 | 2 | C | 7 | 0 | 0 | 1 |
| | | 1 | A | 7 | 0 | 0 | |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| Ceftiofur | 200 | 2 | B | 7 | 0 | 0 | 0.11 |
| | | 2 | C | 7 | 0 | 0 | |
| | | 1 | D | 21 | 3 | 0 | |
| | | 1 | E | 24 | 0 | 0 | |
| | | 1 | F | 16 | 0 | 0 | |
| Cefalonium | 14 | 2 | D | 21 | 3 | 0 | 0.11 |
| | | 2 | E | 24 | 0 | 0 | |
| | | 2 | F | 16 | 0 | 0 | |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 16 | 0 | 0 | |
| Erythromycin | 100 | 1 | C | 15 | 1 | 0 | 1 |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| | | 1 | A | 24 | 0 | 0 | |
| Tylosin | 75 | 1 | B | 16 | 0 | 0 | 1 |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| | | 2 | C | 24 | 0 | 0 | |
| Sulfadiazine | NA | 1 | A | 24 | 0 | 0 | - |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 23 | 1 | 0 | |
| | | 2 | B | 20 | 4 | 0 | |
| Sulfadi-methoxin | NA | 2 | C | 7 | 9 | 0 | - |
| | | 1 | A | 8 | 16 | 0 | |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 23 | 1 | 0 | |
| | | 2 | A | 15 | 9 | 0 | |
| Sulfamethazine | 1,000 | 2 | B | 16 | 0 | 0 | 1 |
| | | 2 | C | 24 | 0 | 0 | |
| | | 1 | A | 7 | 0 | 0 | |
| | | 1 | B | 6 | 1 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| Sulfathiazol | 400 | 2 | A | 7 | 0 | 0 | 0.06 |
| | | 2 | B | 7 | 0 | 0 | |
| | | 2 | C | 7 | 0 | 0 | |
| | | 1 | A | 16 | 0 | 0 | |
| | | 1 | B | 24 | 0 | 0 | |

Continuation Annex Table 3

| Substance | Concentration CCß A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CCß A) |
|-----------------------------|------------------------|------------------------|-------|----------------------------------|----------------------------------|------------------------------|---|
| Sulfadoxin | NA | 1 | A | 1 | 6 | 0 | - |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 4 | 3 | 0 | |
| | | 2 | A | 3 | 4 | 0 | |
| | | 2 | B | 6 | 1 | 0 | |
| | | 2 | C | 4 | 3 | 0 | |
| Sulfamethoxy- pyridazine | 500 | 1 | A | 24 | 0 | 0 | 1 |
| | | 1 | B | 24 | 0 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 24 | 0 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| Chlortetra- cycline | NA | 1 | A | 7 | 0 | 0 | - |
| | | 1 | B | 0 | 7 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| | | 2 | B | 0 | 7 | 0 | |
| | | 2 | C | 7 | 0 | 0 | |
| Oxytetracycline | 800 | 1 | A | 7 | 0 | 0 | 1 |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| | | 2 | B | 7 | 0 | 0 | |
| | | 2 | C | 7 | 0 | 0 | |
| Tetracycline | 1,000 | 1 | A | 7 | 0 | 0 | 1 |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| | | 2 | B | 7 | 0 | 0 | |
| | | 2 | C | 7 | 0 | 0 | |
| Dihydro- streptomycin | 600 | 1 | A | 7 | 0 | 0 | 1 |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| | | 2 | B | 7 | 0 | 0 | |
| | | 2 | C | 7 | 0 | 0 | |
| Streptomycin | 1,500 | 1 | A | 7 | 0 | 0 | 1 |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| | | 2 | B | 7 | 0 | 0 | |
| | | 2 | C | 7 | 0 | 0 | |
| Gentamicin | 200 | 1 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 24 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 24 | 0 | 0 | |
| | | 2 | C | 24 | 0 | 0 | |
| Neomycin | 400 | 1 | A | 7 | 0 | 0 | 1 |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| | | 2 | B | 7 | 0 | 0 | |
| | | 2 | C | 7 | 0 | 0 | |
| Chlor- amphenicol | 7,000 | 1 | A | 7 | 0 | 0 | 1 |
| | | 1 | B | 7 | 0 | 0 | |
| | | 1 | C | 7 | 0 | 0 | |
| | | 2 | A | 7 | 0 | 0 | |
| | | 2 | B | 7 | 0 | 0 | |
| | | 2 | C | 7 | 0 | 0 | |

Validierungsbericht

Validation Report

BRT MRL-Suchtest
BRT MRL-Screening Test



1) Introduction

The BRT MRL-Screening Test (AiM – Analytik in Milch GmbH, www.aimbavaria.com) is a microbiological inhibitor test for the qualitative broad-spectrum detection of antibiotic residues in cow milk. The validation study was carried out at the laboratory of Milchprüfring Bayern e. V. (MPR Bayern, www.mpr-bayern.de), a large raw milk testing laboratory performing 1.8 million inhibitor tests per year, under the conduct of Silvia Orlandini (AEOS) and Christian Baumgartner (MPR Bayern), in accordance with the Commission Decision 2002/657/EC and the CRL Guidelines (Anonymous, 2010).

2) Test Principle, Test Procedure, Reading Methods and Plate Batches

The BRT MRL-Screening Test (Figure 1) is a modified Brilliant Black Reduction Test (BRT) containing the test bacteria *G. stearotherophilus* var. *calidolactis* C953, the redox indicator brilliant black, nutrients and other supplements. Antibiotic residues present in a sample can inhibit the growth of the test bacteria, thus preventing or decelerating the reduction of the color indicator brilliant black and the consecutive color change of the test medium from blue to yellow. BRT tests generally detect a broad spectrum of antibiotics and are particularly sensitive to beta-lactams. The BRT MRL-Screening Test is distinguished by an increased sensitivity towards certain antibiotic substances compared to the BRT Inhibitor Test.

In Germany, the test is used as a screening method for the detection of anti-infectives in quality control in the dairy industry as well as in monitoring tests and it is part of the official register of inspection procedures according to § 64 LFGB (German Food, Feed and Consumer Goods Code, L 01.00-11). Furthermore, it is produced according to Commission Decision 91/180/EEC.




Figure 1. BRT MRL-Screening Test plates before (A) and after (B) incubation

Within the framework of this validation, the BRT MRL-Screening Test was evaluated in microtiter plate format. The plates were stored refrigerated (6 - 10 °C) until use. Additional to the samples (100 µl milk volume), each plate contained four positive (raw milk spiked with 4 µg/kg Penicillin G, remaining blue after incubation) and four negative controls (inhibitor-free raw milk, turning yellow after incubation) in order to enable a correct evaluation. According to the manufacturer's instructions, the plates

were incubated at 65 °C in a temperature-surveilled water bath until the complete discoloration of the negative control (color change from blue to yellow, Figure 1) indicated the ideal reading time (2 hrs 30 ± 15 min). Thereafter, the milk was rinsed off the cavities and the plates were assessed with 2 different reading methods: Visual examination performed by 3 technical assistants trained particularly for this purpose and photometric evaluation, using 2 instruments (ELISA reader (Multiskan Ascent V1.24, Thermo Labsystems)).

The photometric measurements were evaluated conforming to the relativized absorption method described by Beer and Suhren (1993). Accordingly, the measuring wavelength of 450 nm and the reference wavelength of 620 nm were chosen for reading. The recorded absorption values of the analyzed samples were converted into relative percentage values by setting the average absorption level of the negative controls (yellow color after incubation) as 0% and that of the positive controls (blue color after incubation) as 100%, other absorption levels (samples) were set in relation to negative (0%) and positive (100%) control.

The conversion formula is as follows:

$$(S-NC)/(PC-NC) \times 100 = X \%$$

where

S is the analyzed sample's absorption level

NC is the average of the four negative controls absorption levels

PC is the average of the four positive controls absorption levels

X relative percentage value of the analyzed sample

The photometric evaluation was regarded as reference method in this validation study as it provides objective, comparable and documented results and is commonly used by large laboratories.

The interpretation of the samples reading results was carried out in two different ways, in compliance with the method L 01.01-5 (§ 64 LFGB, inspection tests for milk quality payment) all samples exhibiting at least the color of the positive control respectively exceeding the threshold value of 65% (photometric evaluation) were interpreted as positive (indicated as class A) as well as all samples displaying a color which was clearly different from the negative control or exceeding the threshold value of 40% (indicated as class B), according to L 01.00-11 (§ 64 LFGB, German Food, Feed and Consumer Goods Code, MRL-Screening test). All samples gaining <40% by photometric evaluation or appeared as yellow as the negative control were categorized as negative (Table 1).

For statistical purposes, the "quantitative" relative percentage photometric results were converted to the same format as the "qualitative" visual data. Thus, the number 1 was assigned to any photometric percentage value of ≥65 %, whereas results with percentages in the range of 40% - <65 % were referred to with 2 and negative results with 0, equaling <40 % (Table 1).

Table 1. Relation of reading systems and classes of results

| Reading System | Classes of Results | | |
|----------------|--------------------|------------------|----------|
| | Positive Class A | Positive Class B | Negative |
| Visual (V) | 1 | 2 | 0 |
| ELISA (E) | ≥65% | 40% - <65% | <40% |

56,798 data results were obtained from the evaluation of 142 BRT MRL-Screening Test plates and treated statistically using "R" software (Version 3.5.0 (2018-04-23)). The confidence interval (CI) was calculated according to the AOAC approach for qualitative data.

For the validation, 7 batches of plates (Table 2) were provided by the manufacturer.

Table 2. BRT MRL-Screening Test plate batches provided for the validation

| Batch | Range of Batch Numbers |
|-------|------------------------|
| A | 31201018 - 31202886 |
| B | 31301015 - 31303866 |
| C | 31602068 - 31616386 |
| D | 31101233 - 31101837 |
| E | 31301596 - 31315814 |
| F | 31705769 - 31708043 |
| G | 32901085 - 32902143 |

3) Raw Milk Samples

A large quantity of high quality raw ex-farm bulk milk was collected, analyzed for milk quality and components (Table 3) and proven to be free of antibiotic residues by analysis with highly sensitive microbial inhibitor tests (BRT hi-sense and BRT ultra-sense, AiM GmbH, Munich, Germany) and receptor tests (BetaStar® 100, Neogen Corporation, Lansing, USA; Charm® MRL Beta-lactam Test, Charm Sciences Inc., Lawrence, USA; SNAP® Beta-Lactam ST-Test, IDEXX GmbH, Ludwigsburg, Germany). Additionally, the raw milk was tested with the AiM Penase Test (AiM GmbH, Munich, Germany) and proven to be free of penicillinase. Thereafter, the raw milk was aliquoted, frozen and stored until use. For the establishment of the rate of positive results not caused by residues of veterinary drugs, 704 ex-farm bulk milk samples, originating from routine milk quality payment testing, were analyzed with the BRT MRL-Screening Test.

Table 3. Analysis results of the raw milk batch used for the validation samples

| Type of Milk | FC [g/100 ml] ^a | PC [g/100 ml] ^b | pH | SCC/ml ^c | CFU/ml ^d |
|----------------|----------------------------|----------------------------|------|---------------------|---------------------|
| Blank raw Milk | 4.17 | 3.51 | 6.65 | 77,000 | 5,000 |

^a Fat content; ^b Protein content; ^c Somatic cell count; ^d Colony forming units

For the preparation of positive samples, blank raw cow milk was defrosted, spiked with a highly concentrated stock solution to obtain the desired level of antibiotic

residue and frozen again. When required, the milk samples were defrosted overnight at 6 - 8 °C and used the next day. To verify the correct concentration of the stock solutions and the spiked raw milk samples, serial dilutions of the prepared positive samples were analyzed with microbiological inhibitor and - if available for a certain substance - receptor tests, then the obtained results were compared with the detection limits of the individual tests. No receptor tests were available for Erythromycin, Tylosin, Neomycin and Gentamicin, Therefore the correct concentrations of the individual stock solutions were verified with LC - MS/MS analysis.

The approach of using a single batch of raw milk as base for the preparation of the spiked milk samples enhances the comparability of results obtained on different validation days and thus objectifies the assessment of the validation results, as irregularities are not attributable to deviating milk qualities. Ex-farm tank milk was chosen as basic matrix for the validation as this is the target product of the BRT MRL-Screening Test.

4) Detection Capability

Materials and Methods

Involved in the validation study were 30 antibiotic compounds (Table 6), the concentrations of the samples to analyze were chosen according to the manufacturer's specification, the choice of increment from concentration to concentration depended on the spiked standards' concentrations (Table 4) as well as on practical aspects as two classes of results had to be considered, leading to two different detection limits (CC β A and CC β B).

Table 4. Correlation of concentration and increment of the spiked raw milk samples

| Concentration [$\mu\text{g}/\text{kg}$] | Increment [$\mu\text{g}/\text{kg}$] |
|---|---|
| 1-10 | 1 |
| 11-20 | 2 |
| 21-50 | 5 |
| 51-100 | 10 |
| 101-250 | 25 |
| 251-500 | 50 |
| 501-1,000 | 100 |
| 1,000-5,000 | 500 |

Correlated with the proximity to the respective EU Maximum Residue Limit (MRL) for antibiotic residues in milk, the standards were measured with 20, 40 or 60 replicates (Table 5).

Table 5. Number of replicates depending on the proximity to the respective MRL

| Closeness to MRL | No. of Replicates |
|-------------------------|--------------------------|
| ≤0.5 MRL | 20 |
| >0.5 MRL and <0.9 MRL | 40 |
| ≥0.9 MRL and ≤ MRL | 60 |
| > MRL | 20 |

For the determination of the detection capability three different batches of plates were used at all times. The lowest concentration obtaining a minimum of 95% positive results was considered as detection limit (CCβ). Based on the different interpretation methods, CCβ A and CCβ B (Section 2) were established in parallel for each substance. The detection limits determined with photometric evaluation were considered as reference values.

Results and Discussion

Table 6. Established detection limits (photometric reading) compared with the EU MRL levels. Marked in red are the substances exceeding the EU MRLs.

| Group of Antibiotics | Substance | MRL EU [µg/kg] | CCβ A [µg/kg] | CCβ B [µg/kg] |
|-----------------------------|------------------------|-----------------------|----------------------|----------------------|
| Penicillins | Benzylpenicillin | 4 | 2 | 1.5 |
| | Ampicillin | 4 | 2.5 | 2 |
| | Amoxicillin | 4 | 3 | 2.5 |
| | Cloxacillin | 30 | 25 | 18 |
| | Dicloxacillin | 30 | 12.5 | 10 |
| | Nafcillin | 30 | 10 | 8 |
| | Oxacillin | 30 | 8 | 8 |
| Cephalosporins | Cefalexin | 100 | 300 | 250 |
| | Cefapirin | 60 | 5 | 5 |
| | Cefoperazone | 50 | 30 | 20 |
| | Cefazolin | 50 | 7 | 6 |
| | Cefquinome | 20 | 300 | 200 |
| | Ceftiofur | 100 | 150 | 100 |
| | Cefalonium | 20 | 12 | 10 |
| Macrolides | Erythromycin | 40 | 80 | 50 |
| | Tylosin | 50 | 75 | 30 |
| Sulfonamides | Sulfadiazine | 100 | 400 | 100 |
| | Sulfadimethoxin | 100 | 600 | 100 |
| | Sulfamethazine | 100 | >1,000 | 200 |
| | Sulfathiazol | 100 | 200 | 60 |
| | Sulfadoxin | 100 | 1,500 | 300 |
| | Sulfamethoxypyridazine | 100 | 500 | 100 |
| Tetracyclines | Chlortetracycline | 100 | 800 | 400 |
| | Oxytetracycline | 100 | 400 | 200 |
| | Tetracycline | 100 | 600 | 300 |
| Aminoglycosides | Dihydrostreptomycin | 200 | 600 | 400 |
| | Streptomycin | 200 | 1,000 | 500 |
| | Gentamicin | 100 | 150 | 80 |
| | Neomycin | 1,500 | 300 | 200 |
| Fenicol | Chloramphenicol | - | 5,000 | 3,500 |

The particular sensitivity of *G. stearothermophilus* for beta-lactams and especially for penicillins is reflected in the detection limits of the different groups of antibiotics. All penicillins were detected below MRL as well as 5 out of 7 cephalosporins (Ceftiofur only CCβ B). Out of the groups of the macrolides, sulfonamides and aminoglycosides Tylosin, Sulfadiazine, Sulfadimethoxin, Sulfathiazol, Sulfamethoxypyridazine and Gentamicin conformed with the regulatory limits with CCβ B, but not with CCβ A, whereas for Neomycin CCβ A and CCβ B were defined to be below MRL. The detection limits of other tested substances exceeded the respective MRLs. CCβ A could not be determined for Sulfamethazine, as the positive response was below 65% relative absorption at the highest concentrations tested.

Chloramphenicol, for which no MRL is established – it is prohibited for use in food producing animals (Commission Regulation (EU) No 37/2010) – can be tested positive at 3,500 µg/kg (CCβ B) or 5,000 µg/kg (CCβ A). The detection limits for the BRT MRL-Screening Test established with the reference method (photometric evaluation) are reported in Table 6, detection limits established with visual reading are reported in the Annex.

In conclusion, the most important antibiotics used in Germany for the treatment of dairy cows (penicillins and cephalosporins), are detected predominantly below EU MRL. A broad range of other inhibitors can be identified as well, however, mostly in concentrations exceeding the regulatory limit.

5) Dose-Response Curves

Materials and Methods




Figure 2. Incubated BRT MRL-Screening Test plate inoculated with four positive and four negative controls as well as raw milk samples spiked with 7 different concentrations of an antibiotic substance

Dose-response curves were established for all antibiotics analyzed in the validation based on the class A results (Section 2) obtained within the framework of the detection capability study with both photometric and visual evaluation. For this purpose, 7 samples containing increasing concentrations were examined for each substance, with the aim of identifying the concentrations resulting in approximately 25%, 50%, 75% and 100% positive rates and to determine the highest concentration with 0% positive results. Furthermore, lower and upper CIs were calculated for the class A results under consideration of both reading systems and included in the dose-response curves (Figure 2 and Annex Table 2).

Results and Discussion

Figure 3 and Annex Figure 1 depict dose-response curves of all substances included in the validation of the BRT MRL-Screening Test. The response rates generated with the respective concentrations of each substance are specified in Annex Table 2. It was not always possible to obtain dose-response curves entirely corresponding to the requirements of 0%, 25%, 50%, 75% and 100% positive results. Bactericidal substances like beta-lactams mostly exhibited steeply increasing dose-response curves. For Benzylpenicillin, e. g., the positive response rate was 1% at 1 µg/kg, 78% at 1.5 µg/kg already and 100% of samples were detected positive at 2 µg/kg. Substances like the sulfonamides and macrolides displayed more consistent curve increments, probably due to their bacteriostatic character. Sulfadoxin obtained 18% positive results at 200 µg/kg, 43% at 300 µg/kg, 60% respectively 78% at 400 µg/kg and 600 µg/kg. At 800 µg/kg and 1,000 µg/kg, the positive responses were >95%, CCB A was established at 1,500 µg/kg.

Principally, the confidence interval is narrow at the concentrations of the CCB and at concentrations close to 0% of positive results. Bactericidal substances tend to exhibit narrow CIs also at concentrations in between 0% and CCB, which indicates that most results of samples with different concentrations are interpreted in the same way with the different reading systems (photometric and visual) and individual readers.

In contrast, bacteriostatic substances often show bigger variations in the results at the concentrations below the CCB. The bacteriostatic activity causes different degrees of inhibition and consequently of color development, which can be more difficult to interpret by human eye. While the interpretation with photometric reading systems is well standardized, the visual interpretation leads to bigger variances in the results and thus to wider CIs.




Figure 3. Dose-response curves of the bactericidal antibiotics Benzylpenicillin and Cefapirin and of the bacteriostatic substances Sulfadoxin and Erythromycin.

Red line = dose-response curve; red shade = CI; Black line = CCB A (photometric reading);

6) Selectivity

Materials and Methods

Marker substances of commonly used classes of veterinary drugs other than antibiotics were analyzed with photometric reading in order to determine the selectivity of the BRT MRL-Screening Test. The investigated compounds included the anti-inflammatories Flunixin, Metamizole (NSAIDs) and Prednisolone (glucocorticoid) as well as antiparasitic substances (Triclabendazole and Deltamethrin). Furthermore, the polyether-antibiotic Monensin, used for ketosis treatment in dairy cows, was tested. The substances were spiked at a concentration of 100 x EU MRL and inoculated with 6 replicates (Table 7).

Table 7. Selectivity: Concentrations of analyzed substances and test results

| Use | Drug Class | Substance | MRL [$\mu\text{g}/\text{kg}$] | Concentration [$\mu\text{g}/\text{kg}$] | False positive Results | |
|------------------------------|----------------------|----------------|---------------------------------|---|------------------------|---------|
| | | | | | Class A | Class B |
| Anti-inflammatory Substances | NSAID | Flunixin | 40 | 4,000 | 0/6 | 0/6 |
| | NSAID | Metamizol | 50 | 5,000 | 0/6 | 0/6 |
| | Glucocorticoid | Prednisolon | 6 | 600 | 0/6 | 0/6 |
| Antiparasitics | Anthelmintic | Triclabendazol | 10 | 1,000 | 0/6 | 0/6 |
| | Ectoparasite | Deltamethrin | 20 | 2,000 | 0/6 | 0/6 |
| Ketosis Treatment | Polyether-Antibiotic | Monensin | 2 | 200 | 0/6 | 1/6 |

Results and Discussion

Highly concentrated samples of Flunixin, Metamizole, Prednisolone, Triclabendazole, and Deltamethrin did not inhibit the growth of the test germs, leading to negative results. Only 1 false-positive result was obtained for Monensin out of 6 replicates on interpretation in comparison with the negative control (Class B). Compared with the positive control (Class A) all samples appeared negative. Even though Monensin is used for ketosis treatment, it is a bactericidal substance (polyether-antibiotic), which modifies the ruminal flora by inhibiting predominantly gram-positive bacteria, but not gram-negative germs, leading to an improved ruminal metabolism and reduced incidence of ketosis. Monensin is administered locally in the rumen, it is subject to a high first-pass metabolism, residual amounts in the blood circulation are excreted via the bile. Despite the antibiotic mode of action, false-positive results after the treatment of a cow with Monensin are highly unlikely due to its pharmacokinetic properties and the apparently low sensitivity of the BRT MRL-Screening Test for this substance. Nevertheless, accidental pollution of the bulk milk with the drug should be avoided.

Principally, the observed results signify a high specificity of the BRT MRL-Screening Test for the detection of antibiotic substances opposed to other classes of veterinary drugs.

7) Batch-to-Batch Variability

Materials and Methods

In order to evaluate potential deviations in the detection capabilities of different plate batches statistically, Fisher's exact tests (method: two-sided) were applied at the concentration of the CC β A obtained with photometric reading. Contingency tables were created for the datasets of ELISA reader 1 and ELISA reader 2 to provide a basic picture of the interrelation between the two variables plate batches and number of results (class A) per batch. Due to the duration of the validation study and the limited shelf-life of the BRT MRL-Screening Test plates, two sets of plate batches (A, B, C and D, E, F) had to be used.

The Fisher's test was selected because the test is more precise than Chi square for this number of observations, the null hypothesis is based on the batches independence (the probability of the results is the same for the different batches). The Fisher's exact test was applied only to the analytes for which a CC β A could be determined. If the significance level is $\alpha = 0.05$ and the p-value < 0.05 , the null hypothesis is rejected, which would mean that there is a probability for batch-to-batch differences concerning the detection capability at the CC β A.

Results and Discussion

The Fisher's test examinations for the concentrations at CC β A indicate that there are no significant differences in between the detection sensitivities of the different plate batches used in the validation. All substances, except for Gentamicin, Sulfadiazine and Sulfadimethoxin realized p-value = 1 - for Gentamicin, Sulfadiazine and Sulfadimethoxin the p values were $0.05 \leq p < 1$ (Table 8). In addition to the p-values (CC β A), Annex Table 3 comprises the numbers of results per class (1-2-0), plate batch and individual ELISA reader at the concentration of the CC β A.

Table 8. Contingency table created with the Fisher Test for the concentration at CC β A obtained with photometric reading

| Group of Antibiotics | Substance | MRL | CC β A [μ g/kg] | p Value | | Group of Antibiotics | Substance | MRL | CC β A [μ g/kg] | p Value | |
|----------------------|------------------|-----|----------------------------|---------|---------|----------------------|------------------------|-------------------|----------------------------|---------|---------|
| | | | | ELISA 1 | ELISA 2 | | | | | ELISA 1 | ELISA 2 |
| Penicillins | Benzympenicillin | 4 | 2 | 1 | 1 | Sulfonamides | Sulfadiazine | 100 | 400 | 0.11 | 0.11 |
| | Ampicillin | 4 | 2.5 | 1 | 1 | | Sulfadimethoxin | 100 | 600 | 0.11 | 0.33 |
| | Amoxicillin | 4 | 3 | 1 | 1 | | Sulfamethazine | 100 | > 1,000 | - | - |
| | Cloxacillin | 30 | 25 | 1 | 1 | | Sulfathiazol | 100 | 200 | 1 | 1 |
| | Dicloxacillin | 30 | 12.5 | 1 | 1 | | Sulfadoxin | 100 | 1,500 | 1 | 1 |
| | Nafcillin | 30 | 10 | 1 | 1 | | Sulfamethoxypyridazine | 100 | 500 | 1 | 1 |
| | Oxacillin | 30 | 8 | 1 | 1 | | Tetracyclines | Chlortetracycline | 100 | 800 | 1 |
| Cephalosporines | Cefalexin | 100 | 300 | 1 | 1 | Oxytetracycline | | 100 | 400 | 1 | 1 |
| | Cefapirin | 60 | 5 | 1 | 1 | Tetracycline | | 100 | 600 | 1 | 1 |
| | Cefoperazone | 50 | 30 | 1 | 1 | Aminoglycosides | Dihydrostreptomycin | 200 | 600 | 1 | 1 |
| | Cefazolin | 50 | 7 | 1 | 1 | | Streptomycin | 200 | 1,000 | 1 | 1 |
| | Cefquinome | 20 | 300 | 1 | 1 | | Gentamicin | 100 | 150 | 0.11 | 0.33 |
| | Ceftiofur | 100 | 150 | 1 | 1 | | Neomycin | 1,500 | 300 | 1 | 1 |
| | Cefalonium | 20 | 12 | 1 | 1 | Fenicols | Chloramphenicol | - | 5,000 | 1 | 1 |
| Macrolides | Erythromycin | 40 | 80 | 1 | 1 | | | | | | |
| | Tylosin | 50 | 75 | 1 | 1 | | | | | | |

Significance levels: Low: $p < 0.05$; Medium: $p < 0.01$; High: $p < 0.001$

8) False-Positive and False-Negative Rate

Materials and Methods

With each BRT MRL-Screening Test plate used during the validation study, 4 positive and negative control samples (Section 2) as well as additional 16 negative raw milk samples, adding up to 20 negative milk samples, were inoculated. By means of these samples, the rates of false-positive and false-negative results were established.

Within the framework of this validation, 142 test plates were analyzed, including 568 positive control samples and 2,840 samples of negative raw milk in total. Thus, 2,840 (positive control) respectively 14,200 (negative milk) results were obtained with photometric evaluation (2 readers) and visual reading (3 technicians, Table 9).

Table 9. Numbers of positive and negative samples and obtained results used for the establishment of the false-negative and false-positive rates

| Type of Milk Sample | No. Plates | No. Samples | No. Results ELISA Readers | No. Results Visual | Total No. Results |
|---------------------|------------|-------------|---------------------------|--------------------|-------------------|
| Positive Control | 142 | 568 | 1,136 | 1,704 | 2,840 |
| Negative Milk | | 2,840 | 5,680 | 8,520 | 14,200 |

Results and Discussion

No false-positive or false-negative results were observed when analyzing the results of the negative milk samples and positive control samples by photometric evaluation or visual reading, leading to false-positive and false-negative rates of 0% (Table 10).

Table 10. Rates of false-negative and false-positive results of all applied reading methods and readers

| Type of Milk Sample | Rate of false Results [%] | | | | |
|---------------------|---------------------------|---------|----------|----------|----------|
| | ELISA 1 | ELISA 2 | Visual 1 | Visual 2 | Visual 3 |
| Positive Control | 0 | 0 | 0 | 0 | 0 |
| Negative Milk | 0 | 0 | 0 | 0 | 0 |

The maximum relative percentage value (Section 2) obtained with photometric reading for negative samples was 35%, whereas the minimum relative percentage value for positive samples was 94% (Table 11). These values demonstrate that with the chosen thresholds for photometric reading (65% class A; 40% class B; Table 1) the false interpretation of positive as well as negative samples can be avoided.

Table 11. Minimum and maximum photometric percentage results obtained with two photometric instruments

| Type of Milk Sample | No. Results ELISA Readers | Photometric Values Min/Max [%] |
|---------------------|---------------------------|--------------------------------|
| Positive Control | 1,136 | 94 |
| Negative Milk | 5,680 | 35 |

In conclusion, the absence of false-negative and false-positive results indicates that the validity of positive as well as negative results obtained for raw milk samples by analysis with the BRT MRL-Screening Test is very high.

9) Rate of Positive Results not caused by Residues of Veterinary Drugs

Materials and Methods

In order to demonstrate that the BRT MRL-Screening Test performs properly with a broad range of samples, the rate of positive results not caused by residues of veterinary drugs was established by analyzing 704 ex-farm bulk milk samples, originating from routine inhibitor analysis (milk quality payment testing at MPR Bayern). In order to verify the correct performance of the test all samples were examined in parallel on two different microbiological inhibitor tests (BRT Inhibitor Test and BRT hi-sense). To confirm detected inhibitors, screening-positive samples were tested on the BRT Inhibitor Test, then evaluated with receptor tests (BetaStar® 100, Neogen Corporation, Lansing, USA; Charm MRL Beta-lactam 1-Minute Test, Charm Sciences Inc., Lawrence, USA; SNAP Beta-Lactam ST Plus, IDEXX GmbH, Ludwigsburg, Germany) and identified and quantified by analysis with the biosensor MCR-3 (GWK Präzisionstechnik GmbH, Munich, Germany). The MCR-3 is an antibody-based rapid micro-array chip reader, which is capable of the simultaneous detection and quantification of 13 antibiotic substances. Furthermore, confirmed inhibitor-positive samples were quantified by LC-MS/MS analysis.

Results and Discussion

2 out of 704 samples (0.28%, Table 12) were detected positive by the BRT MRL-Screening Test. Both results were confirmed positive by evaluation with other inhibitor tests and receptor tests, the causative substance was identified as Cloxacillin by MCR-3- as well as LC-MS/MS-analysis. Cloxacillin was present in the samples at 64.8 µg/kg respectively 50.6 µg/kg. Thus, the rate of positive results not caused by residues of veterinary drugs was 0%, as all positive samples detected were confirmed to contain antibiotic inhibitors. The correct analysis of routine samples demonstrates the robust performance of the BRT MRL-Screening Test with a broad range of samples and it's applicability for real-life laboratory use.

Table 12. Routine samples analysis results

| Total No. Samples | Negative Samples | | Positive Samples | | | |
|-------------------|------------------|--------|------------------|-------|----------------|--------------------|
| | No. | Rate | No. | Rate | False positive | Confirmed positive |
| 704 | 702 | 99.72% | 2 | 0.28% | 0% | 100% |

10) Participation in an International Interlaboratory Study and Comparability

Materials and Methods

The BRT MRL-Screening Test was validated in an international interlaboratory study in order to demonstrate its robust performance and suitability for real-life laboratory applications. This interlaboratory study was conducted in parallel with the international 10th proficiency test for inhibitors, organized by the QSE GmbH. 61 laboratories belonging to 55 companies - originating from 10 countries - ,out of 148 laboratories taking part in the 10th proficiency test, assisted with the examination of provided BRT MRL-Screening Test plates for the interlaboratory study as a part of the validation.

Within the framework of the 10th proficiency test, 15 randomized and coded lyophilized UHT-milk samples were analyzed - 8 samples contained antibiotics, 7 samples consisted of inhibitor-free milk (Table 13). The antibiotics Penicillin G, Cloxacillin, Ampicillin and Cefapirin, which are often used for treatment of lactating cows, had to be detected at MRL level. These proficiency test sets were used for the interlaboratory study of the BRT MRL-Screening Test, too.

The reported results of the interlaboratory study of the BRT MRL-Screening Test and the 10th proficiency test were evaluated in parallel and compared in order to assess the performance of the validated test in correlation with other commonly used inhibitor tests (both microbiological and receptor tests).

Table 13. Composition of the proficiency test sets

| Substance | Concentration [$\mu\text{g}/\text{kg}$] | No. Samples |
|------------------|---|-------------|
| Benzylpenicillin | 4 | 2 |
| Ampicillin | 4 | 2 |
| Cefapirin | 60 | 2 |
| Cloxacillin | 30 | 2 |
| - | - | 7 |

Results and Discussion

In total, 945 results were reported for the BRT MRL-Screening Test by the interlaboratory study participants, 100% of these results were correct. No false-positive or false-negative results were observed (Figure 4).

This high rate of correct results obtained in different laboratories signifies once more that the BRT MRL-Screening Test is suitable for routine analyses as all positive and negative samples were identified properly and all examined substances were detected at MRL level.




Figure 4. Rate of correct and false results (%) obtained by the interlaboratory study within the framework of the validation of the BRT MRL-Screening Test

As part of a comparability study, the results obtained in the framework of the 10th proficiency test were contrasted with the results of the interlaboratory study of the BRT MRL-Screening Test. 2,513 results for inhibitor-free milk and 2,872 results for inhibitor-positive samples were forwarded by the 10th proficiency test participants in total. The participating laboratories indicated if microbiological test systems or receptor tests had been used for the examination of the samples. Taking into account both types of test systems, 0.7% of the inhibitor-free milk samples were detected false-positive (Figure 5). Only 0.5% of the samples analyzed with microbiological test systems were reported false-positive (Figure 6), compared with 1.0% of the samples examined with receptor tests (Figure 7). Regarding the inhibitor-positive samples, 5% in total were identified as false-negative. Especially Cloxacillin (14.3%) and Ampicillin (3.3%), but also a few samples of Benzylpenicillin (1.7%) and Cefapirin (0.7%) were not identified correctly (Figure 5). The false-negative rate was higher for receptor test systems (6.9%) than for microbiological test systems (3.7%).




Figure 5. Rates of correct and false results (%) of all test systems (microbiological and receptor tests, 10th proficiency test)

Compared with other tests evaluated in the context of the 10th proficiency test, the BRT MRL-Screening Test demonstrated an excellent performance, as no false results were observed within the interlaboratory study.




Figure 6. Rates of correct and false results (%) of microbiological test systems (10th proficiency test)




Figure 7. Rates of correct and false results (%) of receptor test systems (10th proficiency test)

11) Conclusions

The BRT MRL-Screening Test is capable of the detection of all of the 7 penicillins and 5 out of 7 cephalosporins as well as 6 out of 16 compounds belonging to other antibiotic groups investigated in this study at or below MRL level – depending on the interpretation method. This means that the most important antibiotic compounds used in Germany for the treatment of dairy cows are detected predominantly below MRL. A broad range of other inhibitors can be identified above MRL as well. The BRT MRL-Screening Test displays a high selectivity for antibiotic residues, marker substances of other veterinary classes were not detected at high concentrations. The Batch-to-Batch-Variability proved to be low, no significant differences were observed for positive result rates obtained with different plate batches. The validity of obtained results is high as no false-positive or false-negative results were observed in the analysis of positive and negative control samples. With the correct analysis of a broad range of routine milk quality payment samples, the good performance of the BRT MRL-Screening Test in an international interlaboratory study (100% correct results) and in comparison with other inhibitor tests used by laboratories participating in an international proficiency test, which was organized in parallel, it could be demonstrated that the test is fit for routine laboratory use.

12) References

COMMISSION DECISION C1 14 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results (notified under document number C(2002) 3044) (Text with EEA relevance) (2002/657/EC)
(OJ L 221, 17.8.2002, p. 8)

COMMUNITY REFERENCE LABORATORIES RESIDUES (CRLs) 20/1/2010 - Guidelines for the validation of screening methods for residues of veterinary medicines (initial validation and transfer)

ISO 13969 IDF 183 Milk and Milk products - Guidelines for a standardized description of microbial inhibitor tests

ISO 18330 IDF 188 Milk and milk products - Guidelines for the standardized description of immunoassays or receptor assays for the detection of antimicrobial residues

German Federal Office of Consumer Protection and Food Safety
Amtliche Sammlung von Untersuchungsverfahren nach § 64 LFGB (vormals §35 LMBG) Band 1 (L), L 01.01-5: Nachweis von Hemmstoffen in Sammelmilch, Agar-Diffusions-Verfahren (Brillantschwarz-Reduktionstest), Januar 2012

German Federal Office of Consumer Protection and Food Safety
Amtliche Sammlung von Untersuchungsverfahren nach § 64 LFGB (vormals §35 LMBG) Band 1 (L), L 01.00-11: Suchverfahren auf das Vorhandensein von Antiinfektiva in Milch, Agar-Diffusions-Verfahren mit *Bacillus stearothermophilus* (Brillantschwarz-Reduktionstest), Februar 1996

BEER, P. and G. SUHREN (1993): Approach for an inhibitor test kit validation program, IDF-Workshop on Residues of Antibiotics and Other Antimicrobial Inhibitors in Raw and Heat-Treated Milk, Copenhagen, collected abstracts

R Core Team, 2018. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>

AOAC Binary Data Interlaboratory Study Workbook Version 2.3

QSE GmbH, 2017: 10th proficiency test for inhibitors, Final report

13) Acknowledgements

Authors and responsible persons:

Dr. Christian Baumgartner (Milchprüfing Bayern e. V.) and Dr. Silvia Orlandini (AEOS)

The authors acknowledge the manufacturer's staff for providing all the necessary equipment and the initial training in the preliminary phase of the validation study as well as the staff of MPR Bayern, who were involved in the validation study, Christine Habel and Kerstin Karl.



Accredited laboratory according to ISO/IEC 17025



COPYRIGHT

No part of the publication (scientific data, graphs, images, etc.) protected by this copyright notice may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage and retrieval system, without written permission from the copyright owner.
All rights reserved.





© Milchprüfing Bayern e. V.
Hochstatt 2, 85283 Wolnzach, Germany
Tel: +49 8442 210, Fax: +49 8444 5210
E-Mail: validation@mpr-bayern.de





Date of publication: 09.11.2018





ANNEX





Annex Table1. Established detection limits (visual reading) compared with the EU MRL levels. Marked in red are the substances exceeding the EU MRLs.





| Group of Antibiotics | Substance | MRL EU [$\mu\text{g}/\text{kg}$] | CC β A [$\mu\text{g}/\text{kg}$] | CC β B [$\mu\text{g}/\text{kg}$] |
|------------------------|------------------------|------------------------------------|--|--|
| Penicillins | Benzylpenicillin | 4 | 2 | 1.5 |
| | Ampicillin | 4 | 2.5 | 2.5 |
| | Amoxicillin | 4 | 3 | 2.5 |
| | Cloxacillin | 30 | 25 | 20 |
| | Dicloxacillin | 30 | 12.5 | 10 |
| | Nafcillin | 30 | 10 | 8 |
| | Oxacillin | 30 | 8 | 8 |
| Cephalosporins | Cefalexin | 100 | 300 | 250 |
| | Cefapirin | 60 | 5 | 5 |
| | Cefoperazone | 50 | 30 | 25 |
| | Cefazolin | 50 | 7 | 6 |
| | Cefquinome | 20 | 200 | 200 |
| | Ceftiofur | 100 | 150 | 100 |
| | Cefalonium | 20 | 12 | 10 |
| Macrolides | Erythromycin | 40 | 80 | 60 |
| | Tylosin | 50 | 75 | 40 |
| Sulfonamides | Sulfadiazine | 100 | 300 | 100 |
| | Sulfadimethoxin | 100 | 400 | 100 |
| | Sulfamethazine | 100 | >1,000 | 200 |
| | Sulfathiazol | 100 | 200 | 60 |
| | Sulfadoxin | 100 | 400 | 300 |
| | Sulfamethoxypyridazine | 100 | 300 | 100 |
| Tetracyclines | Chlortetracycline | 100 | 600 | 400 |
| | Oxytetracycline | 100 | 600 | 300 |
| | Tetracycline | 100 | 400 | 300 |
| Aminoglycosides | Dihydrostreptomycin | 200 | 700 | 500 |
| | Streptomycin | 200 | 1,500 | 800 |
| | Gentamicin | 100 | 125 | 80 |
| | Neomycin | 1,500 | 300 | 200 |
| Fenicol | Chloramphenicol | - | 5,000 | 3,500 |





















Annex Figure 1. Dose-response curves of antibiotic substances included in the validation of the BRT MRL-Screening Test
 Red line = dose-response curve; red shade = CI; Black line = CC β A (photometric reading); Dotted line = highest concentration analyzed

Annex Table 2. Numbers and percentages of results per concentrations of samples for each class of results (1-2-0) and both reading systems (photometric and visual) separately as well as joint for both reading systems including the CI for class A results.

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC&B A | Lower 95%-CI (CC&B A) | Upper 95%-CI (CC&B A) | No. of Results (pos. Class B) | Percentage of CC&B B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|----------------------|-----------------------|-----------------------|-------------------------------|----------------------|---------------------------|
| Benzylpenicillin | Photometric | 0.5 | 80 | 0 | 0.00 | - | - | 1 | 0.01 | 79 |
| | | 0.75 | 80 | 0 | 0.00 | - | - | 2 | 0.03 | 78 |
| | | 1 | 80 | 0 | 0.00 | - | - | 17 | 0.21 | 63 |
| | | 1.5 | 80 | 58 | 0.73 | - | - | 22 | 1.00 | 0 |
| | | 2 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 2.5 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 3 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 0.5 | 120 | 0 | 0.00 | - | - | 0 | 0.00 | 120 |
| | | 0.75 | 120 | 0 | 0.00 | - | - | 5 | 0.04 | 115 |
| | | 1 | 120 | 2 | 0.02 | - | - | 19 | 0.18 | 99 |
| | | 1.5 | 120 | 98 | 0.82 | - | - | 22 | 1.00 | 0 |
| | | 2 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 2.5 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 3 | 119 | 119 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 0.5 | 200 | 0 | 0.00 | 0.00 | 0.02 | 1 | - | 199 |
| | | 0.75 | 200 | 0 | 0.00 | 0.00 | 0.02 | 7 | - | 193 |
| | | 1 | 200 | 2 | 0.01 | 0.00 | 0.04 | 36 | - | 162 |
| | | 1.5 | 200 | 156 | 0.78 | 0.62 | 0.94 | 44 | - | 0 |
| | | 2 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 |
| | | 2.5 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 |
| | 3 | 199 | 199 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| Ampicillin | Photometric | 1 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 1.5 | 80 | 0 | 0.00 | - | - | 6 | 0.08 | 74 |
| | | 2 | 80 | 2 | 0.03 | - | - | 78 | 1.00 | 0 |
| | | 2.5 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 3 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 3.5 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 4 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 1 | 120 | 0 | 0.00 | - | - | 0 | 0.00 | 120 |
| | | 1.5 | 120 | 0 | 0.00 | - | - | 2 | 0.02 | 118 |
| | | 2 | 120 | 4 | 0.03 | - | - | 106 | 0.92 | 10 |
| | | 2.5 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 3 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| 3.5 | | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 4 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Photometric + Visual | 1 | 200 | 0 | 0.00 | 0.00 | 0.02 | 0 | - | 200 | |
| | 1.5 | 200 | 0 | 0.00 | 0.00 | 0.02 | 8 | - | 192 | |
| | 2 | 200 | 6 | 0.03 | 0.01 | 0.06 | 184 | - | 10 | |
| | 2.5 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| | 3 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| | 3.5 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| 4 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| Amoxicillin | Photometric | 1 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 1.5 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 2 | 80 | 0 | 0.00 | - | - | 68 | 0.85 | 12 |
| | | 2.5 | 80 | 68 | 0.85 | - | - | 12 | 1.00 | 0 |
| | | 3 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 3.5 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 4 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 1 | 120 | 0 | 0.00 | - | - | 1 | 0.01 | 119 |
| | | 1.5 | 120 | 0 | 0.00 | - | - | 8 | 0.07 | 112 |
| | | 2 | 120 | 12 | 0.10 | - | - | 79 | 0.76 | 29 |
| | | 2.5 | 120 | 94 | 0.78 | - | - | 26 | 1.00 | 0 |
| | | 3 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| 3.5 | | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 4 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Photometric + Visual | 1 | 200 | 0 | 0.00 | 0.00 | 0.02 | 1 | - | 199 | |
| | 1.5 | 200 | 0 | 0.00 | 0.00 | 0.02 | 8 | - | 192 | |
| | 2 | 200 | 12 | 0.06 | 0.03 | 0.10 | 147 | - | 41 | |
| | 2.5 | 200 | 162 | 0.81 | 0.67 | 0.95 | 38 | - | 0 | |
| | 3 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| | 3.5 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| 4 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| Cloxacillin | Photometric | 12 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 14 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 16 | 80 | 13 | 0.16 | - | - | 44 | 0.71 | 23 |
| | | 18 | 80 | 48 | 0.60 | - | - | 32 | 1.00 | 0 |
| | | 20 | 80 | 72 | 0.90 | - | - | 8 | 1.00 | 0 |
| | | 25 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 30 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 12 | 120 | 0 | 0.00 | - | - | 0 | 0.00 | 120 |
| | | 14 | 120 | 0 | 0.00 | - | - | 0 | 0.00 | 120 |
| | | 16 | 120 | 11 | 0.09 | - | - | 48 | 0.49 | 61 |
| | | 18 | 120 | 49 | 0.41 | - | - | 47 | 0.80 | 24 |
| | | 20 | 120 | 102 | 0.85 | - | - | 18 | 1.00 | 0 |
| 25 | | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 30 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Photometric + Visual | 12 | 200 | 0 | 0.00 | 0.00 | 0.02 | 0 | - | 200 | |
| | 14 | 200 | 0 | 0.00 | 0.00 | 0.02 | 0 | - | 200 | |
| | 16 | 200 | 24 | 0.12 | 0.08 | 0.17 | 92 | - | 84 | |
| | 18 | 200 | 97 | 0.49 | 0.34 | 0.63 | 79 | - | 24 | |
| | 20 | 200 | 174 | 0.87 | 0.82 | 0.91 | 26 | - | 0 | |
| | 25 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| 30 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%- CI (CCB A) | Upper 95%- CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|---------------------|-----------------------|-----------------------|-------------------------------|---------------------|---------------------------|
| Cefapirin | Photometric | 2 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 3 | 48 | 0 | 0.00 | - | - | 16 | 0.33 | 32 |
| | | 4 | 48 | 0 | 0.00 | - | - | 8 | 0.17 | 40 |
| | | 5 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 6 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 8 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 10 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 2 | 72 | 0 | 0.00 | - | - | 0 | 0.00 | 72 |
| | | 3 | 72 | 0 | 0.00 | - | - | 8 | 0.11 | 64 |
| | | 4 | 72 | 0 | 0.00 | - | - | 5 | 0.07 | 67 |
| 5 | | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 6 | | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| Cefoperazone | Photometric + Visual | 8 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 10 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 2 | 120 | 0 | 0.00 | 0.00 | 0.03 | 0 | - | 120 |
| | | 3 | 120 | 0 | 0.00 | 0.00 | 0.03 | 24 | - | 96 |
| | | 4 | 120 | 0 | 0.00 | 0.00 | 0.03 | 13 | - | 107 |
| | Visual | 10 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 15 | 80 | 0 | 0.00 | - | - | 6 | 0.08 | 74 |
| | | 20 | 80 | 2 | 0.03 | - | - | 76 | 0.98 | 2 |
| | | 25 | 80 | 68 | 0.85 | - | - | 12 | 1.00 | 0 |
| | | 30 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| Visual | 35 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 40 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 10 | 120 | 0 | 0.00 | - | - | 0 | 0.00 | 120 | |
| | 15 | 120 | 0 | 0.00 | - | - | 7 | 0.06 | 113 | |
| | 20 | 120 | 14 | 0.12 | - | - | 97 | 0.93 | 9 | |
| Cefazolin | Photometric + Visual | 25 | 120 | 97 | 0.81 | - | - | 23 | 1.00 | 0 |
| | | 30 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 35 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 40 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 10 | 200 | 0 | 0.00 | 0.00 | 0.02 | 0 | - | 200 |
| | Visual | 15 | 200 | 0 | 0.00 | 0.00 | 0.02 | 13 | - | 187 |
| | | 20 | 200 | 16 | 0.08 | 0.05 | 0.13 | 173 | - | 11 |
| | | 25 | 200 | 165 | 0.83 | 0.68 | 0.97 | 35 | - | 0 |
| | | 30 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 |
| | | 35 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 |
| Cefquinome | Photometric | 40 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 |
| | | 4 | 48 | 0 | 0.00 | - | - | 3 | 0.06 | 45 |
| | | 5 | 48 | 0 | 0.00 | - | - | 40 | 0.83 | 8 |
| | | 6 | 48 | 30 | 0.63 | - | - | 18 | 1.00 | 0 |
| | | 7 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 8 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 9 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 10 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 4 | 72 | 0 | 0.00 | - | - | 5 | 0.07 | 67 |
| | | 5 | 72 | 0 | 0.00 | - | - | 51 | 0.71 | 21 |
| Cefazolin | Photometric + Visual | 6 | 72 | 28 | 0.39 | - | - | 44 | 1.00 | 0 |
| | | 7 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 8 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 9 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 10 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric | 4 | 120 | 0 | 0.00 | 0.00 | 0.03 | 8 | - | 112 |
| | | 5 | 120 | 0 | 0.00 | 0.00 | 0.03 | 91 | - | 29 |
| | | 6 | 120 | 58 | 0.48 | 0.00 | 0.97 | 62 | - | 0 |
| | | 7 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 8 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| Cefquinome | Photometric | 9 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 10 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 50 | 48 | 0 | 0.00 | - | - | 16 | 0.33 | 32 |
| | | 60 | 48 | 0 | 0.00 | - | - | 16 | 0.33 | 32 |
| | | 100 | 48 | 0 | 0.00 | - | - | 36 | 0.75 | 12 |
| | Visual | 200 | 48 | 40 | 0.83 | - | - | 8 | 1.00 | 0 |
| | | 300 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 500 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 50 | 72 | 1 | 0.01 | - | - | 20 | 0.29 | 51 |
| Photometric + Visual | 60 | 72 | 1 | 0.01 | - | - | 26 | 0.38 | 45 | |
| | 100 | 72 | 8 | 0.11 | - | - | 54 | 0.86 | 10 | |
| | 200 | 72 | 69 | 0.96 | - | - | 3 | 1.00 | 0 | |
| | 300 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 400 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| Cefazolin | Photometric | 500 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 50 | 120 | 1 | 0.01 | 0.00 | 0.05 | 36 | - | 83 |
| | | 60 | 120 | 1 | 0.01 | 0.00 | 0.05 | 42 | - | 77 |
| | | 100 | 120 | 8 | 0.07 | 0.03 | 0.13 | 90 | - | 22 |
| | | 200 | 120 | 109 | 0.91 | 0.84 | 0.95 | 11 | - | 0 |
| | Visual | 300 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 400 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 500 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%- CI (CCB A) | Upper 95%- CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) |
|----------------------|----------------|---------------|----------------------|-------------------------------|---------------------|-----------------------|-----------------------|-------------------------------|---------------------|---------------------------|
| Ceftiofur | Photometric | 25 | 128 | 0 | 0.00 | - | - | 0 | 0.00 | 128 |
| | | 50 | 128 | 0 | 0.00 | - | - | 35 | 0.27 | 93 |
| | | 100 | 128 | 42 | 0.33 | - | - | 86 | 1.00 | 0 |
| | | 150 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 300 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 25 | 192 | 0 | 0.00 | - | - | 0 | 0.00 | 192 |
| | | 50 | 192 | 0 | 0.00 | - | - | 21 | 0.11 | 171 |
| | | 100 | 192 | 97 | 0.51 | - | - | 91 | 0.98 | 4 |
| | | 150 | 192 | 190 | 0.99 | - | - | 2 | 1.00 | 0 |
| | | 200 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 300 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 25 | 320 | 0 | 0.00 | 0.00 | 0.01 | 0 | - | 320 | |
| | 50 | 320 | 0 | 0.00 | 0.00 | 0.01 | 56 | - | 264 | |
| | 100 | 320 | 139 | 0.43 | 0.27 | 0.60 | 177 | - | 4 | |
| | 150 | 320 | 318 | 0.99 | 0.98 | 1.00 | 2 | - | 0 | |
| | 200 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 300 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 400 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Cefalonium | Photometric | 6 | 80 | 0 | 0.00 | - | - | 0 | 0.00 | 80 |
| | | 8 | 80 | 0 | 0.00 | - | - | 50 | 0.63 | 30 |
| | | 10 | 80 | 56 | 0.70 | - | - | 24 | 1.00 | 0 |
| | | 12 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 14 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 16 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 20 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 6 | 120 | 0 | 0.00 | - | - | 0 | 0.00 | 120 |
| | | 8 | 120 | 0 | 0.00 | - | - | 33 | 0.28 | 87 |
| | | 10 | 120 | 43 | 0.36 | - | - | 77 | 1.00 | 0 |
| | | 12 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 14 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 16 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 20 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 6 | 200 | 0 | 0.00 | 0.00 | 0.02 | 0 | - | 200 | |
| | 8 | 200 | 0 | 0.00 | 0.00 | 0.02 | 83 | - | 117 | |
| | 10 | 200 | 99 | 0.50 | 0.03 | 0.96 | 101 | - | 0 | |
| | 12 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| | 14 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| | 16 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| | 20 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | |
| Erythromycin | Photometric | 30 | 128 | 0 | 0.00 | - | - | 45 | 0.35 | 83 |
| | | 40 | 128 | 2 | 0.02 | - | - | 117 | 0.93 | 9 |
| | | 50 | 128 | 16 | 0.13 | - | - | 112 | 1.00 | 0 |
| | | 60 | 128 | 41 | 0.32 | - | - | 87 | 1.00 | 0 |
| | | 80 | 128 | 127 | 0.99 | - | - | 1 | 1.00 | 0 |
| | | 100 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 120 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 30 | 192 | 0 | 0.00 | - | - | 21 | 0.11 | 171 |
| | | 40 | 192 | 9 | 0.05 | - | - | 86 | 0.49 | 97 |
| | | 50 | 192 | 60 | 0.31 | - | - | 106 | 0.86 | 26 |
| | | 60 | 192 | 91 | 0.47 | - | - | 99 | 0.99 | 2 |
| | | 80 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 100 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 120 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 30 | 320 | 0 | 0.00 | 0.00 | 0.01 | 66 | - | 254 | |
| | 40 | 320 | 11 | 0.03 | 0.02 | 0.06 | 203 | - | 106 | |
| | 50 | 320 | 76 | 0.24 | 0.00 | 0.51 | 218 | - | 26 | |
| | 60 | 320 | 132 | 0.41 | 0.08 | 0.74 | 186 | - | 2 | |
| | 80 | 320 | 319 | 1.00 | 0.98 | 1.00 | 1 | - | 0 | |
| | 100 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 120 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Tylosin | Photometric | 15 | 128 | 0 | 0.00 | - | - | 2 | 0.02 | 126 |
| | | 20 | 128 | 2 | 0.02 | - | - | 49 | 0.40 | 77 |
| | | 30 | 128 | 7 | 0.05 | - | - | 116 | 0.96 | 5 |
| | | 40 | 128 | 77 | 0.60 | - | - | 51 | 1.00 | 0 |
| | | 50 | 128 | 116 | 0.91 | - | - | 12 | 1.00 | 0 |
| | | 75 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 100 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 15 | 192 | 0 | 0.00 | - | - | 9 | 0.05 | 183 |
| | | 20 | 192 | 3 | 0.02 | - | - | 29 | 0.17 | 160 |
| | | 30 | 192 | 11 | 0.06 | - | - | 103 | 0.59 | 78 |
| | | 40 | 192 | 107 | 0.56 | - | - | 82 | 0.98 | 3 |
| | | 50 | 192 | 160 | 0.83 | - | - | 32 | 1.00 | 0 |
| | | 75 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 100 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 15 | 320 | 0 | 0.00 | 0.00 | 0.01 | 11 | - | 309 | |
| | 20 | 320 | 5 | 0.02 | 0.01 | 0.04 | 78 | - | 237 | |
| | 30 | 320 | 18 | 0.06 | 0.04 | 0.09 | 219 | - | 83 | |
| | 40 | 320 | 184 | 0.58 | 0.46 | 0.69 | 133 | - | 3 | |
| | 50 | 320 | 276 | 0.86 | 0.82 | 0.90 | 44 | - | 0 | |
| | 75 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 100 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%- CI (CCB A) | Upper 95%- CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) |
|----------------------|----------------|---------------|----------------------|-------------------------------|---------------------|-----------------------|-----------------------|-------------------------------|---------------------|---------------------------|
| Sulfadiazine | Photometric | 50 | 128 | 0 | 0.00 | - | - | 36 | 0.28 | 92 |
| | | 100 | 128 | 3 | 0.02 | - | - | 123 | 0.98 | 2 |
| | | 200 | 128 | 50 | 0.39 | - | - | 78 | 1.00 | 0 |
| | | 300 | 128 | 100 | 0.78 | - | - | 28 | 1.00 | 0 |
| | | 400 | 128 | 122 | 0.95 | - | - | 6 | 1.00 | 0 |
| | | 600 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 800 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 50 | 192 | 1 | 0.01 | - | - | 66 | 0.35 | 125 |
| | | 100 | 192 | 45 | 0.23 | - | - | 146 | 0.99 | 1 |
| | | 200 | 192 | 160 | 0.83 | - | - | 32 | 1.00 | 0 |
| | | 300 | 192 | 191 | 0.99 | - | - | 1 | 1.00 | 0 |
| | | 400 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 800 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 50 | 320 | 1 | 0.00 | 0.00 | 0.02 | 102 | - | 217 | |
| | 100 | 320 | 48 | 0.15 | 0.00 | 0.43 | 269 | - | 3 | |
| | 200 | 320 | 210 | 0.66 | 0.32 | 0.99 | 110 | - | 0 | |
| | 300 | 320 | 291 | 0.91 | 0.87 | 0.94 | 29 | - | 0 | |
| | 400 | 320 | 314 | 0.98 | 0.96 | 0.99 | 6 | - | 0 | |
| | 600 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 800 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Sulfamethoxin | Photometric | 50 | 128 | 0 | 0.00 | - | - | 30 | 0.23 | 98 |
| | | 100 | 128 | 0 | 0.00 | - | - | 126 | 0.98 | 2 |
| | | 200 | 128 | 43 | 0.34 | - | - | 85 | 1.00 | 0 |
| | | 300 | 128 | 66 | 0.52 | - | - | 62 | 1.00 | 0 |
| | | 400 | 128 | 104 | 0.81 | - | - | 24 | 1.00 | 0 |
| | | 600 | 128 | 123 | 0.96 | - | - | 5 | 1.00 | 0 |
| | | 800 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 50 | 192 | 1 | 0.01 | - | - | 43 | 0.23 | 148 |
| | | 100 | 192 | 31 | 0.16 | - | - | 152 | 0.95 | 9 |
| | | 200 | 192 | 125 | 0.65 | - | - | 67 | 1.00 | 0 |
| | | 300 | 192 | 159 | 0.83 | - | - | 33 | 1.00 | 0 |
| | | 400 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 800 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 50 | 320 | 1 | 0.00 | 0.00 | 0.02 | 73 | - | 246 | |
| | 100 | 320 | 31 | 0.10 | 0.07 | 0.13 | 278 | - | 11 | |
| | 200 | 320 | 168 | 0.53 | 0.13 | 0.92 | 152 | - | 0 | |
| | 300 | 320 | 225 | 0.70 | 0.39 | 1.00 | 95 | - | 0 | |
| | 400 | 320 | 296 | 0.93 | 0.89 | 0.95 | 24 | - | 0 | |
| | 600 | 320 | 315 | 0.98 | 0.96 | 0.99 | 5 | - | 0 | |
| | 800 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Sulfamethazine | Photometric | 50 | 48 | 0 | 0.00 | - | - | 2 | 0.04 | 46 |
| | | 100 | 48 | 1 | 0.02 | - | - | 27 | 0.58 | 20 |
| | | 200 | 48 | 2 | 0.04 | - | - | 46 | 1.00 | 0 |
| | | 300 | 48 | 5 | 0.10 | - | - | 43 | 1.00 | 0 |
| | | 500 | 48 | 11 | 0.23 | - | - | 37 | 1.00 | 0 |
| | | 750 | 48 | 29 | 0.60 | - | - | 19 | 1.00 | 0 |
| | | 1,000 | 48 | 31 | 0.65 | - | - | 17 | 1.00 | 0 |
| | Visual | 50 | 72 | 0 | 0.00 | - | - | 11 | 0.15 | 61 |
| | | 100 | 72 | 5 | 0.07 | - | - | 35 | 0.56 | 32 |
| | | 200 | 72 | 29 | 0.40 | - | - | 43 | 1.00 | 0 |
| | | 300 | 72 | 39 | 0.54 | - | - | 33 | 1.00 | 0 |
| | | 500 | 72 | 59 | 0.82 | - | - | 13 | 1.00 | 0 |
| | | 750 | 72 | 62 | 0.86 | - | - | 10 | 1.00 | 0 |
| | | 1,000 | 72 | 68 | 0.94 | - | - | 4 | 1.00 | 0 |
| Photometric + Visual | 50 | 120 | 0 | 0.00 | 0.00 | 0.03 | 13 | - | 107 | |
| | 100 | 120 | 6 | 0.05 | 0.02 | 0.11 | 62 | - | 52 | |
| | 200 | 120 | 31 | 0.26 | 0.00 | 0.69 | 89 | - | 0 | |
| | 300 | 120 | 44 | 0.37 | 0.00 | 0.89 | 76 | - | 0 | |
| | 500 | 120 | 70 | 0.58 | 0.17 | 0.99 | 50 | - | 0 | |
| | 750 | 120 | 91 | 0.76 | 0.57 | 0.95 | 29 | - | 0 | |
| | 1,000 | 120 | 99 | 0.83 | 0.63 | 1.00 | 21 | - | 0 | |
| Sulfathiazol | Photometric | 40 | 128 | 0 | 0.00 | - | - | 103 | 0.80 | 25 |
| | | 60 | 128 | 1 | 0.01 | - | - | 127 | 1.00 | 0 |
| | | 80 | 128 | 24 | 0.19 | - | - | 104 | 1.00 | 0 |
| | | 100 | 128 | 40 | 0.31 | - | - | 88 | 1.00 | 0 |
| | | 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 40 | 192 | 17 | 0.09 | - | - | 77 | 0.49 | 98 |
| | | 60 | 192 | 52 | 0.27 | - | - | 137 | 0.98 | 3 |
| | | 80 | 191 | 93 | 0.49 | - | - | 98 | 1.00 | 0 |
| | | 100 | 192 | 156 | 0.81 | - | - | 36 | 1.00 | 0 |
| | | 200 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 40 | 320 | 17 | 0.05 | 0.03 | 0.08 | 180 | - | 123 | |
| | 60 | 320 | 53 | 0.17 | 0.00 | 0.49 | 264 | - | 3 | |
| | 80 | 319 | 117 | 0.37 | 0.00 | 0.81 | 202 | - | 0 | |
| | 100 | 320 | 196 | 0.61 | 0.17 | 1.00 | 124 | - | 0 | |
| | 200 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 400 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 600 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%-CI (CCB A) | Upper 95%-CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) |
|-------------------------|----------------------|---------------|----------------------|-------------------------------|---------------------|----------------------|----------------------|-------------------------------|---------------------|---------------------------|
| Sulfadoxin | Photometric | 200 | 48 | 0 | 0.00 | - | - | 45 | 0.94 | 3 |
| | | 300 | 48 | 0 | 0.00 | - | - | 48 | 1.00 | 0 |
| | | 400 | 48 | 0 | 0.00 | - | - | 48 | 1.00 | 0 |
| | | 600 | 48 | 21 | 0.44 | - | - | 27 | 1.00 | 0 |
| | | 800 | 48 | 43 | 0.90 | - | - | 5 | 1.00 | 0 |
| | | 1,000 | 48 | 44 | 0.92 | - | - | 4 | 1.00 | 0 |
| | | 1,500 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 200 | 72 | 21 | 0.29 | - | - | 45 | 0.92 | 6 |
| | | 300 | 72 | 51 | 0.71 | - | - | 21 | 1.00 | 0 |
| | | 400 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 800 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1,500 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 200 | 120 | 21 | 0.18 | 0.00 | 0.46 | 90 | - | 9 |
| | | 300 | 120 | 51 | 0.43 | 0.00 | 0.95 | 69 | - | 0 |
| | | 400 | 120 | 72 | 0.60 | 0.00 | 1.00 | 48 | - | 0 |
| | | 600 | 120 | 93 | 0.78 | 0.41 | 1.00 | 27 | - | 0 |
| 800 | | 120 | 115 | 0.96 | 0.91 | 0.98 | 5 | - | 0 | |
| 1,000 | | 120 | 116 | 0.97 | 0.92 | 0.99 | 4 | - | 0 | |
| 1,500 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| Sulfamethoxy-pyridazine | Photometric | 50 | 128 | 0 | 0.00 | - | - | 107 | 0.84 | 21 |
| | | 100 | 128 | 0 | 0.00 | - | - | 128 | 1.00 | 0 |
| | | 200 | 128 | 78 | 0.61 | - | - | 50 | 1.00 | 0 |
| | | 300 | 128 | 113 | 0.88 | - | - | 15 | 1.00 | 0 |
| | | 500 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 750 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1,000 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 50 | 192 | 12 | 0.06 | - | - | 128 | 0.73 | 52 |
| | | 100 | 192 | 49 | 0.26 | - | - | 143 | 1.00 | 0 |
| | | 200 | 192 | 169 | 0.88 | - | - | 23 | 1.00 | 0 |
| | | 300 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 500 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 750 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1,000 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 50 | 320 | 12 | 0.04 | 0.02 | 0.06 | 235 | - | 73 |
| | | 100 | 320 | 49 | 0.15 | 0.00 | 0.56 | 271 | - | 0 |
| | | 200 | 320 | 247 | 0.77 | 0.52 | 1.00 | 73 | - | 0 |
| | | 300 | 320 | 305 | 0.95 | 0.92 | 0.97 | 15 | - | 0 |
| 500 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 750 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| 1,000 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Chlortetra-cycline | Photometric | 100 | 48 | 1 | 0.02 | - | - | 14 | 0.31 | 33 |
| | | 200 | 48 | 0 | 0.00 | - | - | 32 | 0.67 | 16 |
| | | 300 | 48 | 0 | 0.00 | - | - | 45 | 0.94 | 3 |
| | | 400 | 48 | 11 | 0.23 | - | - | 37 | 1.00 | 0 |
| | | 600 | 48 | 38 | 0.79 | - | - | 10 | 1.00 | 0 |
| | | 800 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1,000 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 100 | 72 | 4 | 0.06 | - | - | 18 | 0.31 | 50 |
| | | 200 | 72 | 0 | 0.00 | - | - | 46 | 0.64 | 26 |
| | | 300 | 72 | 9 | 0.13 | - | - | 56 | 0.90 | 7 |
| | | 400 | 72 | 25 | 0.35 | - | - | 47 | 1.00 | 0 |
| | | 600 | 72 | 70 | 0.97 | - | - | 2 | 1.00 | 0 |
| | | 800 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 100 | 120 | 5 | 0.04 | 0.02 | 0.09 | 32 | - | 83 |
| | | 200 | 120 | 0 | 0.00 | 0.00 | 0.03 | 78 | - | 42 |
| | | 300 | 120 | 9 | 0.08 | 0.04 | 0.14 | 101 | - | 10 |
| | | 400 | 120 | 36 | 0.30 | 0.19 | 0.42 | 84 | - | 0 |
| 600 | | 120 | 108 | 0.90 | 0.83 | 0.94 | 12 | - | 0 | |
| 800 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 1,000 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| Oxytetra-cycline | Photometric | 100 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 200 | 48 | 0 | 0.00 | - | - | 48 | 1.00 | 0 |
| | | 300 | 48 | 25 | 0.52 | - | - | 23 | 1.00 | 0 |
| | | 400 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 800 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1,000 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 100 | 72 | 0 | 0.00 | - | - | 2 | 0.03 | 70 |
| | | 200 | 72 | 3 | 0.04 | - | - | 45 | 0.67 | 24 |
| | | 300 | 72 | 27 | 0.38 | - | - | 42 | 0.96 | 3 |
| | | 400 | 72 | 64 | 0.89 | - | - | 8 | 1.00 | 0 |
| | | 600 | 72 | 69 | 0.96 | - | - | 3 | 1.00 | 0 |
| | | 800 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 100 | 120 | 0 | 0.00 | 0.00 | 0.03 | 2 | - | 118 |
| | | 200 | 120 | 3 | 0.03 | 0.01 | 0.07 | 93 | - | 24 |
| | | 300 | 120 | 52 | 0.43 | 0.08 | 0.79 | 65 | - | 3 |
| | | 400 | 120 | 112 | 0.93 | 0.87 | 0.97 | 8 | - | 0 |
| 600 | | 120 | 117 | 0.98 | 0.93 | 0.99 | 3 | - | 0 | |
| 800 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 1,000 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%- CI (CCB A) | Upper 95%- CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) | | |
|-----------|----------------------|----------------------|----------------------|-------------------------------|---------------------|-----------------------|-----------------------|-------------------------------|---------------------|---------------------------|------|-----|
| | Photometric | 100 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 | | |
| | | 150 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 | | |
| | | 200 | 48 | 0 | 0.00 | - | - | 23 | 0.48 | 25 | | |
| | | 300 | 48 | 0 | 0.00 | - | - | 48 | 1.00 | 0 | | |
| | | 400 | 48 | 39 | 0.81 | - | - | 9 | 1.00 | 0 | | |
| | | 600 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | 800 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Tetracycline | Visual | 100 | 72 | 0 | 0.00 | - | - | 10 | 0.14 | 62 | |
| | | | 150 | 72 | 0 | 0.00 | - | - | 30 | 0.42 | 42 | |
| | | | 200 | 72 | 3 | 0.04 | - | - | 53 | 0.78 | 16 | |
| | | | 300 | 72 | 18 | 0.25 | - | - | 54 | 1.00 | 0 | |
| | | | 400 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | | 600 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | | 800 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 100 | 120 | 0 | 0.00 | 0.00 | 0.03 | 10 | - | 110 | | |
| | | 150 | 120 | 0 | 0.00 | 0.00 | 0.03 | 30 | - | 90 | | |
| | | 200 | 120 | 3 | 0.03 | 0.01 | 0.07 | 76 | - | 41 | | |
| | | 300 | 120 | 18 | 0.15 | 0.00 | 0.56 | 102 | - | 0 | | |
| | | 400 | 120 | 111 | 0.93 | 0.86 | 0.96 | 9 | - | 0 | | |
| | | 600 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| | | 800 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| | Photometric | 200 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 | | |
| | | 300 | 48 | 0 | 0.00 | - | - | 42 | 0.88 | 6 | | |
| | | 400 | 48 | 4 | 0.08 | - | - | 44 | 1.00 | 0 | | |
| | | 500 | 48 | 22 | 0.46 | - | - | 26 | 1.00 | 0 | | |
| | | 600 | 48 | 46 | 0.96 | - | - | 2 | 1.00 | 0 | | |
| | | 700 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | 800 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | Dihydro-streptomycin | Visual | 200 | 72 | 0 | 0.00 | - | - | 3 | 0.04 | 69 |
| | 300 | | | 72 | 0 | 0.00 | - | - | 26 | 0.36 | 46 | |
| | 400 | | | 72 | 11 | 0.15 | - | - | 51 | 0.86 | 10 | |
| | 500 | | | 72 | 43 | 0.60 | - | - | 28 | 0.99 | 1 | |
| | 600 | | | 72 | 63 | 0.88 | - | - | 9 | 1.00 | 0 | |
| | 700 | | | 72 | 69 | 0.96 | - | - | 3 | 1.00 | 0 | |
| | 800 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | | |
| | Photometric + Visual | 200 | 120 | 0 | 0.00 | 0.00 | 0.03 | 3 | - | 117 | | |
| | | 300 | 120 | 0 | 0.00 | 0.00 | 0.03 | 68 | - | 52 | | |
| | | 400 | 120 | 15 | 0.13 | 0.08 | 0.20 | 95 | - | 10 | | |
| | | 500 | 120 | 65 | 0.54 | 0.33 | 0.75 | 54 | - | 1 | | |
| | | 600 | 120 | 109 | 0.91 | 0.84 | 0.95 | 11 | - | 0 | | |
| | | 700 | 120 | 117 | 0.98 | 0.93 | 0.99 | 3 | - | 0 | | |
| | | 800 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| | Photometric | 300 | 48 | 0 | 0.00 | - | - | 11 | 0.23 | 37 | | |
| | | 400 | 48 | 0 | 0.00 | - | - | 28 | 0.58 | 20 | | |
| | | 500 | 48 | 0 | 0.00 | - | - | 46 | 0.96 | 2 | | |
| | | 600 | 48 | 14 | 0.29 | - | - | 34 | 1.00 | 0 | | |
| | | 800 | 48 | 32 | 0.67 | - | - | 16 | 1.00 | 0 | | |
| | | 1,000 | 48 | 47 | 0.98 | - | - | 1 | 1.00 | 0 | | |
| | | 1,500 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | Streptomycin | Visual | 300 | 72 | 0 | 0.00 | - | - | 5 | 0.07 | 67 |
| | | | | 400 | 72 | 0 | 0.00 | - | - | 16 | 0.22 | 56 |
| | | | | 500 | 72 | 0 | 0.00 | - | - | 42 | 0.58 | 30 |
| 600 | 72 | | | 15 | 0.21 | - | - | 41 | 0.78 | 16 | | |
| 800 | 72 | | | 42 | 0.58 | - | - | 28 | 0.97 | 2 | | |
| 1,000 | 72 | | | 56 | 0.78 | - | - | 16 | 1.00 | 0 | | |
| 1,500 | 72 | | | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Photometric + Visual | 300 | 120 | 0 | 0.00 | 0.00 | 0.03 | 16 | - | 104 | | |
| | | 400 | 120 | 0 | 0.00 | 0.00 | 0.03 | 44 | - | 76 | | |
| | | 500 | 120 | 0 | 0.00 | 0.00 | 0.03 | 88 | - | 32 | | |
| | | 600 | 120 | 29 | 0.24 | 0.03 | 0.45 | 75 | - | 16 | | |
| | | 800 | 120 | 74 | 0.62 | 0.52 | 0.72 | 44 | - | 2 | | |
| | | 1,000 | 120 | 103 | 0.86 | 0.78 | 0.91 | 17 | - | 0 | | |
| | | 1,500 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| | Photometric | 40 | 128 | 0 | 0.00 | - | - | 18 | 0.14 | 110 | | |
| | | 60 | 128 | 0 | 0.00 | - | - | 104 | 0.81 | 24 | | |
| | | 80 | 128 | 7 | 0.05 | - | - | 120 | 0.99 | 1 | | |
| | | 100 | 128 | 68 | 0.53 | - | - | 60 | 1.00 | 0 | | |
| | | 125 | 128 | 83 | 0.65 | - | - | 45 | 1.00 | 0 | | |
| | | 150 | 128 | 123 | 0.96 | - | - | 5 | 1.00 | 0 | | |
| | | 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | | Gentamicin | Visual | 40 | 192 | 1 | 0.01 | - | - | 11 | 0.06 | 180 |
| 60 | 192 | | | 4 | 0.02 | - | - | 134 | 0.72 | 54 | | |
| 80 | 192 | | | 49 | 0.26 | - | - | 141 | 0.99 | 2 | | |
| 100 | 192 | | | 137 | 0.71 | - | - | 55 | 1.00 | 0 | | |
| 125 | 192 | | | 186 | 0.97 | - | - | 6 | 1.00 | 0 | | |
| 150 | 192 | | | 192 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 200 | 192 | | | 192 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Photometric + Visual | 40 | 320 | 1 | 0.00 | 0.00 | 0.02 | 29 | - | 290 | | |
| | | 60 | 320 | 4 | 0.01 | 0.00 | 0.03 | 238 | - | 78 | | |
| | | 80 | 320 | 56 | 0.18 | 0.00 | 0.56 | 261 | - | 3 | | |
| | | 100 | 320 | 205 | 0.64 | 0.43 | 0.85 | 115 | - | 0 | | |
| | | 125 | 320 | 269 | 0.84 | 0.62 | 1.00 | 51 | - | 0 | | |
| | | 150 | 320 | 315 | 0.98 | 0.96 | 0.99 | 5 | - | 0 | | |
| 200 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%- CI (CCB A) | Upper 95%- CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|---------------------|-----------------------|-----------------------|-------------------------------|---------------------|---------------------------|
| Neomycin | Photometric | 60 | 48 | 0 | 0.00 | - | - | 2 | 0.04 | 46 |
| | | 80 | 48 | 0 | 0.00 | - | - | 26 | 0.54 | 22 |
| | | 100 | 48 | 0 | 0.00 | - | - | 13 | 0.27 | 35 |
| | | 200 | 48 | 19 | 0.40 | - | - | 29 | 1.00 | 0 |
| | | 300 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 500 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 60 | 72 | 0 | 0.00 | - | - | 7 | 0.10 | 65 |
| | | 80 | 72 | 3 | 0.04 | - | - | 24 | 0.38 | 45 |
| | | 100 | 72 | 3 | 0.04 | - | - | 30 | 0.46 | 39 |
| | | 200 | 72 | 41 | 0.57 | - | - | 31 | 1.00 | 0 |
| | | 300 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 500 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 60 | 120 | 0 | 0.00 | 0.00 | 0.03 | 9 | - | 111 |
| 80 | | 120 | 3 | 0.03 | 0.01 | 0.07 | 50 | - | 67 | |
| 100 | | 120 | 3 | 0.03 | 0.01 | 0.07 | 43 | - | 74 | |
| 200 | | 120 | 60 | 0.50 | 0.18 | 0.82 | 60 | - | 0 | |
| 300 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 400 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 500 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| Chlor- amphenicol | Photometric | 2,000 | 48 | 0 | 0.00 | - | - | 13 | 0.27 | 35 |
| | | 3,000 | 48 | 0 | 0.00 | - | - | 43 | 0.90 | 5 |
| | | 3,500 | 48 | 1 | 0.02 | - | - | 47 | 1.00 | 0 |
| | | 4,000 | 48 | 8 | 0.17 | - | - | 40 | 1.00 | 0 |
| | | 5,000 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 6,000 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 7,000 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 2,000 | 72 | 0 | 0.00 | - | - | 32 | 0.44 | 40 |
| | | 3,000 | 72 | 7 | 0.10 | - | - | 53 | 0.83 | 12 |
| | | 3,500 | 72 | 18 | 0.25 | - | - | 54 | 1.00 | 0 |
| | | 4,000 | 72 | 38 | 0.53 | - | - | 34 | 1.00 | 0 |
| | | 5,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 6,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 7,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 2,000 | 120 | 0 | 0.00 | 0.00 | 0.03 | 45 | - | 75 |
| 3,000 | | 120 | 7 | 0.06 | 0.03 | 0.12 | 96 | - | 17 | |
| 3,500 | | 120 | 19 | 0.16 | 0.00 | 0.56 | 101 | - | 0 | |
| 4,000 | | 120 | 46 | 0.38 | 0.00 | 0.79 | 74 | - | 0 | |
| 5,000 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 6,000 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 7,000 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |

Annex Table 3. Contingency table created with the Fisher Test for the concentration at CCB A obtained with photometric reading, including the numbers of results of the different classes of results (1-2-0) for the different plate batches and ELISA readers

| Substance | Concentration CCB A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CCB A) |
|--------------------------|---------------------|---------------------|-------|-------------------------------|-------------------------------|---------------------------|-------------------------------------|
| Benzyl-penicillin | 2 | 1 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| Ampicillin | 2.5 | 2 | C | 8 | 0 | 0 | 1 |
| | | 1 | A | 16 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| Amoxicillin | 3 | 2 | B | 8 | 0 | 0 | 1 |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| Cloxacillin | 25 | 1 | D | 16 | 0 | 0 | 1 |
| | | 1 | E | 16 | 0 | 0 | |
| | | 1 | F | 8 | 0 | 0 | |
| | | 2 | D | 16 | 0 | 0 | |
| | | 2 | E | 16 | 0 | 0 | |
| Dicloxacillin | 12.5 | 2 | F | 8 | 0 | 0 | 1 |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| Nafcillin | 10 | 2 | B | 8 | 0 | 0 | 1 |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| Oxacillin | 8 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| Cefalexin | 300 | 2 | C | 8 | 0 | 0 | 1 |
| | | 1 | D | 8 | 0 | 0 | |
| | | 1 | E | 8 | 0 | 0 | |
| | | 1 | F | 8 | 0 | 0 | |
| | | 2 | D | 8 | 0 | 0 | |
| Cefapirin | 5 | 2 | E | 8 | 0 | 0 | 1 |
| | | 2 | F | 8 | 0 | 0 | |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| Cefoperazone | 30 | 2 | A | 8 | 0 | 0 | 1 |
| | | 2 | B | 8 | 0 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |

Continuation Annex Table 3

| Substance | Concentration CCB A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CCB A) |
|----------------------|------------------------|------------------------|-------|----------------------------------|----------------------------------|------------------------------|---|
| Cefazolin | 7 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| Cefquinome | 300 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| Ceftiofur | 150 | 1 | A | 24 | 0 | 0 | 1 |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| | | 2 | C | 24 | 0 | 0 | |
| Cefalonium | 12 | 1 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| Erythromycin | 80 | 1 | A | 24 | 0 | 0 | 1 |
| | | 1 | B | 23 | 1 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 24 | 0 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| Tylosin | 75 | 1 | D | 16 | 0 | 0 | 1 |
| | | 1 | E | 24 | 0 | 0 | |
| | | 1 | F | 24 | 0 | 0 | |
| | | 2 | D | 16 | 0 | 0 | |
| | | 2 | E | 24 | 0 | 0 | |
| | | 2 | F | 24 | 0 | 0 | |
| Sulfadiazine | 400 | 1 | A | 24 | 0 | 0 | 0.11 |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 21 | 3 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| | | 2 | C | 21 | 3 | 0 | |
| Sulfadi- methoxin | 600 | 1 | A | 24 | 0 | 0 | 0.11 |
| | | 1 | B | 21 | 3 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 22 | 2 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| Sulfamethazine | NA | 1 | A | 7 | 1 | 0 | - |
| | | 1 | B | 5 | 3 | 0 | |
| | | 1 | C | 3 | 5 | 0 | |
| | | 2 | A | 7 | 1 | 0 | |
| | | 2 | B | 6 | 2 | 0 | |
| | | 2 | C | 3 | 5 | 0 | |
| Sulfathiazol | 200 | 1 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 24 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 24 | 0 | 0 | |
| | | 2 | C | 24 | 0 | 0 | |

Continuation Annex Table 3

| Substance | Concentration CCB A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CCB A) |
|-----------------------------|------------------------|------------------------|-------|----------------------------------|----------------------------------|------------------------------|---|
| Sulfadoxin | 1,500 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| Sulfamethoxy- pyridazine | 500 | 1 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 24 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 24 | 0 | 0 | |
| | | 2 | C | 24 | 0 | 0 | |
| Chlortetra- cycline | 800 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| Oxytetracycline | 400 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| Tetracycline | 600 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| Dihydro- streptomycin | 600 | 1 | D | 8 | 0 | 0 | 1 |
| | | 1 | E | 8 | 0 | 0 | |
| | | 1 | F | 7 | 1 | 0 | |
| | | 2 | D | 8 | 0 | 0 | |
| | | 2 | E | 8 | 0 | 0 | |
| | | 2 | F | 7 | 1 | 0 | |
| Streptomycin | 1,000 | 1 | D | 7 | 1 | 0 | 1 |
| | | 1 | E | 8 | 0 | 0 | |
| | | 1 | F | 8 | 0 | 0 | |
| | | 2 | D | 8 | 0 | 0 | |
| | | 2 | E | 8 | 0 | 0 | |
| | | 2 | F | 8 | 0 | 0 | |
| Gentamicin | 150 | 1 | A | 24 | 0 | 0 | 0.11 |
| | | 1 | B | 21 | 3 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 22 | 2 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| Neomycin | 300 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| Chlor- amphenicol | 5,000 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |

Validierungsbericht **Validation Report**

BRT hi-sense



1) Introduction

The BRT hi-sense (AiM – Analytik in Milch GmbH, www.aimbavaria.com) is a highly sensitive microbiological inhibitor test for the qualitative broad-spectrum detection of antibiotic residues in cow milk. The validation study was carried out at the laboratory of Milchprüfring Bayern e. V. (MPR Bayern, www.mpr-bayern.de), a large raw milk testing laboratory performing 1.8 million inhibitor tests per year, under the conduct of Silvia Orlandini (AEOS) and Christian Baumgartner (MPR Bayern), in accordance with the Commission Decision 2002/657/EC and the CRL Guidelines (Anonymous, 2010).

2) Test Principle, Test Procedure, Reading Methods and Plate Batches

The BRT hi-sense (Figure 1) is a modified Brilliant Black Reduction Test (BRT) containing the test bacteria *G. stearotherophilus* var. *calidolactis* C953, the redox indicator brilliant black, nutrients as well as other supplements and additives, making the test more sensitive than the original BRT. Antibiotic residues present in a sample can inhibit the growth of the test bacteria, thus preventing or decelerating the reduction of the color indicator brilliant black and the consecutive color change of the test medium from blue to yellow. BRT tests generally detect a broad spectrum of antibiotics, the BRT hi-sense is distinguished by an exceptionally high detection capability for inhibitors. Substances of most relevant classes are detected below MRL level and beta-lactams in particular – for which the test germ possesses a naturally high sensitivity – are detected at very low levels.

The use of antibiotics in the field of farming is more and more within the focus of the public as consumers ask for healthy and residue-free food. Basis for the production of such dairy products is high-quality ex-farm milk, free from residues. The BRT hi-sense was developed in response to the growing demand for tests capable of the detection of anti-infectives at very sensitive levels. It is produced according to Commission Decision 91/180/EEC and § 64 LFGB (German Food, Feed and Consumer Goods Code, Methods L 01.00-11 and L 01.01-5).




Figure 1. BRT hi-sense test plates before (A) and after (B) incubation

Within the framework of this validation, the BRT hi-sense was evaluated in microtiter plate format. The plates were stored refrigerated (6 - 10 °C) until use. Additional to

the samples (100 µl milk volume), each plate contained four positive (raw milk spiked with 4 µg/kg Penicillin G, remaining blue after incubation) and four negative controls (inhibitor-free raw milk, turning yellow after incubation) in order to enable a correct evaluation. According to the manufacturer's instructions, the plates were incubated at 65 °C in a temperature-surveilled water bath until the complete discoloration of the negative control (color change from blue to yellow, Figure 1) indicated the ideal reading time (3 hrs 30 ± 30 min). Thereafter, the milk was rinsed off the cavities and the plates were assessed with 2 different reading methods: Visual examination performed by 3 technical assistants trained particularly for this purpose and photometric evaluation, using 2 instruments (ELISA reader (Multiskan Ascent V1.24, Thermo Labsystems)).

The photometric measurements were evaluated conforming to the relativized absorption method described by Beer and Suhren (1993). Accordingly, the measuring wavelength of 450 nm and the reference wavelength of 620 nm were chosen for reading. The recorded absorption values of the analyzed samples were converted into relative percentage values by setting the average absorption level of the negative controls (yellow color after incubation) as 0% and that of the positive controls (blue color after incubation) as 100%, other absorption levels (samples) were set in relation to negative (0%) and positive (100%) control.

The conversion formula is as follows:

$$(S-NC)/(PC-NC) \times 100 = X \%$$

where

- S is the analyzed sample's absorption level
- NC is the average of the four negative controls absorption levels
- PC is the average of the four positive controls absorption levels
- X relative percentage value of the analyzed sample

The photometric evaluation was regarded as reference method in this validation study as it provides objective, comparable and documented results and is commonly used by large laboratories.

The interpretation of the samples reading results was carried out in two different ways, in compliance with the method L 01.01-5 (§ 64 LFGB, inspection tests for milk quality payment) all samples exhibiting at least the color of the positive control respectively exceeding the threshold value of 65% (photometric evaluation) were interpreted as positive (indicated as class A) as well as all samples displaying a color which was clearly different from the negative control or exceeding the threshold value of 40% (indicated as class B), according to L 01.00-11 (§ 64 LFGB, German Food, Feed and Consumer Goods Code, MRL Screening test). All samples gaining <40% by photometric evaluation or appeared as yellow as the negative control were categorized as negative (Table 1).

For statistical purposes, the "quantitative" relative percentage photometric results were converted to the same format as the "qualitative" visual data. Thus, the number 1 was assigned to any photometric percentage value of ≥65 %, whereas results with

percentages in the range of 40% - <65% were referred to with 2 and negative results with 0, equaling <40% (Table 1).

Table 1. Relation of reading systems and classes of results

| Reading System | Classes of Results | | |
|----------------|--------------------|------------------|----------|
| | Positive Class A | Positive Class B | Negative |
| Visual (V) | 1 | 2 | 0 |
| ELISA (E) | ≥65% | 40% - <65% | <40% |

64,400 data results were obtained from the evaluation of 161 BRT hi-sense plates and treated statistically using "R" software (Version 3.5.0 (2018-04-23)). The confidence interval (CI) was calculated according to the AOAC approach for qualitative data.

For the validation, 7 batches of plates (Table 2) were provided by the manufacturer.

Table 2. BRT hi-sense plate batches provided for the validation

| Batch | Range of Batch Numbers |
|-------|------------------------|
| A | 70701203 - 70705645 |
| B | 70901061 - 70905373 |
| C | 71203201 - 71208367 |
| D | 70401004 - 70402315 |
| E | 71201207 - 71203904 |
| F | 71601311 - 71603483 |
| G | 73001003 - 73003175 |

3) Raw Milk Samples

A large quantity of high quality raw ex-farm bulk milk was collected, analyzed for milk quality and components (Table 3) and proven to be free of antibiotic residues by analysis with highly sensitive microbial inhibitor tests (BRT hi-sense and BRT ultra-sense, AiM GmbH, Munich, Germany) and receptor tests (BetaStar[®] 100, Neogen Corporation, Lansing, USA; Charm[®] MRL Beta-lactam Test, Charm Sciences Inc., Lawrence, USA; SNAP[®] Beta-Lactam ST-Test, IDEXX GmbH, Ludwigsburg, Germany). Additionally, the raw milk was tested with the AiM Penase Test (AiM GmbH, Munich, Germany) and proven to be free of penicillinase. Thereafter, the raw milk was aliquoted, frozen and stored until use. For the establishment of the rate of positive results not caused by residues of veterinary drugs, 704 ex-farm bulk milk samples, originating from routine milk quality payment testing, were analyzed with the BRT hi-sense.

Table 3. Analysis results of the raw milk batch used for the validation samples

| Type of Milk | FC [g/100 ml] ^a | PC [g/100 ml] ^b | pH | SCC/ml ^c | CFU/ml ^d |
|----------------|----------------------------|----------------------------|------|---------------------|---------------------|
| Blank raw Milk | 4.17 | 3.51 | 6.65 | 77,000 | 5,000 |

^a Fat content; ^b Protein content; ^c Somatic cell count; ^d Colony forming units

For the preparation of positive samples, blank raw cow milk was defrosted, spiked with a highly concentrated stock solution to obtain the desired level of antibiotic residue and frozen again. When required, the milk samples were defrosted overnight at 6 - 8 °C and used the next day. To verify the correct concentration of the stock solutions and the spiked raw milk samples, serial dilutions of the prepared positive samples were analyzed with microbiological inhibitor and - if available for a certain substance - receptor tests, then the obtained results were compared with the detection limits of the individual tests. No receptor tests were available for Erythromycin, Tylosin, Neomycin and Gentamicin, therefore the correct concentrations of the individual stock solutions were verified with LC - MS/MS analysis.

The approach of using a single batch of raw milk as base for the preparation of the spiked milk samples enhances the comparability of results obtained on different validation days and thus objectifies the assessment of the validation results, as irregularities are not attributable to deviating milk qualities. Ex-farm tank milk was chosen as basic matrix for the validation as this is the target product of the BRT hi-sense.

4) Detection Capability

Materials and Methods

Involved in the validation study were 30 antibiotic compounds (Table 6), the concentrations of the samples to analyze were chosen according to the manufacturer's specification, the choice of increment from concentration to concentration depended on the spiked standards' concentrations (Table 4) as well as on practical aspects as two classes of results had to be considered, leading to two different detection limits (CC β A and CC β B).

Table 4. Correlation of concentration and increment of the spiked raw milk samples

| Concentration [μ g/kg] | Increment [μ g/kg] |
|-----------------------------|-------------------------|
| 1-10 | 1 |
| 11-20 | 2 |
| 21-50 | 5 |
| 51-100 | 10 |
| 101-250 | 25 |
| 251-500 | 50 |
| 501-1,000 | 100 |
| 1,000-5,000 | 500 |

Correlated with the proximity to the respective EU Maximum Residue Limit (MRL) for antibiotic residues in milk, the standards were measured with 20, 40 or 60 replicates (Table 5).

Table 5. Number of replicates depending on the proximity to the respective MRL

| Closeness to MRL | No. of Replicates |
|-------------------------|--------------------------|
| ≤0.5 MRL | 20 |
| >0.5 MRL and <0.9 MRL | 40 |
| ≥0.9 MRL and ≤ MRL | 60 |
| > MRL | 20 |

For the determination of the detection capability, three different batches of plates were used at all times. The lowest concentration obtaining a minimum of 95% positive results was considered as detection limit (CC β). Based on the different interpretation methods, CC β A and CC β B (Section 2) were established in parallel for each substance. The detection limits determined with photometric evaluation were considered as reference values.

Results and Discussion

The high sensitivity of the BRT hi-sense in general and in particular for beta-lactams is reflected in the detection limits obtained for the different groups of antibiotics. All of the 14 beta-lactams were detected at or below MRL with both methods of interpretation (CC β A and CC β B) except for Cefalexin, for which only CC β B was identified below MRL, whereas CC β A was - with 125 $\mu\text{g}/\text{kg}$ - slightly above MRL (100 $\mu\text{g}/\text{kg}$). The detection limits for some beta-lactams were determined far below MRL. Benzylpenicillin, e. g., obtained a CC β A of 1 $\mu\text{g}/\text{kg}$, which is only $\frac{1}{4}$ of the MRL (4 $\mu\text{g}/\text{kg}$) and Cefapirin (CC β A 3 $\mu\text{g}/\text{kg}$) was found positive even 20 x below MRL (60 $\mu\text{g}/\text{kg}$).

At least one substance each of all other classes of antibiotics forming part of this validation was classified at or below MRL with both CC β A and CC β B. All macrolides, sulfonamides and tetracyclines conformed with the regulatory limit with CC β B with the exception of Sulfadoxin and Chlortetracycline.

Chloramphenicol, for which no MRL is established – it is prohibited for use in food producing animals (Commission Regulation (EU) No 37/2010) – can be tested positive at 2,000 $\mu\text{g}/\text{kg}$ (CC β B) or 4,000 $\mu\text{g}/\text{kg}$ (CC β A). The detection limits for the BRT hi-sense established with the reference method (photometric evaluation) are reported in Table 6, detection limits established with visual reading are reported in Annex Table 1.

In conclusion, antibiotics of all classes analyzed in this validation, comprising the most important compounds used in Germany for the treatment of dairy cows, are detected below EU MRL – especially beta-lactams far below MRL in some cases. Therefore, the BRT hi-sense complies with the requirement of detecting anti-infectives at very low levels and satisfies the public demand.

Table 6. Established detection limits (photometric reading) compared with the EU MRL levels. Marked in red are the substances exceeding the EU MRLs.

| Group of Antibiotics | Substance | MRL EU [$\mu\text{g}/\text{kg}$] | CCB A [$\mu\text{g}/\text{kg}$] | CCB B [$\mu\text{g}/\text{kg}$] |
|----------------------|------------------------|------------------------------------|-----------------------------------|-----------------------------------|
| Penicillins | Benzylpenicillin | 4 | 1 | 0.6 |
| | Ampicillin | 4 | 1.5 | 1.25 |
| | Amoxicillin | 4 | 1.5 | 1.25 |
| | Cloxacillin | 30 | 10 | 9 |
| | Dicloxacillin | 30 | 6 | 5 |
| | Nafcillin | 30 | 4 | 4 |
| | Oxacillin | 30 | 4 | 3 |
| Cephalosporins | Cefalexin | 100 | 125 | 100 |
| | Cefapirin | 60 | 3 | 2.5 |
| | Cefoperazone | 50 | 20 | 15 |
| | Cefazolin | 50 | 4 | 3 |
| | Cefquinome | 20 | 20 | 20 |
| | Ceftiofur | 100 | 10 | 10 |
| | Cefalonium | 20 | 6 | 5 |
| Macrolides | Erythromycin | 40 | 80 | 40 |
| | Tylosin | 50 | 40 | 20 |
| Sulfonamides | Sulfadiazine | 100 | 200 | 60 |
| | Sulfadimethoxin | 100 | 200 | 50 |
| | Sulfamethazine | 100 | 400 | 100 |
| | Sulfathiazol | 100 | 60 | 40 |
| | Sulfadoxin | 100 | 400 | 150 |
| | Sulfamethoxypyridazine | 100 | 100 | 40 |
| Tetracyclines | Chlortetracycline | 100 | 300 | 150 |
| | Oxytetracycline | 100 | 100 | 75 |
| | Tetracycline | 100 | 150 | 75 |
| Aminoglycosides | Dihydrostreptomycin | 200 | 300 | 150 |
| | Streptomycin | 200 | 500 | 250 |
| | Gentamicin | 100 | 40 | 10 |
| | Neomycin | 1,500 | 150 | 60 |
| Fenicol | Chloramphenicol | - | 4,000 | 2,000 |

5) Dose-Response Curves

Materials and Methods

Dose-response curves were established for all antibiotics analyzed in the validation based on the class A results (Section 2) obtained within the framework of the detection capability study with both photometric and visual evaluation. For this purpose, 7 samples containing increasing concentrations were examined for each substance, with the aim of identifying the concentrations resulting in approximately 25%, 50%, 75% and 100% positive rates and to determine the highest concentration with 0% positive results. Furthermore, lower and upper CIs were calculated for the class A results under consideration of both reading systems and included in the dose-response curves (Figure 2 and Annex Table 2).




Figure 2. Incubated BRT hi-sense plate inoculated with four positive and four negative controls as well as raw milk samples spiked with 7 different concentrations of an antibiotic substance

Results and Discussion

Figure 3 and Annex Figure 1 depict dose-response curves of all substances included in the validation of the BRT hi-sense. The response rates generated with the respective concentrations of each substance are specified in Annex Table 2. It was not always possible to obtain dose-response curves entirely corresponding to the requirements of 0%, 25%, 50%, 75% and 100% positive results. Bactericidal substances like beta-lactams mostly exhibited steeply increasing dose-response curves. For Amoxicillin, e. g., the positive response rate was 2% at 1 $\mu\text{g}/\text{kg}$, 67% at 1.25 $\mu\text{g}/\text{kg}$ already and 99% of samples were detected positive at 1.5 $\mu\text{g}/\text{kg}$. Substances like the sulfonamides and macrolides displayed more consistent curve increments, probably due to their bacteriostatic character. Tylosin obtained 6% positive results at 15 $\mu\text{g}/\text{kg}$ and ca. 22% respectively 42% at 20 $\mu\text{g}/\text{kg}$ and 25 $\mu\text{g}/\text{kg}$. At 30 $\mu\text{g}/\text{kg}$ the positive response was 74%, CC β A was established at 40 $\mu\text{g}/\text{kg}$. Principally, the confidence interval is narrow at the concentrations of the CC β and at concentrations close to 0% of positive results. Bactericidal substances tend to exhibit narrow CIs also at concentrations in between 0% and CC β , which indicates that most results of samples with different concentrations are interpreted in the same way with the different reading systems (photometric and visual) and individual readers. In contrast, bacteriostatic substances often show bigger variations in the results at the concentrations below the CC β . The bacteriostatic activity causes different degrees of inhibition and consequently of color development, which can be more difficult to interpret by human eye. While the interpretation with photometric reading systems is well standardized, the visual interpretation leads to bigger variances in the results and thus to wider CIs.




Figure 3. Dose-response curves of the bactericidal antibiotics Amoxicillin and Cefalonium and of the bacteriostatic substances Sulfadoxin and Tylosin.

Red line = dose-response curve; red shade = CI; Black line = CCB A (photometric reading);

6) Selectivity

Materials and Methods

Marker substances of commonly used classes of veterinary drugs other than antibiotics were analyzed with photometric reading in order to determine the selectivity of the BRT hi-sense. The investigated compounds included the anti-inflammatories Flunixin, Metamizole (NSAIDs) and Prednisolone (glucocorticoid) as well as antiparasitic substances (Triclabendazole and Deltamethrin). Furthermore, the polyether-antibiotic Monensin, used for ketosis treatment in dairy cows, was tested. The substances were spiked at a concentration of 100 x EU MRL and inoculated with 6 replicates (Table 7).

Results and Discussion

Highly concentrated samples of Flunixin, Metamizole, Prednisolone, Triclabendazole, Deltamethrin and Monensin did not appear positive when interpreted in comparison with the positive control (class A, Table 7). Furthermore, no positive class B (comparison with negative control) results were obtained for Metamizol and Triclabendazol. However, false-positive class B results were observed with Deltamethrin (1 out of 6 replicates), Flunixin (2/6 replicates) and Prednisolone (3/6 replicates). When analyzing milk samples spiked with Monensin, all 6 replicates generated positive class B responses.

Monensin is used for ketosis treatment, it is a bactericidal substance (polyether-antibiotic), which modifies the ruminal flora by inhibiting predominantly gram-positive bacteria, but not gram-negative germs, leading to an improved ruminal metabolism and reduced incidence of ketosis. Monensin is administered locally in the rumen, it is subject to a high first-pass metabolism, residual amounts in the blood circulation are excreted via the bile. Despite the antibiotic mode of action and the positive class B results in the selectivity study, false-positive results after the treatment of a cow with Monensin are unlikely due to its pharmacokinetic properties. The same is valid for Deltamethrin, Flunixin and Prednisolone as none of these compounds are excreted via the milk. Nevertheless, accidental direct pollution of bulk milk with these drugs should be avoided.

Principally, the observed results signify a high specificity of the BRT hi-sense for the detection of antibiotics opposed to other classes of veterinary drugs on interpretation according to class A. Positive results obtained with class B should always be confirmed with a second measurement in order to exclude non-antibacterial substances.

Table 7. Selectivity: Concentrations of analyzed substances and test results

| Use | Drug Class | Substance | MRL [$\mu\text{g}/\text{kg}$] | Concentration [$\mu\text{g}/\text{kg}$] | False positive Results | |
|------------------------------|----------------------|----------------|---------------------------------|---|------------------------|---------|
| | | | | | Class A | Class B |
| Anti-inflammatory Substances | NSAID | Flunixin | 40 | 4,000 | 0/6 | 2/6 |
| | NSAID | Metamizol | 50 | 5,000 | 0/6 | 0/6 |
| | Glucocorticoid | Prednisolon | 6 | 600 | 0/6 | 3/6 |
| Antiparasitics | Anthelmintic | Triclabendazol | 10 | 1,000 | 0/6 | 0/6 |
| | Ectoparasite | Deltamethrin | 20 | 2,000 | 0/6 | 1/6 |
| Ketosis Treatment | Polyether-Antibiotic | Monensin | 2 | 200 | 0/6 | 6/6 |

7) Batch-to-Batch Variability

Materials and Methods

In order to evaluate potential deviations in the detection capabilities of different plate batches statistically, Fisher's exact tests (method: two-sided) were applied at the concentration of the CC β A obtained with photometric reading. Contingency tables were created for the datasets of ELISA reader 1 and ELISA reader 2 to provide a basic picture of the interrelation between the two variables plate batches and number of results (class A) per batch. Due to the duration of the validation study and the limited shelf-life of the BRT hi-sense plates, two sets of plate batches (A, B, C and D, E, F) had to be used.

The Fisher's test was selected because the test is more precise than Chi square for this number of observations, the null hypothesis is based on the batches independence (the probability of the results is the same for the different batches). The Fisher's exact test was applied only to the analytes for which a CC β A could be determined. If the significance level is $\alpha = 0.05$ and the p-value < 0.05 , the null hypothesis is rejected, which would mean that there is a probability for batch-to-batch differences concerning the detection capability at the CC β A.

Results and Discussion

The Fisher's test examinations for the concentrations at CC β A indicate that there are no significant differences in between the detection sensitivities of the different plate batches used in the validation. All substances, except for Sulfathiazol, Sulfamethoxypridazine and Streptomycin, realized p-value = 1 - for Sulfathiazol, Sulfamethoxypridazine and Streptomycin the p values were $0.05 \leq p < 1$ (Table 8). In addition to the p-values (CC β A), Annex Table 3 comprises the numbers of results per class (1-2-0), plate batch and individual ELISA reader at the concentration of the CC β A.

Table 8. Contingency table created with the Fisher Test for the concentration at CCB A obtained with photometric reading

| Group of Antibiotics | Substance | MRL | CCBA [$\mu\text{g}/\text{kg}$] | p Value | | Group of Antibiotics | Substance | MRL | CCBA [$\mu\text{g}/\text{kg}$] | p Value | |
|----------------------|----------------------------------|-----|----------------------------------|---------|----------|----------------------|-------------------------|-----|----------------------------------|---------|---------|
| | | | | ELISA 1 | ELISA 2 | | | | | ELISA 1 | ELISA 2 |
| Penicillins | Benzyloxyphenoxymethylpenicillin | 4 | 1 | 1 | 1 | Sulfonamides | Sulfadiazine | 100 | 200 | 1 | 1 |
| | Ampicillin | 4 | 1.5 | 1 | 1 | | Sulfadimethoxin | 100 | 200 | 1 | 1 |
| | Amoxicillin | 4 | 1.5 | 1 | 1 | | Sulfamethazine | 100 | 400 | 1 | 1 |
| | Cloxacillin | 30 | 10 | 1 | 1 | | Sulfathiazol | 100 | 60 | 0.06 | 1 |
| | Dicloxacillin | 30 | 6 | 1 | 1 | | Sulfadoxin | 100 | 400 | 1 | 1 |
| | Nafcillin | 30 | 4 | 1 | 1 | | Sulfamethoxyipyridazine | 100 | 100 | 0.06 | 0.25 |
| Cephalosporines | Oxacillin | 30 | 4 | 1 | 1 | Tetracyclines | Chlortetracycline | 100 | 300 | 1 | 1 |
| | Cefalexin | 100 | 125 | 1 | 1 | | Oxytetracycline | 100 | 100 | 1 | 1 |
| | Cefapirin | 60 | 3 | 1 | 1 | | Tetracycline | 100 | 150 | 1 | 1 |
| | Cefoperazone | 50 | 20 | 1 | 1 | Aminoglycosides | Dihydrostreptomycin | 200 | 300 | 1 | 1 |
| | Cefazolin | 50 | 4 | 1 | 1 | | Streptomycin | 200 | 500 | 0.11 | 0.11 |
| | Cefquinome | 20 | 20 | 1 | 1 | | Gentamicin | 100 | 40 | 1 | 1 |
| Ceftiofur | 100 | 10 | 1 | 1 | Neomycin | | 1,500 | 150 | 1 | 1 | |
| Macrolides | Cefalonium | 20 | 6 | 1 | 1 | Fenicols | Chloramphenicol | - | 4,000 | 1 | 1 |
| | Erythromycin | 40 | 80 | 1 | 1 | | | | | | |
| | Tylosin | 50 | 40 | 1 | 1 | | | | | | |

Significance levels: Low: $p < 0.05$; Medium: $p < 0.01$; High: $p < 0.001$

8) False-Positive and False-Negative Rate

Materials and Methods

With each BRT hi-sense plate used during the validation study, 4 positive and negative control samples (Section 2) as well as additional 16 negative raw milk samples, adding up to 20 negative milk samples, were inoculated. By means of these samples, the rates of false-positive and false-negative results were established.

Within the framework of this validation, 161 test plates were analyzed, including 644 positive control samples and 3,220 samples of negative raw milk in total. Thus, 3,220 (positive control) respectively 16,100 (negative milk) results were obtained with photometric evaluation (2 readers) and visual reading (3 technicians, Table 9).

Table 9. Numbers of positive and negative samples and obtained results used for the establishment of the false-negative and false-positive rates

| Type of Milk Sample | No. Plates | No. Samples | No. Results ELISA Readers | No. Results Visual | Total No. Results |
|---------------------|------------|-------------|---------------------------|--------------------|-------------------|
| Positive Control | 161 | 644 | 1,288 | 1,932 | 3,220 |
| Negative Milk | | 3,220 | 6,440 | 9,660 | 16,100 |

Results and Discussion

When analyzing the results of the negative milk samples, 13 false-positive results out of 16,100 results were observed by photometric and visual evaluation, generating a false-positive rate of 0.1%. These false-positive results were probably caused by carry-over of spiked samples inoculated in adjacent cavities.

No false-negative results were obtained when analyzing the results of the positive samples, indicating a false-negative rate of 0%.

Table 10. Rates of false-negative and false-positive results of all applied reading methods and readers

| Type of Milk Sample | Rate of false Results [%] | | | | |
|---------------------|---------------------------|---------|----------|----------|----------|
| | ELISA 1 | ELISA 2 | Visual 1 | Visual 2 | Visual 3 |
| Positive Control | 0 | 0 | 0 | 0 | 0 |
| Negative Milk | 0.1 | 0.1 | 0.1 | 0.1 | 0 |

99.9% of the results obtained with negative milk generated photometric values <40%, only 0.1% of the negative milk results were false-positive with >40%. The maximum relative percentage value (Section 2) obtained with photometric reading for valid negative measurements was 39%. The minimum relative percentage value for positive samples was 90% (Table 11). These numbers demonstrate that with the chosen thresholds for photometric reading (65% class A; 40% class B; Table 1), the false interpretation of positive as well as negative samples can mostly be avoided.

Table 11. Minimum and maximum photometric percentage values of valid results (99.9%) obtained with two photometric instruments

| Type of Milk Sample | No. Results ELISA Readers | Photometric Values Min/Max [%] |
|---------------------|---------------------------|--------------------------------|
| Positive Control | 1,288 | 90 |
| Negative Milk | 6,440 | 39 |

In conclusion, the relative absence of false-negative and false-positive results imply that the validity of positive as well as negative results obtained for raw milk samples by analysis with the BRT hi-sense is very high.

9) Rate of positive Results not caused by Residues of Veterinary Drugs

Materials and Methods

In order to demonstrate that the BRT hi-sense performs properly with a broad range of samples, the rate of positive results not caused by residues of veterinary drugs was established by analyzing 704 ex-farm bulk milk samples, originating from routine inhibitor analysis (milk quality payment testing at MPR Bayern). In order to verify the correct performance of the test all samples were examined in parallel on two different microbiological inhibitor tests (BRT Inhibitor Test and BRT MRL Screening Test). To confirm detected inhibitors, screening-positive samples were tested on the BRT Inhibitor Test, then evaluated with receptor tests (BetaStar® 100, Neogen Corporation, Lansing, USA; Charm MRL Beta-lactam 1-Minute Test, Charm Sciences Inc., Lawrence, USA; SNAP Beta-Lactam ST Plus , IDEXX GmbH, Ludwigsburg, Germany) and identified and quantified by analysis with the biosensor MCR-3 (GWK Präzisionstechnik GmbH, Munich, Germany). The MCR-3 is an antibody-based rapid micro-array chip reader, which is capable of the simultaneous detection and

quantification of 13 antibiotic substances. Furthermore, confirmed inhibitor-positive samples were quantified by LC-MS/MS analysis.

Results and Discussion

2 out of 704 samples (0.28%, Table 12) were detected positive by the BRT hi-sense. Both results were confirmed positive by evaluation with other inhibitor tests and receptor tests, the causative substance was identified as Cloxacillin by MCR-3- as well as LC-MS/MS-analysis. Cloxacillin was present in the samples at 64.8 µg/kg respectively 50.6 µg/kg. Thus, the rate of positive results not caused by residues of veterinary drugs was 0%, as all positive samples detected were confirmed to contain antibiotic inhibitors. The correct analysis of routine samples demonstrates the robust performance of the BRT hi-sense with a broad range of samples and it's applicability for real-life laboratory use

Table 12. Routine samples analysis results

| Total No. Samples | Negative Samples | | Positive Samples | | | |
|-------------------|------------------|--------|------------------|-------|----------------|--------------------|
| | No. | Rate | No. | Rate | False positive | Confirmed positive |
| 704 | 702 | 99.72% | 2 | 0.28% | 0% | 100% |

10) Participation in an International Interlaboratory Study and Comparability

Materials and Methods

The BRT hi-sense was validated in an international interlaboratory study in order to demonstrate its robust performance and suitability for real-life laboratory applications. This interlaboratory study was conducted in parallel with the international 10th proficiency test for inhibitors, organized by the QSE GmbH. 61 laboratories belonging to 55 companies - originating from 10 countries - ,out of 148 laboratories taking part in the 10th proficiency test, assisted with the examination of provided BRT hi-sense plates for the interlaboratory study as a part of the validation. Within the framework of the 10th proficiency test, 15 randomized and coded lyophilized UHT-milk samples were analyzed - 8 samples contained antibiotics, 7 samples consisted of inhibitor-free milk (Table 13). The antibiotics Penicillin G, Cloxacillin, Ampicillin and Cefapirin, which are often used for treatment of lactating cows, had to be detected at MRL level. These proficiency test sets were used for the interlaboratory study of the BRT hi-sense, too.

The reported results of the interlaboratory study of the BRT hi-sense and the 10th proficiency test were evaluated in parallel and compared in order to assess the performance of the validated test in correlation with other commonly used inhibitor tests (both microbiological and receptor tests).

Table 13. Composition of the proficiency test sets

| Substance | Concentration [$\mu\text{g}/\text{kg}$] | No. Samples |
|------------------|---|-------------|
| Benzylpenicillin | 4 | 2 |
| Ampicillin | 4 | 2 |
| Cefapirin | 60 | 2 |
| Cloxacillin | 30 | 2 |
| - | - | 7 |

Results and Discussion

In total, 915 results were reported for the BRT hi-sense by the interlaboratory study participants, 99.8% of these results were correct, with the only exception of 5 inhibitor-free samples, which were evaluated false-positive by one participant, probably due to a too short incubation time. No false-negative results were observed (Figure 4).

This high rate of correct results obtained in different laboratories signifies once more that the BRT hi-sense is suitable for routine analyses as all positive and nearly all negative samples were identified properly and all examined substances were detected at MRL level.




Figure 4. Rate of correct and false results (%) obtained by the interlaboratory study within the framework of the validation of the BRT hi-sense

As part of a comparability study, the results obtained in the framework of the 10th proficiency test were contrasted with the results of the interlaboratory study of the BRT hi-sense. 2,513 results for inhibitor-free milk and 2,872 results for inhibitor-positive samples were forwarded by the 10th proficiency test participants in total. The participating laboratories indicated if microbiological test systems or receptor tests had been used for the examination of the samples. Taking into account both types of test systems, 0.7% of the inhibitor-free milk samples were detected false-positive (Figure 5). Only 0.5% of the samples analyzed with microbiological test systems were reported false-positive (Figure 6), compared with 1.0% of the samples examined with receptor tests (Figure 7). Regarding the inhibitor-positive samples, 5% in total were

identified as false-negative. Especially Cloxacillin (14.3%) and Ampicillin (3.3%), but also a few samples of Benzylpenicillin (1.7%) and Cefapirin (0.7%) were not identified correctly (Figure 5). The false-negative rate was higher for receptor test systems (6.9%) than for microbiological test systems (3.7%).

Compared with other tests evaluated in the context of the 10th proficiency test, the BRT hi-sense demonstrated an excellent performance, as an extremely low number of false results were observed within the interlaboratory study.




Figure 5. Rates of correct and false results (%) of all test systems (microbiological and receptor tests, 10th proficiency test)




Figure 6. Rates of correct and false results (%) of microbiological test systems (10th proficiency test)




Figure 7. Rates of correct and false results (%) of receptor test systems (10th proficiency test)

11) Conclusions

The BRT hi-sense is capable of the sensitive detection of all beta-lactams and of at least one substance each of all other classes of antibiotics forming part of this validation at or below MRL with both CC β A and CC β B. In total, 25 out of 30 antibiotic compounds investigated in this study were detected at or below MRL level – depending on the interpretation method. This means that the most important antibiotic compounds used in Germany for the treatment of dairy cows are detected predominantly below MRL. The BRT hi-sense displays a high selectivity for antibiotic residues, marker substances of other veterinary classes were not detected at high concentrations when interpreted in comparison with the positive control (class A). On comparison with the negative control false-positive results can occur, even though unlikely as result of a cow's treatment. Positive results should be confirmed with a second measurement. The Batch-to-Batch-Variability proved to be low, no significant differences were observed for positive result rates obtained with different plate batches. The validity of obtained results is high as extremely low false-positive and false-negative rates were observed in the analysis of positive and negative control samples. With the correct analysis of a broad range of routine milk quality payment samples, the good performance of the BRT hi-sense in an international interlaboratory study (99.8% correct results) and in comparison with other inhibitor tests used by laboratories participating in an international proficiency test, which was organized in parallel, the BRT hi-sense proves to be fit for routine laboratory use.

12) References

COMMISSION DECISION C1 14 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results (notified under document number C(2002) 3044) (Text with EEA relevance) (2002/657/EC)

(OJ L 221, 17.8.2002, p. 8)

COMMUNITY REFERENCE LABORATORIES RESIDUES (CRLs) 20/1/2010 - Guidelines for the validation of screening methods for residues of veterinary medicines (initial validation and transfer)

ISO 13969 IDF 183 Milk and Milk products - Guidelines for a standardized description of microbial inhibitor tests

ISO 18330 IDF 188 Milk and milk products - Guidelines for the standardized description of immunoassays or receptor assays for the detection of antimicrobial residues

German Federal Office of Consumer Protection and Food Safety

Amtliche Sammlung von Untersuchungsverfahren nach § 64 LFGB (vormals §35 LMBG) Band 1 (L), L 01.01-5: Nachweis von Hemmstoffen in Sammelmilch, Agar-Diffusions-Verfahren (Brillantschwarz-Reduktionstest), Januar 2012

German Federal Office of Consumer Protection and Food Safety

Amtliche Sammlung von Untersuchungsverfahren nach § 64 LFGB (vormals §35 LMBG) Band 1 (L), L 01.00-11: Suchverfahren auf das Vorhandensein von Antiinfektiva in Milch, Agar-Diffusions-Verfahren mit *Bacillus stearothermophilus* (Brillantschwarz-Reduktionstest), Februar 1996

BEER, P. and G. SUHREN (1993): Approach for an inhibitor test kit validation program, IDF-Workshop on Residues of Antibiotics and Other Antimicrobial Inhibitors in Raw and Heat-Treated Milk, Copenhagen, collected abstracts

R Core Team, 2018. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>

AOAC Binary Data Interlaboratory Study Workbook Version 2.3

QSE GmbH, 2017: 10th proficiency test for inhibitors, Final report

13) Acknowledgements

Authors and responsible persons:

Dr. Christian Baumgartner (Milchprüfing Bayern e. V.) and Dr. Silvia Orlandini (AEOS)

The authors acknowledge the manufacturer's staff for providing all the necessary equipment and the initial training in the preliminary phase of the validation study as well as the staff of MPR Bayern, who were involved in the validation study, Christine Habel and Kerstin Karl.



Accredited laboratory according to ISO/IEC 17025



COPYRIGHT

No part of the publication (scientific data, graphs, images, etc.) protected by this copyright notice may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage and retrieval system, without written permission from the copyright owner.
All rights reserved.





© Milchprüfing Bayern e. V.
Hochstatt 2, 85283 Wolnzach, Germany
Tel: +49 8442 210, Fax: +49 8444 5210
E-Mail: validation@mpr-bayern.de





Date of publication: 09.11.2018





ANNEX





Annex Table1. Established detection limits (visual reading) compared with the EU MRL levels. Marked in red are the substances exceeding the EU MRLs.





| Group of Antibiotics | Substance | MRL EU [$\mu\text{g}/\text{kg}$] | CC β A [$\mu\text{g}/\text{kg}$] | CC β B [$\mu\text{g}/\text{kg}$] |
|------------------------|------------------------|------------------------------------|--|--|
| Penicillins | Benzylpenicillin | 4 | 1 | 0.75 |
| | Ampicillin | 4 | 1.5 | 1.25 |
| | Amoxicillin | 4 | 1.5 | 1.25 |
| | Cloxacillin | 30 | 10 | 9 |
| | Dicloxacillin | 30 | 6 | 5 |
| | Nafcillin | 30 | 4 | 3 |
| | Oxacillin | 30 | 4 | 4 |
| Cephalosporins | Cefalexin | 100 | 150 | 125 |
| | Cefapirin | 60 | 3 | 2.5 |
| | Cefoperazone | 50 | 20 | 15 |
| | Cefazolin | 50 | 4 | 3 |
| | Cefquinome | 20 | 20 | 20 |
| | Ceftiofur | 100 | 15 | 10 |
| | Cefalonium | 20 | 6 | 5 |
| Macrolides | Erythromycin | 40 | 80 | 40 |
| | Tylosin | 50 | 40 | 25 |
| Sulfonamides | Sulfadiazine | 100 | 200 | 60 |
| | Sulfadimethoxin | 100 | 200 | 50 |
| | Sulfamethazine | 100 | >400 | 150 |
| | Sulfathiazol | 100 | >100 | 40 |
| | Sulfadoxin | 100 | 400 | 200 |
| | Sulfamethoxypyridazine | 100 | >200 | 60 |
| Tetracyclines | Chlortetracycline | 100 | 400 | 200 |
| | Oxytetracycline | 100 | 150 | 75 |
| | Tetracycline | 100 | 200 | 100 |
| Aminoglycosides | Dihydrostreptomycin | 200 | 300 | 150 |
| | Streptomycin | 200 | 500 | 300 |
| | Gentamicin | 100 | 40 | 30 |
| | Neomycin | 1,500 | 150 | 60 |
| Fenicol | Chloramphenicol | - | 4,000 | 2,500 |




















Annex Figure 1. Dose-response curves of antibiotic substances included in the validation of the BRT hi-sense
 Red line = dose-response curve; red shade = CI; Black line = CC β A (photometric reading);

Annex Table 2. Numbers and percentages of results per concentrations of samples for each class of results (1-2-0) and both reading systems (photometric and visual) separately as well as joint for both reading systems including the CI for class A results.

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC&A | Lower 95% CI (CC&A) | Upper 95% CI (CC&A) | No. of Results (pos. Class B) | Percentage of CC&B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|--------------------|---------------------|---------------------|-------------------------------|--------------------|---------------------------|
| Benzylpenicillin | Photometric | 0.3 | 48 | 0 | 0.00 | - | - | 2 | 0.04 | 46 |
| | | 0.4 | 48 | 2 | 0.04 | - | - | 30 | 0.67 | 16 |
| | | 0.5 | 48 | 18 | 0.38 | - | - | 14 | 0.67 | 16 |
| | | 0.6 | 48 | 28 | 0.58 | - | - | 19 | 0.98 | 1 |
| | | 0.75 | 48 | 45 | 0.94 | - | - | 3 | 1.00 | 0 |
| | | 1 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 1.5 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 0.3 | 72 | 0 | 0.00 | - | - | 2 | 0.03 | 70 |
| | | 0.4 | 72 | 2 | 0.03 | - | - | 31 | 0.46 | 39 |
| | | 0.5 | 72 | 11 | 0.15 | - | - | 36 | 0.65 | 25 |
| | | 0.6 | 72 | 29 | 0.40 | - | - | 39 | 0.94 | 4 |
| | | 0.75 | 72 | 56 | 0.78 | - | - | 16 | 1.00 | 0 |
| | | 1 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 1.5 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 0.3 | 120 | 0 | 0.00 | 0.00 | 0.03 | 4 | - | 116 |
| | | 0.4 | 120 | 4 | 0.03 | 0.01 | 0.08 | 61 | - | 55 |
| | | 0.5 | 120 | 29 | 0.24 | 0.07 | 0.42 | 50 | - | 41 |
| | | 0.6 | 120 | 57 | 0.48 | 0.29 | 0.66 | 58 | - | 5 |
| | | 0.75 | 120 | 101 | 0.84 | 0.63 | 1.00 | 19 | - | 0 |
| | | 1 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| 1.5 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| Ampicillin | Photometric | 0.5 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 0.75 | 48 | 2 | 0.04 | - | - | 6 | 0.17 | 40 |
| | | 1 | 48 | 7 | 0.15 | - | - | 23 | 0.63 | 18 |
| | | 1.25 | 48 | 43 | 0.90 | - | - | 5 | 1.00 | 0 |
| | | 1.5 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 2 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 2.5 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 0.5 | 72 | 0 | 0.00 | - | - | 0 | 0.00 | 72 |
| | | 0.75 | 72 | 3 | 0.04 | - | - | 11 | 0.19 | 58 |
| | | 1 | 72 | 8 | 0.11 | - | - | 50 | 0.81 | 14 |
| 1.25 | | 72 | 67 | 0.93 | - | - | 5 | 1.00 | 0 | |
| 1.5 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 2 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 2.5 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Photometric + Visual | 0.5 | 120 | 0 | 0.00 | 0.00 | 0.03 | 0 | - | 120 | |
| | 0.75 | 120 | 5 | 0.04 | 0.02 | 0.09 | 17 | - | 98 | |
| | 1 | 120 | 15 | 0.13 | 0.08 | 0.20 | 73 | - | 32 | |
| | 1.25 | 120 | 110 | 0.92 | 0.85 | 0.95 | 10 | - | 0 | |
| | 1.5 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | 2 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 2.5 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| Amoxicillin | Photometric | 0.5 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 0.75 | 48 | 2 | 0.04 | - | - | 8 | 0.21 | 38 |
| | | 1 | 48 | 0 | 0.00 | - | - | 31 | 0.65 | 17 |
| | | 1.25 | 48 | 32 | 0.67 | - | - | 16 | 1.00 | 0 |
| | | 1.5 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 2 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 2.5 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 0.5 | 72 | 0 | 0.00 | - | - | 0 | 0.00 | 72 |
| | | 0.75 | 72 | 1 | 0.01 | - | - | 8 | 0.13 | 63 |
| | | 1 | 72 | 2 | 0.03 | - | - | 37 | 0.54 | 33 |
| 1.25 | | 72 | 48 | 0.67 | - | - | 24 | 1.00 | 0 | |
| 1.5 | 72 | 71 | 0.99 | - | - | 1 | 1.00 | 0 | | |
| 2 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 2.5 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Photometric + Visual | 0.5 | 120 | 0 | 0.00 | 0.00 | 0.03 | 0 | - | 120 | |
| | 0.75 | 120 | 3 | 0.03 | 0.01 | 0.07 | 16 | - | 101 | |
| | 1 | 120 | 2 | 0.02 | 0.00 | 0.06 | 68 | - | 50 | |
| | 1.25 | 120 | 80 | 0.67 | 0.46 | 0.87 | 40 | - | 0 | |
| | 1.5 | 120 | 119 | 0.99 | 0.95 | 1.00 | 1 | - | 0 | |
| | 2 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 2.5 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| Cloxacillin | Photometric | 6 | 48 | 0 | 0.00 | - | - | 15 | 0.31 | 33 |
| | | 7 | 48 | 4 | 0.08 | - | - | 12 | 0.33 | 32 |
| | | 8 | 48 | 0 | 0.00 | - | - | 32 | 0.67 | 16 |
| | | 9 | 48 | 42 | 0.88 | - | - | 6 | 1.00 | 0 |
| | | 10 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 12 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 14 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | Visual | 6 | 72 | 0 | 0.00 | - | - | 5 | 0.07 |
| | 7 | | 72 | 6 | 0.08 | - | - | 13 | 0.26 | 53 |
| | 8 | | 72 | 8 | 0.11 | - | - | 33 | 0.57 | 31 |
| | 9 | | 72 | 52 | 0.72 | - | - | 20 | 1.00 | 0 |
| | 10 | | 72 | 70 | 0.97 | - | - | 2 | 1.00 | 0 |
| | 12 | | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 14 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| Photometric + Visual | 6 | 120 | 0 | 0.00 | 0.00 | 0.03 | 20 | - | 100 | |
| | 7 | 120 | 10 | 0.08 | 0.05 | 0.15 | 25 | - | 85 | |
| | 8 | 120 | 8 | 0.07 | 0.03 | 0.13 | 65 | - | 47 | |
| | 9 | 120 | 94 | 0.78 | 0.57 | 0.99 | 26 | - | 0 | |
| | 10 | 120 | 118 | 0.98 | 0.94 | 1.00 | 2 | - | 0 | |
| | 12 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 14 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%-CI (CCB A) | Upper 95%-CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) | |
|---------------|----------------------|----------------------|----------------------|-------------------------------|---------------------|----------------------|----------------------|-------------------------------|---------------------|---------------------------|------|
| Dicloxacillin | Photometric | 1 | 48 | 0 | 0.00 | - | - | 1 | 0.02 | 47 | |
| | | 2 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 | |
| | | 3 | 48 | 2 | 0.04 | - | - | 0 | 0.04 | 46 | |
| | | 4 | 48 | 0 | 0.00 | - | - | 8 | 0.17 | 40 | |
| | | 5 | 48 | 28 | 0.58 | - | - | 20 | 1.00 | 0 | |
| | | 6 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 8 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | Visual | 1 | 72 | 0 | 0.00 | - | - | 0 | 0.00 | 72 |
| | 2 | | 72 | 0 | 0.00 | - | - | 0 | 0.00 | 72 | |
| | 3 | | 72 | 2 | 0.03 | - | - | 0 | 0.03 | 70 | |
| | 4 | | 72 | 0 | 0.00 | - | - | 3 | 0.04 | 69 | |
| | 5 | | 72 | 13 | 0.18 | - | - | 58 | 0.99 | 1 | |
| | 6 | | 72 | 70 | 0.97 | - | - | 2 | 1.00 | 0 | |
| | 8 | | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | | 1 | 120 | 0 | 0.00 | 0.00 | 0.03 | 1 | - | 119 |
| | | 2 | 120 | 0 | 0.00 | 0.00 | 0.03 | 0 | - | 120 | |
| | | 3 | 120 | 4 | 0.03 | 0.01 | 0.08 | 0 | - | 116 | |
| | | 4 | 120 | 0 | 0.00 | 0.00 | 0.03 | 11 | - | 109 | |
| | | 5 | 120 | 41 | 0.34 | 0.08 | 0.60 | 78 | - | 1 | |
| | | 6 | 120 | 118 | 0.98 | 0.94 | 1.00 | 2 | - | 0 | |
| | | 8 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | | Nafcillin | Photometric | 1.5 | 48 | 0 | 0.00 | - | - | 11 | 0.23 |
| | 2 | | | 48 | 0 | 0.00 | - | - | 22 | 0.46 | 26 |
| | 2.5 | | | 48 | 0 | 0.00 | - | - | 26 | 0.54 | 22 |
| 3 | 48 | | | 10 | 0.21 | - | - | 26 | 0.75 | 12 | |
| 4 | 48 | | | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 5 | 48 | | | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 6 | 48 | | | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| Visual | 1.5 | | | 72 | 0 | 0.00 | - | - | 11 | 0.15 | 61 |
| | 2 | | 72 | 1 | 0.01 | - | - | 27 | 0.39 | 44 | |
| | 2.5 | | 72 | 0 | 0.00 | - | - | 43 | 0.60 | 29 | |
| | 3 | | 72 | 18 | 0.25 | - | - | 52 | 0.97 | 2 | |
| | 4 | | 72 | 70 | 0.97 | - | - | 2 | 1.00 | 0 | |
| | 5 | | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 6 | | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | | 1.5 | 120 | 0 | 0.00 | 0.00 | 0.03 | 22 | - | 98 |
| 2 | | | 120 | 1 | 0.01 | 0.00 | 0.05 | 49 | - | 70 | |
| 2.5 | | | 120 | 0 | 0.00 | 0.00 | 0.03 | 69 | - | 51 | |
| 3 | | | 120 | 28 | 0.23 | 0.16 | 0.31 | 78 | - | 14 | |
| 4 | | | 120 | 118 | 0.98 | 0.94 | 1.00 | 2 | - | 0 | |
| 5 | | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 6 | | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| Oxacillin | | | Photometric | 1.5 | 48 | 0 | 0.00 | - | - | 5 | 0.10 |
| | 2 | | | 48 | 0 | 0.00 | - | - | 2 | 0.04 | 46 |
| | 2.5 | | | 48 | 4 | 0.08 | - | - | 16 | 0.42 | 28 |
| | 3 | 48 | | 8 | 0.17 | - | - | 40 | 1.00 | 0 | |
| | 4 | 48 | | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 6 | 48 | | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 8 | 48 | | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 1.5 | | 72 | 0 | 0.00 | - | - | 2 | 0.03 | 70 |
| | | 2 | 72 | 0 | 0.00 | - | - | 2 | 0.03 | 70 | |
| | | 2.5 | 72 | 3 | 0.04 | - | - | 21 | 0.33 | 48 | |
| | | 3 | 72 | 10 | 0.14 | - | - | 56 | 0.92 | 6 | |
| | | 4 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 6 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 8 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | Photometric + Visual | 1.5 | 120 | 0 | 0.00 | 0.00 | 0.03 | 7 | - | 113 |
| | 2 | | 120 | 0 | 0.00 | 0.00 | 0.03 | 4 | - | 116 | |
| | 2.5 | | 120 | 7 | 0.06 | 0.03 | 0.12 | 37 | - | 76 | |
| | 3 | | 120 | 18 | 0.15 | 0.08 | 0.22 | 96 | - | 6 | |
| | 4 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | 6 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | 8 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | Cefalexin | | Photometric | 60 | 128 | 0 | 0.00 | - | - | 43 | 0.34 |
| | | 70 | | 128 | 4 | 0.03 | - | - | 49 | 0.41 | 75 |
| | | 80 | | 128 | 18 | 0.14 | - | - | 77 | 0.74 | 33 |
| 90 | | 128 | | 22 | 0.17 | - | - | 92 | 0.89 | 14 | |
| 100 | | 128 | | 68 | 0.53 | - | - | 60 | 1.00 | 0 | |
| 125 | | 128 | | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 150 | | 128 | | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| Visual | | 60 | | 192 | 0 | 0.00 | - | - | 10 | 0.05 | 182 |
| | | 70 | 192 | 5 | 0.03 | - | - | 34 | 0.20 | 153 | |
| | | 80 | 192 | 4 | 0.02 | - | - | 91 | 0.49 | 97 | |
| | | 90 | 192 | 22 | 0.11 | - | - | 113 | 0.70 | 57 | |
| | | 100 | 192 | 97 | 0.51 | - | - | 78 | 0.91 | 17 | |
| | | 125 | 192 | 150 | 0.78 | - | - | 42 | 1.00 | 0 | |
| | | 150 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | Photometric + Visual | 60 | 320 | 0 | 0.00 | 0.00 | 0.01 | 53 | - | 267 |
| 70 | | | 320 | 9 | 0.03 | 0.01 | 0.05 | 83 | - | 228 | |
| 80 | | | 320 | 22 | 0.07 | 0.05 | 0.10 | 168 | - | 130 | |
| 90 | | | 320 | 44 | 0.14 | 0.10 | 0.18 | 205 | - | 71 | |
| 100 | | | 320 | 165 | 0.52 | 0.34 | 0.69 | 138 | - | 17 | |
| 125 | | | 320 | 278 | 0.87 | 0.83 | 0.90 | 42 | - | 0 | |
| 150 | | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%-CI (CCB A) | Upper 95%-CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|---------------------|----------------------|----------------------|-------------------------------|---------------------|---------------------------|
| Cefapirin | Photometric | 1 | 48 | 0 | 0.00 | - | - | 2 | 0.04 | 46 |
| | | 1.5 | 48 | 0 | 0.00 | - | - | 4 | 0.08 | 44 |
| | | 2 | 48 | 8 | 0.17 | - | - | 20 | 0.58 | 20 |
| | | 2.5 | 48 | 30 | 0.63 | - | - | 18 | 1.00 | 0 |
| | | 3 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 4 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 5 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1 | 72 | 0 | 0.00 | - | - | 3 | 0.04 | 69 |
| | | 1.5 | 72 | 0 | 0.00 | - | - | 5 | 0.07 | 67 |
| | | 2 | 72 | 8 | 0.11 | - | - | 42 | 0.69 | 22 |
| | Photometric + Visual | 2.5 | 72 | 46 | 0.64 | - | - | 26 | 1.00 | 0 |
| | | 3 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 4 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 5 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1 | 120 | 0 | 0.00 | 0.00 | 0.03 | 5 | - | 115 |
| Cefoperazone | Photometric | 1.5 | 120 | 0 | 0.00 | 0.00 | 0.03 | 9 | - | 111 |
| | | 2 | 120 | 16 | 0.13 | 0.08 | 0.21 | 62 | - | 42 |
| | | 2.5 | 120 | 76 | 0.63 | 0.55 | 0.72 | 44 | - | 0 |
| | | 3 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 4 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | Visual | 5 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 2.5 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 5 | 48 | 0 | 0.00 | - | - | 0 | 0.00 | 48 |
| | | 7.5 | 48 | 1 | 0.02 | - | - | 1 | 0.04 | 46 |
| | | 10 | 48 | 0 | 0.00 | - | - | 5 | 0.10 | 43 |
| | Photometric + Visual | 12.5 | 48 | 9 | 0.19 | - | - | 30 | 0.81 | 9 |
| | | 15 | 48 | 40 | 0.83 | - | - | 8 | 1.00 | 0 |
| | | 20 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 2.5 | 72 | 0 | 0.00 | - | - | 1 | 0.01 | 71 |
| | | 5 | 72 | 0 | 0.00 | - | - | 0 | 0.00 | 72 |
| Visual | 7.5 | 72 | 0 | 0.00 | - | - | 2 | 0.03 | 70 | |
| | 10 | 72 | 0 | 0.00 | - | - | 6 | 0.08 | 66 | |
| | 12.5 | 72 | 11 | 0.15 | - | - | 40 | 0.71 | 21 | |
| | 15 | 72 | 42 | 0.58 | - | - | 30 | 1.00 | 0 | |
| | 20 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| Photometric + Visual | 2.5 | 120 | 0 | 0.00 | 0.00 | 0.03 | 1 | - | 119 | |
| | 5 | 120 | 0 | 0.00 | 0.00 | 0.03 | 0 | - | 120 | |
| | 7.5 | 120 | 1 | 0.01 | 0.00 | 0.05 | 3 | - | 116 | |
| | 10 | 120 | 0 | 0.00 | 0.00 | 0.03 | 11 | - | 109 | |
| | 12.5 | 120 | 20 | 0.17 | 0.02 | 0.31 | 70 | - | 30 | |
| Cefazolin | Photometric | 15 | 120 | 82 | 0.68 | 0.34 | 1.00 | 38 | - | 0 |
| | | 20 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 1 | 48 | 0 | 0.00 | - | - | 4 | 0.08 | 44 |
| | | 1.5 | 48 | 0 | 0.00 | - | - | 3 | 0.06 | 45 |
| | | 2 | 48 | 0 | 0.00 | - | - | 8 | 0.17 | 40 |
| | Photometric + Visual | 2.5 | 48 | 3 | 0.06 | - | - | 23 | 0.54 | 22 |
| | | 3 | 48 | 43 | 0.90 | - | - | 5 | 1.00 | 0 |
| | | 4 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 5 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 1 | 72 | 1 | 0.01 | - | - | 4 | 0.07 | 67 |
| | Visual | 1.5 | 72 | 2 | 0.03 | - | - | 3 | 0.07 | 67 |
| | | 2 | 72 | 0 | 0.00 | - | - | 10 | 0.14 | 62 |
| | | 2.5 | 72 | 3 | 0.04 | - | - | 33 | 0.50 | 36 |
| | | 3 | 72 | 53 | 0.74 | - | - | 18 | 0.99 | 1 |
| | | 4 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 5 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 1 | 120 | 1 | 0.01 | 0.00 | 0.05 | 8 | - | 111 | |
| | 1.5 | 120 | 2 | 0.02 | 0.00 | 0.06 | 6 | - | 112 | |
| | 2 | 120 | 0 | 0.00 | 0.00 | 0.03 | 18 | - | 102 | |
| | 2.5 | 120 | 6 | 0.05 | 0.02 | 0.11 | 56 | - | 58 | |
| Cefquinome | Photometric | 3 | 120 | 96 | 0.80 | 0.60 | 1.00 | 23 | - | 1 |
| | | 4 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 5 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 |
| | | 10 | 128 | 0 | 0.00 | - | - | 18 | 0.14 | 110 |
| | | 20 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 30 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 40 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 60 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 70 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 80 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 10 | 192 | 0 | 0.00 | - | - | 6 | 0.03 | 186 |
| | | 20 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 30 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 40 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 60 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 70 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 80 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 10 | 320 | 0 | 0.00 | 0.00 | 0.01 | 24 | - | 296 | |
| | 20 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 30 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Photometric + Visual | 40 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 60 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 70 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 80 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%-CI (CCB A) | Upper 95%-CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) | |
|----------------------|----------------------|---------------|----------------------|-------------------------------|---------------------|----------------------|----------------------|-------------------------------|---------------------|---------------------------|----|
| Ceftiofur | Photometric | 10 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 15 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 20 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 25 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 30 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 35 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 40 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Visual | 10 | 72 | 46 | 0.64 | - | - | 26 | 1.00 | 0 | |
| | | 15 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 20 | 72 | 71 | 0.99 | - | - | 1 | 1.00 | 0 | |
| | | 25 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 30 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 35 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 40 | 72 | 70 | 0.97 | - | - | 2 | 1.00 | 0 | | |
| | Photometric + Visual | 10 | 120 | 94 | 0.78 | 0.43 | 1.00 | 26 | - | 0 | |
| | | 15 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | | 20 | 120 | 119 | 0.99 | 0.95 | 1.00 | 1 | - | 0 | |
| | | 25 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | | 30 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | | 35 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| | 40 | 120 | 118 | 0.98 | 0.94 | 1.00 | 2 | - | 0 | | |
| | Cefalonium | Photometric | 2 | 48 | 0 | 0.00 | - | - | 2 | 0.04 | 46 |
| | | | 3 | 48 | 2 | 0.04 | - | - | 2 | 0.08 | 44 |
| | | | 4 | 48 | 0 | 0.00 | - | - | 21 | 0.44 | 27 |
| 5 | | | 48 | 38 | 0.79 | - | - | 10 | 1.00 | 0 | |
| 6 | | | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 8 | | | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 10 | | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| Visual | | 2 | 72 | 0 | 0.00 | - | - | 0 | 0.00 | 72 | |
| | | 3 | 72 | 1 | 0.01 | - | - | 3 | 0.06 | 68 | |
| | | 4 | 72 | 0 | 0.00 | - | - | 26 | 0.36 | 46 | |
| | 5 | 72 | 37 | 0.51 | - | - | 35 | 1.00 | 0 | | |
| Photometric + Visual | 6 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | 8 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | 10 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | 2 | 120 | 0 | 0.00 | 0.00 | 0.03 | 2 | - | 118 | | |
| | 3 | 120 | 3 | 0.03 | 0.01 | 0.07 | 5 | - | 112 | | |
| | 4 | 120 | 0 | 0.00 | 0.00 | 0.03 | 47 | - | 73 | | |
| Erythromycin | Photometric | 30 | 128 | 1 | 0.01 | - | - | 62 | 0.49 | 65 | |
| | | 40 | 128 | 5 | 0.04 | - | - | 121 | 0.98 | 2 | |
| | | 50 | 128 | 54 | 0.42 | - | - | 74 | 1.00 | 0 | |
| | | 60 | 128 | 106 | 0.83 | - | - | 22 | 1.00 | 0 | |
| | | 80 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 100 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| Tylosin | Photometric | 120 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 30 | 192 | 1 | 0.01 | - | - | 40 | 0.21 | 151 | |
| | | 40 | 192 | 4 | 0.02 | - | - | 181 | 0.96 | 7 | |
| | | 50 | 192 | 38 | 0.20 | - | - | 154 | 1.00 | 0 | |
| | | 60 | 192 | 90 | 0.47 | - | - | 102 | 1.00 | 0 | |
| | | 80 | 192 | 184 | 0.96 | - | - | 8 | 1.00 | 0 | |
| | 100 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | 120 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Photometric + Visual | 30 | 320 | 2 | 0.01 | 0.00 | 0.02 | 102 | - | 216 | |
| | | 40 | 320 | 9 | 0.03 | 0.01 | 0.05 | 302 | - | 9 | |
| 50 | | 320 | 92 | 0.29 | 0.03 | 0.55 | 228 | - | 0 | | |
| 60 | | 320 | 196 | 0.61 | 0.21 | 1.00 | 124 | - | 0 | | |
| 80 | | 320 | 312 | 0.98 | 0.95 | 0.99 | 8 | - | 0 | | |
| 100 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | |
| 120 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | | |
| Tylosin | Photometric | 15 | 80 | 6 | 0.08 | - | - | 51 | 0.71 | 23 | |
| | | 20 | 80 | 29 | 0.36 | - | - | 49 | 0.98 | 2 | |
| | | 25 | 80 | 46 | 0.58 | - | - | 34 | 1.00 | 0 | |
| | | 30 | 80 | 74 | 0.93 | - | - | 6 | 1.00 | 0 | |
| | | 40 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 50 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 75 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Visual | 15 | 120 | 5 | 0.04 | - | - | 52 | 0.48 | 63 | |
| | | 20 | 120 | 15 | 0.13 | - | - | 90 | 0.88 | 15 | |
| | | 25 | 120 | 37 | 0.31 | - | - | 83 | 1.00 | 0 | |
| 30 | | 120 | 74 | 0.62 | - | - | 46 | 1.00 | 0 | | |
| 40 | | 120 | 119 | 0.99 | - | - | 1 | 1.00 | 0 | | |
| 50 | | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| 75 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | | | |
| Photometric + Visual | 15 | 200 | 11 | 0.06 | 0.03 | 0.10 | 103 | - | 86 | | |
| | 20 | 200 | 44 | 0.22 | 0.04 | 0.40 | 139 | - | 17 | | |
| | 25 | 200 | 83 | 0.42 | 0.11 | 0.72 | 117 | - | 0 | | |
| | 30 | 200 | 148 | 0.74 | 0.37 | 1.00 | 52 | - | 0 | | |
| | 40 | 200 | 199 | 1.00 | 0.97 | 1.00 | 1 | - | 0 | | |
| | 50 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| 75 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%-CI (CCB A) | Upper 95%-CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) | |
|----------------------|----------------------|----------------------|----------------------|-------------------------------|---------------------|----------------------|----------------------|-------------------------------|---------------------|---------------------------|-----|
| Sulfadiazine | Photometric | 40 | 128 | 0 | 0.00 | - | - | 73 | 0.57 | 55 | |
| | | 50 | 128 | 2 | 0.02 | - | - | 106 | 0.84 | 20 | |
| | | 60 | 128 | 0 | 0.00 | - | - | 124 | 0.97 | 4 | |
| | | 80 | 128 | 60 | 0.47 | - | - | 68 | 1.00 | 0 | |
| | | 100 | 128 | 100 | 0.78 | - | - | 28 | 1.00 | 0 | |
| | | 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | 300 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Visual | 40 | 192 | 1 | 0.01 | - | - | 86 | 0.45 | 105 | |
| | | 50 | 192 | 7 | 0.04 | - | - | 172 | 0.93 | 10 | |
| | | 60 | 192 | 27 | 0.14 | - | - | 165 | 1.00 | 0 | |
| | | 80 | 192 | 104 | 0.54 | - | - | 88 | 1.00 | 0 | |
| | | 100 | 192 | 127 | 0.66 | - | - | 65 | 1.00 | 0 | |
| | | 200 | 192 | 190 | 0.99 | - | - | 0 | 0.99 | 0 | |
| | 300 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Sulfadi-methoxin | Photometric + Visual | 40 | 320 | 1 | 0.00 | 0.00 | 0.02 | 159 | - | 160 |
| | | | 50 | 320 | 9 | 0.03 | 0.01 | 0.05 | 278 | - | 30 |
| | | | 60 | 320 | 27 | 0.08 | 0.06 | 0.12 | 289 | - | 4 |
| | | | 80 | 320 | 164 | 0.51 | 0.09 | 0.94 | 156 | - | 0 |
| 100 | | | 320 | 227 | 0.71 | 0.25 | 1.00 | 93 | - | 0 | |
| 200 | | | 320 | 318 | 0.99 | 0.98 | 1.00 | 0 | - | 0 | |
| 300 | | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | |
| Photometric | | 30 | 128 | 8 | 0.06 | - | - | 82 | 0.70 | 38 | |
| | | 40 | 128 | 7 | 0.05 | - | - | 103 | 0.86 | 18 | |
| | | 50 | 128 | 22 | 0.17 | - | - | 104 | 0.98 | 2 | |
| | 60 | 128 | 34 | 0.27 | - | - | 94 | 1.00 | 0 | | |
| | 80 | 128 | 92 | 0.72 | - | - | 36 | 1.00 | 0 | | |
| | 100 | 128 | 113 | 0.88 | - | - | 15 | 1.00 | 0 | | |
| 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | | | |
| Sulfametha-zine | Visual | 30 | 192 | 13 | 0.07 | - | - | 67 | 0.42 | 112 | |
| | | 40 | 192 | 10 | 0.05 | - | - | 103 | 0.59 | 79 | |
| | | 50 | 192 | 24 | 0.13 | - | - | 161 | 0.96 | 7 | |
| | | 60 | 192 | 26 | 0.14 | - | - | 166 | 1.00 | 0 | |
| | | 80 | 192 | 121 | 0.63 | - | - | 71 | 1.00 | 0 | |
| | | 100 | 192 | 162 | 0.84 | - | - | 30 | 1.00 | 0 | |
| | 200 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | | |
| | Photometric + Visual | 30 | 320 | 21 | 0.07 | 0.04 | 0.10 | 149 | - | 150 | |
| | | 40 | 320 | 17 | 0.05 | 0.03 | 0.08 | 206 | - | 97 | |
| | | 50 | 320 | 46 | 0.14 | 0.11 | 0.19 | 265 | - | 9 | |
| 60 | | 320 | 60 | 0.19 | 0.07 | 0.31 | 260 | - | 0 | | |
| 80 | | 320 | 213 | 0.67 | 0.38 | 0.95 | 107 | - | 0 | | |
| 100 | | 320 | 275 | 0.86 | 0.82 | 0.89 | 45 | - | 0 | | |
| 200 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | | | |
| Sulfathiazol | Photometric | 50 | 128 | 0 | 0.00 | - | - | 64 | 0.50 | 64 | |
| | | 75 | 128 | 2 | 0.02 | - | - | 112 | 0.89 | 14 | |
| | | 100 | 128 | 8 | 0.06 | - | - | 120 | 1.00 | 0 | |
| | | 150 | 128 | 56 | 0.44 | - | - | 72 | 1.00 | 0 | |
| | | 200 | 128 | 100 | 0.78 | - | - | 28 | 1.00 | 0 | |
| | | 300 | 128 | 120 | 0.94 | - | - | 8 | 1.00 | 0 | |
| | | 400 | 128 | 126 | 0.98 | - | - | 2 | 1.00 | 0 | |
| | | Visual | 50 | 192 | 0 | 0.00 | - | - | 27 | 0.14 | 165 |
| | 75 | | 192 | 3 | 0.02 | - | - | 69 | 0.38 | 120 | |
| | 100 | | 192 | 2 | 0.01 | - | - | 137 | 0.72 | 53 | |
| | 150 | | 192 | 67 | 0.35 | - | - | 118 | 0.96 | 7 | |
| | 200 | | 192 | 136 | 0.71 | - | - | 56 | 1.00 | 0 | |
| | 300 | | 192 | 149 | 0.78 | - | - | 43 | 1.00 | 0 | |
| | 400 | 192 | 157 | 0.82 | - | - | 35 | 1.00 | 0 | | |
| Photometric + Visual | 50 | 320 | 0 | 0.00 | 0.00 | 0.01 | 91 | - | 229 | | |
| | 75 | 320 | 5 | 0.02 | 0.01 | 0.04 | 181 | - | 134 | | |
| | 100 | 320 | 10 | 0.03 | 0.02 | 0.06 | 257 | - | 53 | | |
| | 150 | 320 | 123 | 0.38 | 0.15 | 0.62 | 190 | - | 7 | | |
| | 200 | 320 | 236 | 0.74 | 0.40 | 1.00 | 84 | - | 0 | | |
| | 300 | 320 | 269 | 0.84 | 0.59 | 1.00 | 51 | - | 0 | | |
| | 400 | 320 | 283 | 0.88 | 0.85 | 0.92 | 37 | - | 0 | | |
| | Sulfathiazol | Photometric | 20 | 80 | 3 | 0.04 | - | - | 26 | 0.36 | 51 |
| 30 | | | 80 | 3 | 0.04 | - | - | 71 | 0.93 | 6 | |
| 40 | | | 80 | 42 | 0.53 | - | - | 38 | 1.00 | 0 | |
| 50 | | | 80 | 34 | 0.43 | - | - | 46 | 1.00 | 0 | |
| 60 | | | 80 | 76 | 0.95 | - | - | 4 | 1.00 | 0 | |
| 80 | | | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| 100 | | | 80 | 79 | 0.99 | - | - | 1 | 1.00 | 0 | |
| Visual | | | 20 | 120 | 1 | 0.01 | - | - | 20 | 0.18 | 99 |
| | | 30 | 120 | 2 | 0.02 | - | - | 39 | 0.34 | 79 | |
| | | 40 | 120 | 47 | 0.39 | - | - | 73 | 1.00 | 0 | |
| | | 50 | 120 | 20 | 0.17 | - | - | 100 | 1.00 | 0 | |
| | | 60 | 120 | 80 | 0.67 | - | - | 40 | 1.00 | 0 | |
| | | 80 | 120 | 109 | 0.91 | - | - | 11 | 1.00 | 0 | |
| 100 | | 120 | 112 | 0.93 | - | - | 8 | 1.00 | 0 | | |
| Photometric + Visual | 20 | 200 | 4 | 0.02 | 0.01 | 0.05 | 46 | - | 150 | | |
| | 30 | 200 | 5 | 0.03 | 0.01 | 0.06 | 110 | - | 85 | | |
| | 40 | 200 | 89 | 0.45 | 0.28 | 0.61 | 111 | - | 0 | | |
| | 50 | 200 | 54 | 0.27 | 0.06 | 0.48 | 146 | - | 0 | | |
| | 60 | 200 | 156 | 0.78 | 0.47 | 1.00 | 44 | - | 0 | | |
| | 80 | 200 | 189 | 0.95 | 0.90 | 0.97 | 11 | - | 0 | | |
| | 100 | 200 | 191 | 0.96 | 0.92 | 0.98 | 9 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%-CI (CCB A) | Upper 95%-CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) |
|-------------------------|----------------------|---------------|----------------------|-------------------------------|---------------------|----------------------|----------------------|-------------------------------|---------------------|---------------------------|
| Sulfadoxin | Photometric | 50 | 128 | 0 | 0.00 | - | - | 22 | 0.17 | 106 |
| | | 75 | 128 | 0 | 0.00 | - | - | 53 | 0.41 | 75 |
| | | 100 | 128 | 2 | 0.02 | - | - | 105 | 0.84 | 21 |
| | | 150 | 128 | 2 | 0.02 | - | - | 124 | 0.98 | 2 |
| | | 200 | 128 | 51 | 0.40 | - | - | 77 | 1.00 | 0 |
| | | 300 | 128 | 108 | 0.84 | - | - | 20 | 1.00 | 0 |
| | | 400 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 50 | 192 | 2 | 0.01 | - | - | 8 | 0.05 | 182 |
| | | 75 | 192 | 1 | 0.01 | - | - | 36 | 0.19 | 155 |
| | | 100 | 192 | 4 | 0.02 | - | - | 93 | 0.51 | 95 |
| | | 150 | 192 | 18 | 0.09 | - | - | 162 | 0.94 | 12 |
| | | 200 | 192 | 73 | 0.38 | - | - | 119 | 1.00 | 0 |
| | | 300 | 192 | 169 | 0.88 | - | - | 23 | 1.00 | 0 |
| | | 400 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Photometric + Visual | 50 | 320 | 2 | 0.01 | 0.00 | 0.02 | 30 | - | 288 |
| | | 75 | 320 | 1 | 0.00 | 0.00 | 0.02 | 89 | - | 230 |
| | | 100 | 320 | 6 | 0.02 | 0.01 | 0.04 | 198 | - | 116 |
| | | 150 | 320 | 20 | 0.06 | 0.04 | 0.09 | 286 | - | 14 |
| | | 200 | 320 | 124 | 0.39 | 0.08 | 0.69 | 196 | - | 0 |
| | | 300 | 320 | 277 | 0.87 | 0.82 | 0.90 | 43 | - | 0 |
| | | 400 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 |
| Sulfamethoxy-pyridazine | Photometric | 40 | 128 | 8 | 0.06 | - | - | 120 | 1.00 | 0 |
| | | 50 | 128 | 36 | 0.28 | - | - | 92 | 1.00 | 0 |
| | | 60 | 128 | 85 | 0.66 | - | - | 43 | 1.00 | 0 |
| | | 80 | 128 | 95 | 0.74 | - | - | 33 | 1.00 | 0 |
| | | 100 | 128 | 125 | 0.98 | - | - | 3 | 1.00 | 0 |
| | | 150 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 40 | 192 | 14 | 0.07 | - | - | 103 | 0.61 | 75 |
| | | 50 | 192 | 37 | 0.19 | - | - | 118 | 0.81 | 37 |
| | | 60 | 192 | 106 | 0.55 | - | - | 86 | 1.00 | 0 |
| | | 80 | 192 | 126 | 0.66 | - | - | 66 | 1.00 | 0 |
| | | 100 | 192 | 165 | 0.86 | - | - | 27 | 1.00 | 0 |
| | | 150 | 192 | 167 | 0.87 | - | - | 25 | 1.00 | 0 |
| | | 200 | 192 | 165 | 0.86 | - | - | 27 | 1.00 | 0 |
| Photometric + Visual | 40 | 320 | 22 | 0.07 | 0.05 | 0.10 | 223 | - | 75 | |
| | 50 | 320 | 73 | 0.23 | 0.09 | 0.36 | 210 | - | 37 | |
| | 60 | 320 | 191 | 0.60 | 0.24 | 0.95 | 129 | - | 0 | |
| | 80 | 320 | 221 | 0.69 | 0.34 | 1.00 | 99 | - | 0 | |
| | 100 | 320 | 290 | 0.91 | 0.87 | 0.93 | 30 | - | 0 | |
| | 150 | 320 | 295 | 0.92 | 0.89 | 0.95 | 25 | - | 0 | |
| | 200 | 320 | 293 | 0.92 | 0.88 | 0.94 | 27 | - | 0 | |
| Chlortetra-cycline | Photometric | 75 | 128 | 0 | 0.00 | - | - | 60 | 0.47 | 68 |
| | | 100 | 128 | 0 | 0.00 | - | - | 65 | 0.51 | 63 |
| | | 150 | 128 | 22 | 0.17 | - | - | 101 | 0.96 | 5 |
| | | 200 | 128 | 58 | 0.45 | - | - | 70 | 1.00 | 0 |
| | | 300 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 400 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 75 | 192 | 0 | 0.00 | - | - | 20 | 0.10 | 172 |
| | | 100 | 192 | 0 | 0.00 | - | - | 44 | 0.23 | 148 |
| | | 150 | 192 | 16 | 0.08 | - | - | 157 | 0.90 | 19 |
| | | 200 | 192 | 54 | 0.28 | - | - | 138 | 1.00 | 0 |
| | | 300 | 192 | 171 | 0.89 | - | - | 21 | 1.00 | 0 |
| | | 400 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 600 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 75 | 320 | 0 | 0.00 | 0.00 | 0.01 | 80 | - | 240 | |
| | 100 | 320 | 0 | 0.00 | 0.00 | 0.01 | 109 | - | 211 | |
| | 150 | 320 | 38 | 0.12 | 0.09 | 0.16 | 258 | - | 24 | |
| | 200 | 320 | 112 | 0.35 | 0.20 | 0.50 | 208 | - | 0 | |
| | 300 | 320 | 299 | 0.93 | 0.90 | 0.96 | 21 | - | 0 | |
| | 400 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 600 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Oxytetra-cycline | Photometric | 25 | 128 | 0 | 0.00 | - | - | 10 | 0.08 | 118 |
| | | 50 | 128 | 4 | 0.03 | - | - | 116 | 0.94 | 8 |
| | | 75 | 128 | 33 | 0.26 | - | - | 95 | 1.00 | 0 |
| | | 100 | 128 | 126 | 0.98 | - | - | 2 | 1.00 | 0 |
| | | 150 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 300 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 |
| | Visual | 25 | 192 | 0 | 0.00 | - | - | 0 | 0.00 | 192 |
| | | 50 | 192 | 1 | 0.01 | - | - | 58 | 0.31 | 133 |
| | | 75 | 192 | 21 | 0.11 | - | - | 161 | 0.95 | 10 |
| | | 100 | 192 | 112 | 0.58 | - | - | 80 | 1.00 | 0 |
| | | 150 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 200 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 300 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 |
| Photometric + Visual | 25 | 320 | 0 | 0.00 | 0.00 | 0.01 | 10 | - | 310 | |
| | 50 | 320 | 5 | 0.02 | 0.01 | 0.04 | 174 | - | 141 | |
| | 75 | 320 | 54 | 0.17 | 0.02 | 0.31 | 256 | - | 10 | |
| | 100 | 320 | 238 | 0.74 | 0.35 | 1.00 | 82 | - | 0 | |
| | 150 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 200 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | 300 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CCB A | Lower 95%-CI (CCB A) | Upper 95%-CI (CCB A) | No. of Results (pos. Class B) | Percentage of CCB B | No. of Results (negative) | |
|----------------------|----------------------|---------------|----------------------|-------------------------------|---------------------|----------------------|----------------------|-------------------------------|---------------------|---------------------------|-----|
| Tetracycline | Photometric | 50 | 128 | 0 | 0.00 | - | - | 58 | 0.45 | 70 | |
| | | 75 | 128 | 8 | 0.06 | - | - | 116 | 0.97 | 4 | |
| | | 100 | 128 | 72 | 0.56 | - | - | 56 | 1.00 | 0 | |
| | | 150 | 128 | 126 | 0.98 | - | - | 2 | 1.00 | 0 | |
| | | 200 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 300 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 400 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 50 | 192 | 2 | 0.01 | - | - | 18 | 0.10 | 172 | |
| | | 75 | 192 | 13 | 0.07 | - | - | 125 | 0.72 | 54 | |
| | | 100 | 192 | 56 | 0.29 | - | - | 134 | 0.99 | 2 | |
| | | 150 | 192 | 143 | 0.74 | - | - | 49 | 1.00 | 0 | |
| | | 200 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 300 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 400 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 50 | 320 | 2 | 0.01 | 0.00 | 0.02 | 76 | - | 242 | |
| | | 75 | 320 | 21 | 0.07 | 0.04 | 0.10 | 241 | - | 58 | |
| | | 100 | 320 | 128 | 0.40 | 0.12 | 0.68 | 190 | - | 2 | |
| | | 150 | 320 | 269 | 0.84 | 0.54 | 1.00 | 51 | - | 0 | |
| | | 200 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | | 300 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | | 400 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | Dihydro-streptomycin | Photometric | 50 | 128 | 0 | 0.00 | - | - | 15 | 0.12 | 113 |
| | | | 100 | 128 | 0 | 0.00 | - | - | 103 | 0.80 | 25 |
| | | | 150 | 128 | 79 | 0.62 | - | - | 48 | 0.99 | 1 |
| 200 | | | 128 | 115 | 0.90 | - | - | 13 | 1.00 | 0 | |
| 300 | | | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| Visual | | 400 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 500 | 128 | 128 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 50 | 192 | 0 | 0.00 | - | - | 2 | 0.01 | 190 | |
| | | 100 | 192 | 7 | 0.04 | - | - | 68 | 0.39 | 117 | |
| | | 150 | 192 | 101 | 0.53 | - | - | 88 | 0.98 | 3 | |
| Streptomycin | Photometric | 200 | 192 | 148 | 0.77 | - | - | 44 | 1.00 | 0 | |
| | | 300 | 192 | 189 | 0.98 | - | - | 3 | 1.00 | 0 | |
| | | 400 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 500 | 192 | 192 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 50 | 320 | 0 | 0.00 | 0.00 | 0.01 | 17 | - | 303 | |
| | Photometric + Visual | 100 | 320 | 7 | 0.02 | 0.01 | 0.04 | 171 | - | 142 | |
| | | 150 | 320 | 180 | 0.56 | 0.25 | 0.88 | 136 | - | 4 | |
| | | 200 | 320 | 263 | 0.82 | 0.58 | 1.00 | 57 | - | 0 | |
| | | 300 | 320 | 317 | 0.99 | 0.97 | 1.00 | 3 | - | 0 | |
| | | 400 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| Gentamicin | Photometric | 500 | 320 | 320 | 1.00 | 0.99 | 1.00 | 0 | - | 0 | |
| | | 100 | 128 | 3 | 0.02 | - | - | 21 | 0.19 | 104 | |
| | | 150 | 128 | 2 | 0.02 | - | - | 70 | 0.56 | 56 | |
| | | 200 | 128 | 8 | 0.06 | - | - | 91 | 0.77 | 29 | |
| | | 250 | 128 | 28 | 0.22 | - | - | 95 | 0.96 | 5 | |
| | Visual | 300 | 128 | 49 | 0.38 | - | - | 76 | 0.98 | 3 | |
| | | 400 | 128 | 101 | 0.79 | - | - | 27 | 1.00 | 0 | |
| | | 500 | 128 | 122 | 0.95 | - | - | 6 | 1.00 | 0 | |
| | | 100 | 192 | 3 | 0.02 | - | - | 11 | 0.07 | 178 | |
| | | 150 | 192 | 1 | 0.01 | - | - | 62 | 0.33 | 129 | |
| Streptomycin | Visual | 200 | 192 | 15 | 0.08 | - | - | 118 | 0.69 | 59 | |
| | | 250 | 192 | 35 | 0.18 | - | - | 146 | 0.94 | 11 | |
| | | 300 | 192 | 63 | 0.33 | - | - | 121 | 0.96 | 8 | |
| | | 400 | 192 | 161 | 0.84 | - | - | 30 | 0.99 | 1 | |
| | | 500 | 192 | 182 | 0.95 | - | - | 10 | 1.00 | 0 | |
| | Photometric + Visual | 100 | 320 | 6 | 0.02 | 0.01 | 0.04 | 32 | - | 282 | |
| | | 150 | 320 | 3 | 0.01 | 0.00 | 0.03 | 132 | - | 185 | |
| | | 200 | 320 | 23 | 0.07 | 0.05 | 0.11 | 209 | - | 88 | |
| | | 250 | 320 | 63 | 0.20 | 0.00 | 0.41 | 241 | - | 16 | |
| | | 300 | 320 | 112 | 0.35 | 0.16 | 0.55 | 197 | - | 11 | |
| Gentamicin | Photometric | 400 | 320 | 262 | 0.82 | 0.77 | 0.87 | 57 | - | 1 | |
| | | 500 | 320 | 304 | 0.95 | 0.92 | 0.97 | 16 | - | 0 | |
| | | 10 | 80 | 58 | 0.73 | - | - | 22 | 1.00 | 0 | |
| | | 20 | 80 | 14 | 0.18 | - | - | 62 | 0.95 | 4 | |
| | | 30 | 80 | 60 | 0.75 | - | - | 20 | 1.00 | 0 | |
| | Visual | 40 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 50 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 60 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 80 | 80 | 80 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 10 | 120 | 68 | 0.57 | - | - | 47 | 0.96 | 5 | |
| Gentamicin | Visual | 20 | 120 | 11 | 0.09 | - | - | 73 | 0.70 | 36 | |
| | | 30 | 120 | 81 | 0.68 | - | - | 39 | 1.00 | 0 | |
| | | 40 | 120 | 114 | 0.95 | - | - | 6 | 1.00 | 0 | |
| | | 50 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 60 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 80 | 120 | 120 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | | 10 | 200 | 126 | 0.63 | 0.49 | 0.77 | 69 | - | 5 | |
| | | 20 | 200 | 25 | 0.13 | 0.09 | 0.18 | 135 | - | 40 | |
| | | 30 | 200 | 141 | 0.71 | 0.50 | 0.91 | 59 | - | 0 | |
| | | 40 | 200 | 194 | 0.97 | 0.94 | 0.99 | 6 | - | 0 | |
| Photometric + Visual | 50 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| | 60 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| | 80 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |
| | 80 | 200 | 200 | 1.00 | 0.98 | 1.00 | 0 | - | 0 | | |

Continuation Annex Table 2

| Substance | Reading System | Concentration | No. of total Results | No. of Results (pos. Class A) | Percentage of CC β A | Lower 95%- CI (CC β A) | Upper 95%- CI (CC β A) | No. of Results (pos. Class B) | Percentage of CC β B | No. of Results (negative) |
|----------------------|----------------------|---------------|----------------------|-------------------------------|----------------------------|------------------------------|------------------------------|-------------------------------|----------------------------|---------------------------|
| Neomycin | Photometric | 40 | 48 | 8 | 0.17 | - | - | 8 | 0.33 | 32 |
| | | 50 | 48 | 4 | 0.08 | - | - | 37 | 0.85 | 7 |
| | | 60 | 48 | 5 | 0.10 | - | - | 41 | 0.96 | 2 |
| | | 70 | 48 | 5 | 0.10 | - | - | 43 | 1.00 | 0 |
| | | 80 | 48 | 38 | 0.79 | - | - | 10 | 1.00 | 0 |
| | | 100 | 48 | 34 | 0.71 | - | - | 14 | 1.00 | 0 |
| | 150 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 40 | 72 | 10 | 0.14 | - | - | 17 | 0.38 | 45 |
| | | 50 | 72 | 4 | 0.06 | - | - | 58 | 0.86 | 10 |
| | | 60 | 72 | 6 | 0.08 | - | - | 63 | 0.96 | 3 |
| | | 70 | 72 | 18 | 0.25 | - | - | 54 | 1.00 | 0 |
| | | 80 | 72 | 46 | 0.64 | - | - | 26 | 1.00 | 0 |
| | | 100 | 72 | 39 | 0.54 | - | - | 33 | 1.00 | 0 |
| | 150 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 40 | 120 | 18 | 0.15 | 0.08 | 0.22 | 25 | - | 77 |
| | | 50 | 120 | 8 | 0.07 | 0.03 | 0.13 | 95 | - | 17 |
| | | 60 | 120 | 11 | 0.09 | 0.05 | 0.16 | 104 | - | 5 |
| | | 70 | 120 | 23 | 0.19 | 0.00 | 0.54 | 97 | - | 0 |
| 80 | | 120 | 84 | 0.70 | 0.41 | 0.99 | 36 | - | 0 | |
| 100 | | 120 | 73 | 0.61 | 0.22 | 1.00 | 47 | - | 0 | |
| 150 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |
| Chlor- amphenicol | Photometric | 1,500 | 48 | 0 | 0.00 | - | - | 41 | 0.85 | 7 |
| | | 2,000 | 48 | 3 | 0.06 | - | - | 45 | 1.00 | 0 |
| | | 2,500 | 48 | 15 | 0.31 | - | - | 33 | 1.00 | 0 |
| | | 3,000 | 48 | 37 | 0.77 | - | - | 11 | 1.00 | 0 |
| | | 4,000 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 5,000 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 6,000 | 48 | 48 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Visual | 1,500 | 72 | 0 | 0.00 | - | - | 24 | 0.33 | 48 |
| | | 2,000 | 72 | 0 | 0.00 | - | - | 67 | 0.93 | 5 |
| | | 2,500 | 72 | 5 | 0.07 | - | - | 67 | 1.00 | 0 |
| | | 3,000 | 72 | 37 | 0.51 | - | - | 35 | 1.00 | 0 |
| | | 4,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | | 5,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 |
| | 6,000 | 72 | 72 | 1.00 | - | - | 0 | 1.00 | 0 | |
| | Photometric + Visual | 1,500 | 120 | 0 | 0.00 | 0.00 | 0.03 | 65 | - | 55 |
| | | 2,000 | 120 | 3 | 0.03 | 0.01 | 0.07 | 112 | - | 5 |
| | | 2,500 | 120 | 20 | 0.17 | 0.02 | 0.31 | 100 | - | 0 |
| | | 3,000 | 120 | 74 | 0.62 | 0.32 | 0.92 | 46 | - | 0 |
| 4,000 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 5,000 | | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | |
| 6,000 | 120 | 120 | 1.00 | 0.97 | 1.00 | 0 | - | 0 | | |

Annex Table 3. Contingency table created with the Fisher Test for the concentration at CCB A obtained with photometric reading, including the numbers of results of the different classes of results (1-2-0) for the different plate batches and ELISA readers

| Substance | Concentration CCB A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CCB A) |
|--------------------------|---------------------|---------------------|-------|-------------------------------|-------------------------------|---------------------------|-------------------------------------|
| Benzyl-penicillin | 1 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| Ampicillin | 1.5 | 2 | C | 8 | 0 | 0 | 1 |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| Amoxicillin | 1.5 | 2 | C | 8 | 0 | 0 | 1 |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| Cloxacillin | 10 | 2 | C | 8 | 0 | 0 | 1 |
| | | 1 | D | 8 | 0 | 0 | |
| | | 1 | E | 8 | 0 | 0 | |
| | | 1 | F | 8 | 0 | 0 | |
| | | 2 | D | 8 | 0 | 0 | |
| Dicloxacillin | 6 | 2 | E | 8 | 0 | 0 | 1 |
| | | 2 | F | 8 | 0 | 0 | |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| Nafcillin | 4 | 2 | A | 8 | 0 | 0 | 1 |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| Oxacillin | 4 | 1 | C | 8 | 0 | 0 | 1 |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |
| | | 1 | A | 8 | 0 | 0 | |
| Cefalexin | 125 | 1 | D | 16 | 0 | 0 | 1 |
| | | 1 | E | 24 | 0 | 0 | |
| | | 1 | F | 24 | 0 | 0 | |
| | | 2 | D | 16 | 0 | 0 | |
| | | 2 | E | 24 | 0 | 0 | |
| Cefapirin | 3 | 2 | F | 24 | 0 | 0 | 1 |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| Cefoperazone | 20 | 2 | B | 8 | 0 | 0 | 1 |
| | | 2 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |

Continuation Annex Table 3


| Substance | Concentration CC β A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CC β A) |
|----------------------|-------------------------------|------------------------|-------|----------------------------------|----------------------------------|------------------------------|--|
| Cefazolin | 4 | 1 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| Cefquinome | 20 | 2 | C | 8 | 0 | 0 | 1 |
| | | 1 | D | 16 | 0 | 0 | |
| | | 1 | E | 24 | 0 | 0 | |
| | | 1 | F | 24 | 0 | 0 | |
| | | 2 | D | 16 | 0 | 0 | |
| Ceftiofur | 10 | 2 | E | 24 | 0 | 0 | 1 |
| | | 2 | F | 24 | 0 | 0 | |
| | | 2 | D | 16 | 0 | 0 | |
| | | 2 | E | 24 | 0 | 0 | |
| | | 2 | F | 24 | 0 | 0 | |
| Cefalonium | 6 | 1 | D | 8 | 0 | 0 | 1 |
| | | 1 | E | 8 | 0 | 0 | |
| | | 1 | F | 8 | 0 | 0 | |
| | | 2 | D | 8 | 0 | 0 | |
| | | 2 | E | 8 | 0 | 0 | |
| Erytromycin | 80 | 2 | F | 8 | 0 | 0 | 1 |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| Tylosin | 40 | 2 | B | 16 | 0 | 0 | 1 |
| | | 2 | C | 24 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| | | 2 | C | 16 | 0 | 0 | |
| Sulfadiazine | 200 | 1 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| Sulfadi- methoxin | 200 | 2 | C | 24 | 0 | 0 | 1 |
| | | 1 | A | 16 | 0 | 0 | |
| | | 1 | B | 24 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| Sulfametha- zine | 400 | 2 | B | 24 | 0 | 0 | 1 |
| | | 2 | C | 24 | 0 | 0 | |
| | | 1 | D | 16 | 0 | 0 | |
| | | 1 | E | 24 | 0 | 0 | |
| | | 1 | F | 23 | 1 | 0 | |
| Sulfathiazol | 60 | 2 | D | 16 | 0 | 0 | 0.06 |
| | | 1 | A | 16 | 0 | 0 | |
| | | 1 | B | 12 | 4 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | 1 |
| | | 2 | C | 8 | 0 | 0 | |

Continuation Annex Table 3

| Substance | Concentration CC β A | No. of ELISA Reader | Batch | No. of Results (pos. Class A) | No. of Results (pos. Class B) | No. of Results (negative) | p-Value Fisher's Exact Test (CC β A) |
|-----------------------------|-------------------------------|------------------------|-------|----------------------------------|----------------------------------|------------------------------|--|
| Sulfadoxin | 400 | 1 | A | 24 | 0 | 0 | 1 |
| | | 1 | B | 16 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 16 | 0 | 0 | |
| Sulfamethoxy- pyridazine | 100 | 2 | C | 24 | 0 | 0 | 0.06 |
| | | 1 | D | 24 | 0 | 0 | |
| | | 1 | E | 24 | 0 | 0 | |
| | | 1 | F | 14 | 2 | 0 | |
| | | 2 | D | 24 | 0 | 0 | |
| Chlortetra- cycline | 300 | 2 | E | 24 | 0 | 0 | 1 |
| | | 2 | F | 15 | 1 | 0 | |
| | | 1 | A | 16 | 0 | 0 | |
| | | 1 | B | 24 | 0 | 0 | |
| | | 1 | C | 24 | 0 | 0 | |
| Oxytetra- cycline | 100 | 2 | A | 16 | 0 | 0 | 1 |
| | | 1 | B | 23 | 1 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| | | 2 | B | 23 | 1 | 0 | |
| Tetracycline | 150 | 2 | C | 16 | 0 | 0 | 1 |
| | | 1 | A | 24 | 0 | 0 | |
| | | 1 | B | 23 | 1 | 0 | |
| | | 1 | C | 16 | 0 | 0 | |
| | | 2 | A | 24 | 0 | 0 | |
| Dihydro- streptomycin | 300 | 2 | B | 23 | 1 | 0 | 1 |
| | | 2 | C | 16 | 0 | 0 | |
| | | 1 | D | 16 | 0 | 0 | |
| | | 1 | E | 24 | 0 | 0 | |
| | | 1 | F | 24 | 0 | 0 | |
| Streptomycin | 500 | 2 | D | 16 | 0 | 0 | 0.11 |
| | | 1 | E | 24 | 0 | 0 | |
| | | 1 | F | 24 | 0 | 0 | |
| | | 2 | A | 16 | 0 | 0 | |
| | | 2 | B | 21 | 3 | 0 | |
| Gentamicin | 40 | 2 | C | 24 | 0 | 0 | 1 |
| | | 1 | D | 8 | 0 | 0 | |
| | | 1 | E | 16 | 0 | 0 | |
| | | 1 | F | 16 | 0 | 0 | |
| | | 2 | D | 8 | 0 | 0 | |
| Neomycin | 150 | 2 | E | 16 | 0 | 0 | 1 |
| | | 2 | F | 16 | 0 | 0 | |
| | | 1 | A | 8 | 0 | 0 | |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| Chlor- amphenicol | 4,000 | 2 | A | 8 | 0 | 0 | 1 |
| | | 1 | B | 8 | 0 | 0 | |
| | | 1 | C | 8 | 0 | 0 | |
| | | 2 | A | 8 | 0 | 0 | |
| | | 2 | B | 8 | 0 | 0 | |
| | | 2 | C | 8 | 0 | 0 | |

Nachweisempfindlichkeiten

Detection sensitivities



**Detection sensitivities of AiM BRT test systems
towards selected anti-infectives in cow milk, µg/kg (ng/ml; ppb)**

| Substance | BRT Inhibitor Test | | BRT MRL-Screening Test | | BRT hi-sense | | MRL (470/2009 EEG resp. 37/2010 EEG) |
|------------------------|--------------------|-------|------------------------|-------|--------------|-------|--|
| | CCβ A | CCβ B | CCβ A | CCβ B | CCβ A | CCβ B | |
| Penicillins | | | | | | | |
| Benzylpenicillin | 2.5 | 2 | 2 | 1.5 | 1 | 0.6 | 4 |
| Oxacillin | 10 | 8 | 8 | 8 | 4 | 3 | 30 |
| Cloxacillin | 25 | 20 | 25 | 18 | 10 | 9 | 30 |
| Amoxicillin | 3 | 2.5 | 3 | 2.5 | 1.5 | 1.3 | 4 |
| Ampicillin | 3.5 | 3 | 2.5 | 2 | 1.5 | 1.3 | 4 |
| Dicloxacin | 15 | 12.5 | 12.5 | 10 | 6 | 5 | 30 |
| Nafcillin | 15 | 10 | 10 | 8 | 4 | 4 | 30 |
| Cephalosporins | | | | | | | |
| Cefalexin | 400 | 300 | 300 | 250 | 125 | 100 | 100 |
| Cefalonium | 14 | 12 | 12 | 10 | 6 | 5 | 20 |
| Cefapirin | 6 | 5 | 5 | 5 | 3 | 2.5 | 60 |
| Cefazolin | 9 | 7 | 7 | 6 | 4 | 3 | 50 |
| Cefoperazone | 35 | 25 | 30 | 20 | 20 | 15 | 50 |
| Ceftiofur | 200 | 150 | 150 | 100 | 10 | 10 | 100 |
| Cefquinome | 500 | 300 | 300 | 200 | 20 | 20 | 20 |
| Aminoglycosides | | | | | | | |
| Streptomycin | 1,500 | 600 | 1,000 | 500 | 500 | 250 | 200 |
| DH-Streptomycin | 600 | 400 | 600 | 400 | 300 | 150 | 200 |
| Gentamicin | 200 | 100 | 150 | 80 | 40 | 10 | 100 |
| Neomycin | 400 | 200 | 300 | 200 | 150 | 60 | 1,500 |
| Macrolides | | | | | | | |
| Erythromycin | 100 | 50 | 80 | 50 | 80 | 40 | 40 |
| Tylosin | 75 | 40 | 75 | 30 | 40 | 20 | 50 |
| Sulfonamides | | | | | | | |
| Sulfadimidine | 1,000 | 300 | > 1,000 | 200 | 400 | 100 | 100 |
| Sulfadoxine | > 1,500 | 400 | 1,500 | 300 | 400 | 150 | 100 |
| Sulfamethoxypyridazine | 500 | 100 | 500 | 100 | 100 | 40 | 100 |
| Sulfadiazine | > 800 | 100 | 400 | 100 | 200 | 60 | 100 |
| Sulfadimethoxine | > 800 | 200 | 600 | 100 | 200 | 50 | 100 |
| Sulfathiazole | 400 | 60 | 200 | 60 | 60 | 40 | 100 |
| Tetracyclines | | | | | | | |
| Tetracycline | 1,000 | 600 | 600 | 300 | 150 | 75 | 100 |
| Chlortetracycline | > 1,000 | 800 | 800 | 400 | 300 | 150 | 100 |
| Oxytetracycline | 800 | 400 | 400 | 200 | 100 | 75 | 100 |
| Others | | | | | | | |
| Lincomycin | 200 | 150 | 200 | 100 | 125 | 75 | 150 |
| Chloramphenicol | 7,000 | 4,000 | 5,000 | 3,500 | 4,000 | 2,000 | illegal |

NKML – NordVal International Certificates no. 051, 052, 053 issued for BRT, valid until 01 March 2023

Data BRT Validation 2018: Reading with ELISA Reader: Measuring wavelength 450 nm, reference wavelength 620 nm

CCβ: Lowest concentration obtaining a minimum of 95% positive results

CCβ A: Evaluation with regard to the colour of the positive control

CCβ B: Evaluation with regard to the colour of the negative control



AiM – Analytik in Milch
Produktions- und Vertriebs-GmbH

Kaiser-Ludwig-Platz 2
80336 München

Tel. +49 89-530 75 120

Fax +49 89-530 75 122

info@aim-bayern.de

www.aim-bayern.de